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Aortic stenosis is a common and potentially fatal condition in which fibro-calcific 
changes within the valve leaflets lead to the obstruction of blood flow. Severe 
symptomatic stenosis is an indication for aortic valve replacement and timely referral 
is essential to prevent adverse clinical events. Calcification is believed to represent 
the central process driving disease progression. 18F-Fluoride positron emission 
tomography computed tomography (PET-CT) and CT aortic valve calcium scoring 
(CT-AVC) quantify calcification activity and burden respectively. The overarching 
aim of this thesis was to evaluate the applications of these techniques to the study 
and management of aortic stenosis. 
METHODS AND RESULTS 
REPRODUCIBILITY 
The scan-rescan reproducibility of 18F-fluoride PET-CT and CT-AVC were 
investigated in 15 patients with mild, moderate and severe aortic stenosis who 
underwent repeated 18F-fluoride PET-CT scans 3.9±3.3 weeks apart. Modified 
techniques enhanced image quality and facilitated clear localization of calcification 
activity. Percentage error was reduced from ±63% to ±10% (tissue-to-background 
ratio most-diseased segment (MDS) mean of 1.55, bias -0.05, limits of agreement -
0·20 to +0·11). Excellent scan-rescan reproducibility was also observed for CT-AVC 
scoring (mean of differences 2% [limits of agreement, 16 to -12%]).  
AORTIC VALVE CALCIUM SCORE: SINGLE CENTRE STUDY 
Sex-specific CT-AVC thresholds (2065 in men and 1271 in women) have been 
proposed as a flow-independent technique for diagnosing severe aortic stenosis. In a 
prospective cohort study, the impact of CT-AVC scores upon echocardiographic 
measures of severity, disease progression and aortic valve replacement (AVR)/death 
were examined. Volunteers (20 controls, 20 with aortic sclerosis, 25 with mild, 33 
with moderate and 23 with severe aortic stenosis) underwent CT-AVC and 
echocardiography at baseline and again at either 1 or 2-year time-points. Women 
required less calcification than men for the same degree of stenosis (p<0.001). 
Baseline CT-AVC measurements appeared to provide the best prediction of 
subsequent disease progression. After adjustment for age, sex, peak aortic jet 
velocity (Vmax) ≥ 4m/s and aortic valve area (AVA)<1 cm2, the published CT-AVC 
thresholds were the only independent predictor of AVR/death (hazard ratio = 6.39, 
95% confidence intervals, 2.90-14.05, p<0.001). 
AORTIC VALVE CALCIUM SCORE: MULTICENTRE STUDY 
CT-AVC thresholds were next examined in an international multicenter registry 
incorporating a wide range of patient populations, scanner vendors and analysis 
platforms.  Eight centres contributed data from 918 patients (age 77±10, 60% male, 
Vmax 3.88±0.90 m/s) who had undergone ECG-gated CT within 3 months of 
echocardiography. Of these 708 (77%) had concordant echocardiographic 
assessments, in whom our own optimum sex-specific CT-AVC thresholds (women 
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1377, men 2062 AU) were nearly identical to those previously published. These 
thresholds provided excellent discrimination for severe stenosis (c-statistic: women 
0.92, men 0.88) and independently predicted AVR and death after adjustment for 
age, sex, Vmax ≥4 m/s and AVA <1 cm2 (hazards ratio, 3.02 [95% confidence 
intervals, 1.83-4.99], p<0.001). In patients with discordant echocardiographic 
assessments (n=210), CT-AVC thresholds predicted an adverse prognosis. 
 
BICUSPID AORTIC VALVES 
Within the multicentre study, higher continuity-derived estimates of aortic valve area 
were observed in patients with bicuspid valves (n=68, 1.07±0.35 cm) compared to 
those with tri-leaflet valves (0.89±0.36 cm p<0.001,). This was despite no 
differences in measurements of Vmax (p=0.152), or CT-AVC scores (p=0.313). The 
accuracy of AVA measurments in bicuspid valves was therefore tested against  
alternative markers of disease severity. AVA measurements in bicuspid valves 
demonstrated extremely weak associations with CT-AVC scores (r2=0.08, p=0.02) 
and failed to correlate with downstream markers of disease severity in the valve and 
myocardium and against clinical outcomes. AVA measurements in bicuspid patients 
also failed to independently predict AVR/death  after adjustment for Vmax ≥4 m/s, 
age and gender. In this population CT-AVC thresholds (women 1377, men 2062 AU) 
again provided excellent discrimination for severe stenosis. 
 
CONCLUSIONS 
Optimised 18F-fluoride PET-CT scans quantify and localise calcification activity, 
consolidating its potential as a biomarker or end-point in clinical trials of novel 
therapies. CT calcium scoring of aortic valves is a reproducible technique, which 
provides diagnostic clarity in addition to powerful prediction of disease progression 
and adverse clinical events.  
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LAY SUMMARY 
Aortic Stenosis is a condition whereby one of the major heart valves through which 
blood exits the heart (the aortic valve) becomes progressively narrowed (stenosed) 
over a number of years. It is already the commonest form of valve disease in the 
western world and is set to become increasingly common. It is usually caused by the 
formation of calcium (calcification) on the valve leaflets and can eventually put a 
strain on the heart which has to work harder to pump blood through a narrowed 
valve. Presently, the only available treatment involves replacing the heart valve with 
an artificial valve once a patient with severe aortic stenosis develops symptoms such 
as breathlessness, chest pain or blackouts.  
 
It was previously believed that calcium simply settled on the valve in a passive 
manner however it is now becoming increasingly apparent that the calcification 
process actually resembles that of bone formation and is now considered to be the 
central driver of disease progression. The overarching aim of this thesis was to 
explore whether advances in cardiac imaging could be harnessed to measure valve 
calcification and subsequently improve patient care. 
 
Positron emission tomography (PET) is an imaging technique used to study 
calcification processes at a molecular level within the bone. We have recently shown 
that PET can also be to measure the amount of calcium actively forming within the 
aortic valve. In this thesis, I have refined this technique such that it is currently being 
used in a clinical trial examining whether medical treatments currently used to treat 
bone disorders, can slow the progression of aortic stenosis.  
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Ultrasound technology (echocardiography) is relied upon heavily by clinicans to 
grade the severity of the valve narrowing as mild, moderate or severe thereby 
identifying those patients who should be referred for surgery. However in 
approximately a quarter of cases, the different measurements used to grade severity 
can give conflicting information creating uncertainty as to the best course of action. 
Computed Tomography (CT) is a scanning technique which creates detailed pictures 
using  X-rays, it can be used to measure the amount of established calcium on the 
valve (calcium scoring). I have shown how CT calcium scoring only provides an 
alternative method for identifying patients with severe disease, but also identifies 
those at risk of faster disease progression and worse clinical outcomes. We therefore 
believe it should be used as an additional test in cases of uncertainty to provide 
clarity with respect to diagnosis and management of patients with aortic stenosis. 
Indeed CT calcium scoring has recently been included in the European Society of 
Cardiology guidelines for the management of aortic stenosis.  
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OVERVIEW 
Aortic stenosis is a global health concern.  Severe stenosis is estimated to affect 3.4% 
of people above the age of 75 and the prevalence is continuing to increase. The 
disease process is characterised by progressive fibro-calcific processes within the 
valve leaflets leading to their restricted mobility and eventually the obstruction of 
blood flow from the heart. The onset of symptoms heralds a bleak prognosis unless 
patients undergo either aortic valve replacement surgery or trans-catheter 
implantation. Echocardiographic measurements of severity are used to distinguish 
between those patients in whom valve replacement is indicated and those in whom 
continued watchful waiting is safe. Consequently, clinical uncertainty arises when 
echocardiographic measurements give different readouts for severity.  
 
Calcification is the central pathological process driving disease progression, 
therefore even a highly subjective, semi-quantitative, echocardiographic estimation 
of valvular calcium burden provides prognostic information more powerful than all 
other variables relied upon to grade disease severity. The poor reproducibility and a 
lack of confidence in subjective assessments may explain why echocardiographic 
calcium scoring has largely been overlooked in routine clinical practice. 18F-
Fluoride positron emission tomography computed tomography (18F-fluoride PET-
CT) and computed tomography calcium scoring (CT-AVC) can more accurately 
quantify calcification activity and burden respectively, thereby creating an 
opportunity to profoundly improve patient care. The purpose of this thesis is to study 
how these techniques should be applied to improve outcomes for patients with aortic 
stenosis.  
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Chapter 1: INTRODUCTION 
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The normal aortic valve consists of three leaflets, each of which is a thin, flexible 
and mobile structure (1). In aortic stenosis, these leaflets become progressively 
thickened, fibrosed and calcified thereby restricting their mobility and obstructing 
the flow of blood from the heart. The onset of symptoms in combination with severe 
stenosis heralds a bleak prognosis with mortality rates of 26% and 48% at 1 and 2 
years respectively (2-4). The only available treatment is an aortic valve replacement 
(AVR) or a trans-catheter aortic valve implantation (TAVI), however not all patients 
are suitable candidates for these procedures (5, 6).  There are currently no medical 
therapies capable of modifying disease progression. 
1.1 PREVALANCE 
Aortic stenosis is common. Previous cross-sectional studies have estimated a 
population based prevalence of 0.2-0.4 % with a strong age correlation (7, 8). By 
pooling the data from 7 population-based studies, a recent meta-analysis estimated a 
prevalence of 12.4% in those aged ≥75 years. Within this age group alone, this 
corresponded to approximately 4.9 million people in 19 European countries. If only 
symptomatic severe AS is considered, this translated to 3.4% (1.0 million), a number 
projected to double by 2050 (9).  
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1.2 NATURAL HISTORY 
There is considerable individual variability with respect to rates of hemodynamic 
progression and clinical course among adults with aortic stenosis. Collectively, 
prospective studies have observed annualised increases in peak aortic jet velocities of 
0.15-0.3 m/s, mean gradients of 2.7-7 mmHg and decreases in aortic valve area of 
0.03-0.1 cm2 (10-13). Disease progression is largely dictated by baseline severity so 
there is currently no method of identifying patients who will experience progressive 
disease amongst those with mild aortic stenosis (12).  
 
Severe aortic stenosis confers an adverse prognosis (14) even in the absence of 
symptoms (15). However even a diagnosis of mild or moderate aortic stenosis is an 
adverse prognostic marker. Whilst previous studies have implied that non-severe 
aortic stenosis is relatively benign, (16) these data were based on catheter-based 
estimates of disease severity and do not reflect current practice. By contrast, 
Rosenhek et al demonstrated that mortality in patients with mild to moderate aortic 
stenosis was 1.8 times higher than that of an age and gender-matched control 
population and 67 of 171 patients had valve surgery or died within a mean follow-up 
of 51 months (17). Rapid progression of moderate and even mild stenosis to 
haemodynamically severe disease was observed in 46% of patients. The strongest 
predictor of clinical events was the baseline echocardiographic aortic valve calcium 
score (17). These findings have been corroborated by other studies (12, 18). A 
method capable of predicting the natural history would therefore represent a 
significant clinical advance.  
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1.3 THE NORMAL AORTIC VALVE 
The normal aortic valve is a feat of structural engineering, designed to withstand 
significant forces throughout each cardiac cycle and to last a lifetime. It is composed 
of three leaflets each of which consists of three layers (Figure 1.1, (19)). 





Fibrosa layer. This is sited on the aortic aspect of the valve. It consists of type 1 collagen 
fibres aligned in a circumferential distribution and is the principle load-bearing layer.  
Spongiosa Layer. This functions as a shock-absorber and contains extracellular matrix 
components including glycosaminoglycans.  
Ventricularis Layer. Facing the ventricular aspect, this layer consists of elastin fibres 
aligned in a radial distribution, which facilitate cusp closure. 
 
The leaflets are lined by valvular endothelial cells.  The fibroblast-like valvular interstitial cells 






Valvular Endothelial Cells 
Valvular Interstitial Cells 
Circumferentially distributed Collagen Fibres 
Radially distributed Elastin Fibres 
Valvular Interstitial Cells 
Valvular Interstitial Cells  
Interspersed with Glycosaminoglycans 
Valvular Endothelial Cells 
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1.4 PATHOLOGY OF AORTIC STENOSIS 
Aortic stenosis was long dismissed as a degenerative condition whereby ‘wear and 
tear’ resulted in progressive calcium deposition upon the valve. However emerging 
evidence has indicated that it develops as part of a highly complex and tightly 
regulated series of processes each of which may be amenable to medical intervention 
(1). Aortic stenosis can be thought of as occurring in two phases: an early initiation 
phase dominated by valvular lipid deposition, injury and inflammation with many 
similarities to atherosclerosis, and a later propagation phase where pro-calcific and 
osteogenic factors take over and ultimately drive disease progression (Figure 1.2) 
(20).  
1.4.1 Initiation Phase: Inflammation 
The healthy aortic valve consists of two main cell types; valvular endothelial cells 
(VECs) and valvular interstitial cells (VICs).  It is damage to the lining endothelial 
cells, which is thought to represent the primary event in the disease process. The 
mechanism of injury is not fully understood and will almost certainly vary between 
individuals depending on the primary aetiology.  For example in those with bicuspid 
aortic valves, mechanical stress may provide the initial injurious stimulus as a 
bileaflet valve is unable to dissipate the haemodynamic stress as effectively as a tri-
leaflet valve (21).  Evidence for the central role of mechanical stress in the pathology 
of aortic stenosis can also be found in those with tri-leaflet valves as subsequent 
calcium distribution often occurs at sites of highest mechanical stress (22).  Clearly 
however all aortic valves are subject to significant haemodynamic stress during the 
lifetime of an individual and not everyone develops aortic stenosis.   Additional 
pathophysiological insights are provided by the apparent similarities with 
                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
 21 
atherosclerosis.  Age, smoking, hypertension, hyperlipidaemia and diabetes are all 
associated with an increased likelihood of developing aortic stenosis (23-25) 
implicating these injurious stimuli as facilitators of endothelial injury.  The early 
stages of aortic stenosis share histological similarities with atherosclerosis however 
again, not all patients with atherosclerosis develop aortic stenosis and whilst these 
pathologies undoubtedly overlap, they are not simply different manifestations of the 
same disease process (26).  In the majority of patients, the development of aortic 
stenosis is likely to require a series of pathological ‘hits’ reflecting a complex 
interplay of environmental and genetic factors. 
1.4.2 Initiation Phase: Lipids 
Lipids: in particular lipoprotein (a) and oxidized low-density lipoprotein (LDL) are 
postulated to play a key role in the pathogenesis of aortic stenosis.  Observational 
studies have identified cholesterol and its related lipoproteins as independent risk 
factors for the development of aortic stenosis (23-25, 27). Genetic predisposition to 
elevated LDL is associated with aortic valve calcification and aortic stenosis (27).  
Furthermore a strong genome-wide association was recently established between a 
single nucleotide polymorphism in the locus of lipoprotein (a) and the incidence of 
aortic valve calcification (28).   
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Initiation phase. Endothelial injury (1) facilitates the infiltration of oxidized lipids and 
inflammatory cells (2) into the valve and the release of pro-inflammatory mediators (3). 
These trigger the very early stages of valve calcification.   
 
Propagation phase.   Pro-inflammatory processes induce valvular interstitial cells to 
undergo osteogenic differentiation (5) via several different mechanisms, including the 
binding of RANKL to RANK.  Differentiated cells within the aortic valve first lay down a 
collagen matrix and other bone-related proteins causing valvular thickening and stiffening (6) 
before producing calcium (7).  Apoptotic remnants of some VICs and inflammatory cells (8) 
create a nidus for apoptosis-mediated calcification (9).   Calcification of the valve (10) 
induces compliance mismatch resulting in increased mechanical stress and injury (11).  This 
results in further calcification via osteogenic differentiation and apoptosis (12). Hence a self-
perpetuating cycle of calcification, valve injury, apoptosis and osteogenic activation is 
established that drives the propagation phase of the disease.  
 
Abbreviations: RANKL, receptor activator of nuclear kappa B ligand; RANK, receptor 
activator of nuclear kappa B; BMP, bone morphogenic protein; LDL, low density lipoprotein.  
 
Pawade et al. JACC. 2014 (29) 
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Endothelial injury permits the infiltration of LDL, lipoprotein (a), macrophages and 
T lymphocytes, thus establishing an inflammatory milieu (22).  Another features of 
aortic stenosis is increased oxidative stress partly due to uncoupling of nitric oxide 
synthase pathway (30).  Whether this is a cause or consequence of endothelial injury 
is unclear but this perpetuates the oxidation of LDLs and further inflammation.  
Interestingly in established aortic stenosis, the degree of inflammation is similar in 
bicuspid and tri-leaflet valves(31) 
1.4.3 Inflammation and Calcification 
Regions of microcalcification that co-localize with sites of lipid deposition are 
observed at this early stage. These microscopic deposits of mineralization are more 
prominent in early valve lesions than would be typical of atherosclerosis suggesting 
that the pathologies may now be diverging (22).  Calcification during the initiation 
stage may be mediated by cell death and the release of apoptotic bodies in these 
areas which can form a nidus for subsequent calcium formation (22). Furthermore 
hydroxyapatite deposition evokes further pro-inflammatory responses from 
macrophages, creating a positive feedback loop of calcification and inflammation in 
the early stages of disease (32).  Indeed it seems likely that these mechanisms 
underlie early calcium formation in aortic stenosis and its association with lipid and 
inflammation. 
 
The apparent link between lipid, inflammation and calcification in these early stages 
and the pathological similarities with atherosclerosis, led to the hypothesis that 
statins might be beneficial in patients with aortic stenosis. This was supported by 
encouraging hypercholesterolemic animal models demonstrating that lipid deposition 
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and oxidative stress precede the conversion of valvular interstitial cells to those with 
an osteoblastic phenotype, and that this process is inhibited by atorvastatin (33, 34).  
However when statins were formally tested in three independent randomised 
controlled trials of patients with aortic stenosis, each demonstrated a failure of this 
therapy to halt or retard aortic stenosis progression, despite the serum LDL 
cholesterol concentrations more than halving (11, 35, 36). This has led investigators 
to re-examine the pathophysiology underlying aortic stenosis and to the realization 
that whilst inflammation and lipid deposition may be important in establishing the 
disease (the initiation phase), the latter stages are instead characterized by an 
apparently self-perpetuating cycle of calcium formation and valvular injury (the 
propagation phase, (20). Indeed once this propagation phase has become established, 
disease progression is dictated neither by inflammation nor lipid deposition but 
rather by the relentless accumulation of calcium in the valve leaflets.  This may 
explain the failure of statins to modify disease progression in aortic stenosis, which 
commonly presents once the disease is entrenched within the propagation phase (37, 
38).   
1.4.4 Propagation Phase: Fibrosis 
Skeletal bone formation is characterized by the initial deposition of collagen matrix, 
that provides a scaffold upon which progressive calcification can develop. Similar 
structural processes are believed to occur in the aortic valve with many of the same 
cell mediators and proteins implicated (39). Indeed, in aortic stenosis, collagen is 
deposited in anticipation of the pro-calcific processes that subsequently dominate.  
The renin-angiotensin system (RAS) is believed to play a central role in this. 
Angiotensin converting enzyme (ACE) is up regulated in calcific aortic valve disease 
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and is likely to be delivered to the valve by LDL, its natural vehicle (40).  Here it 
facilitates the conversion of angiotensin I to angiotensin II which mediates pro-
fibrotic effects via the angiotensin II type 1 (AT1) receptor. Although angiotensin II 
is also able to mediate anti-fibrotic and anti-inflammatory effects via angiotensin II 
type 2 (AT2) receptors, differential expression of these receptors in favour of AT1  
has been demonstrated in calcified aortic valves so that a pro-fibrotic profile 
dominates.  Likewise, whilst angiotensin converting enzyme type 2 (ACE-2) exerts 
anti-fibrotic and anti-inflammatory influences via the Ang1-7/Mas pathway, this 
pathway is down regulated in calcified aortic stenosis with reduced expression of 
both ACE-2 and Mas receptors in calcified valves compared to controls (41). 
Increased RAS expression is therefore implicated in the development of fibrosis 
within the valve.  
1.4.5 Propagation Phase: Calcification 
Beyond this initial fibrosis, valvular calcification in aortic stenosis appears to be 
predominantly mediated by the development of osteoblast-like cells. In support of 
this hypothesis, gene profiling studies have demonstrated increased valvular 
expression of several osteoblast-specific proteins including the Cbfa1/Runx2 
transcription factor, essential for osteoblastic differentiation and regulation of 
osteoblast function (42, 43). A number of other extracellular matrix proteins closely 
associated with osteoblast function and more commonly associated with skeletal 
bone formation are also up regulated in calcific aortic valves. These include 
osteopontin and bone sialoprotein: facilitators of the attachment of osteoblasts to the 
bone matrix, which demonstrate up to a 7-fold elevation in gene expression at sites 
of developing calcification (44) (45). Importantly valvular ossification also appears 
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to be dependent upon angiogenesis, supporting the hypothesis that this is an active 
highly-regulated pathological process (39). 
 
The source of osteoblast-like cells within the aortic valve remains controversial. In 
vitro multiple cell types present in the vasculature are capable of undergoing 
differentiation into those with an osteoblast-like phenotype. The most likely 
candidate appears to be the highly plastic valvular interstitial cell (46). The 
differentiation of this cell into an osteoblast phenotype is not fully characterized but 
appears to be a central step in the development of aortic stenosis and regulated by a 
rapidly growing list of molecules and complex pathways. In vivo molecular imaging 
has demonstrated that in the early stages of aortic stenosis, this differentiation 
appears co-ordinated by macrophages (47, 48) via the action of pro-inflammatory 
cytokines (IL-1β, IL-6, IL-8, tumour necrosis factor-α, insulin-like growth factor-1, 
and transforming growth factor-β) (20, 49, 50).  Pro-calcific pathways including the 
Notch, Wnt/catenin and receptor activator of nuclear kappa B (RANK) /RANK 
ligand (RANKL)/ osteoprotegerin (OPG) pathways are also implicated. 
 
Notch belongs to a family of cell surface receptors (Notch 1-4) that are highly 
expressed in the aortic valve, playing an important role in its morphological 
development (51). Individuals with loss of function mutations in Notch-1 have 
higher rates of cardiovascular calcification and aortic stenosis. Indeed, in two 
unrelated families with a high incidence of congenital aortic valve disease, genome-
wide linkage analysis identified loss of function Notch-1 mutations as the cause (51). 
In particular Notch-1 appears important in establishing osteogenic cells in the valve 
via the action of bone morphogenic protein-2 (BMP-2) (52). BMP-2 is a potent 
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osteogenic differentiation factor and part of a family of multifunctional cytokines 
belonging to the transforming growth factor (TGF)-G superfamily. Expression of 
BMP-2 is increased in calcified atherosclerotic lesions and aortic valves (43, 53), and 
it appears to have a central role in the differentiation of plastic cell populations 
towards an osteogenic phenotype. Indeed exposure of normal human VICs to BMP-2 
induces osteoblastic features in these cells (54, 55).  
 
Binding of Wnt to low-density lipoprotein receptor-related protein 5 receptors may 
also activate the canonical Wnt/catenin pathway that is also implicated in osteogenic 
cell differentiation (56).  Additionally, TGF-β1 is able to induce nuclear 
translocation of β-catenin, and increased Wnt signalling, stimulating the osteogenic 
differentiation of mesenchymal progenitor cells (57). The latter process can increase 
in response to mechanical stress and may therefore explain in part, the self-
perpetuating and exponential increase in calcification activity observed once 
osteogenic differentiation has occurred and the propagation phase is established 
(Figure 1) (57, 58).  
1.4.6 The calcification paradox 
Calcium homeostasis is tightly controlled by systemic regulators that govern 
calcification activity both in the bone and the vasculature, consequently there is an 
inverse correlation between bone mineral density and vascular calcification.   
Osteoporosis is associated with age-independent increase in vascular calcification 
and even cardiovascular mortality (59).   Indeed a prospective study of 25,639 men 
and women demonstrated an inverse correlation between bone mineral density and 
incident aortic stenosis in older women (60).  Moreover, other disorders of bone 
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turnover including chronic kidney disease and Paget’s disease also manifest changes 
in the vasculature (61-64). This dichotomy has been termed the calcification paradox 
and is likely to be explained by common pathological pathways having reciprocal 
effects on the bone and vasculature simultaneously.   
 
1.4.7 The RANK/RANKL/OPG axis 
One potential mechanism for this association lies in the activity of the 
RANK/RANKL/OPG pathway. In bone RANKL (a member of the tumour necrosis 
factor cytokine family) binds to RANK (a transmembrane protein expressed on 
marrow stromal cells and pre-osteoclasts) acting as a potent inducer of osteoclast 
differentiation and activity.  This drives demineralization of bone, but is policed by 
osteoprotegerin (OPG), a soluble decoy receptor, which binds RANKL and prevents 
it from activating RANK (Figure 2).  By contrast, RANKL appears to have the 
opposite effect on cells in the vasculature, inducing an osteoblastic phenotype in 
human VIC cells that results in increased matrix calcification, the formation of 
calcific nodules and increased expression of alkaline phosphatase and osteocalcin 
(Figure 2a) (65). RANKL also promotes the osteogenic properties of vascular 
smooth muscle cells, once again via the up regulation of BMP-2.  In a sophisticated 
model attempting to replicate a capillary Davenport et al demonstrated that exposure 
of human arterial endothelial cells to RANKL promoted the osteoblastic activity of 
vascular smooth muscle cells in a paracrine fashion, possibly via the release of 
BMP2 and BMP4 (66). As a consequence whilst OPG-deficient mice develop 
osteoporosis, they simultaneously accelerate vascular calcification in association 
with increased expression of RANKL in both regions (67). A potential explanation 
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for the differential effects of RANK/RANKL/OPG in these two tissues is that in 
bone there is an abundance of pre-osteoclasts that favours the pro-osteoclastic 
properties of RANKL (50). By contrast in the vasculature, this pool is reduced such 
that the pro-osteoblastic effects of this ligand on myofibroblast and smooth muscle 
cells predominate.  
 
Imbalances in RANKL/OPG signalling have been demonstrated in calcific aortic 
valves. In human valve tissue taken from patients with aortic stenosis, 
immunochemistry revealed less OPG positive cells in areas of focal calcification, 
whilst western blotting demonstrated that OPG was not expressed at relevant levels 
in aortic stenosis but was detectable in controls. The converse is true of RANKL 
with increased levels observed in stenotic aortic valves (65). In combination, these 
data support the hypothesis that the RANK/RANKL/OPG axis is implicated in the 
development of aortic valve calcification and provide one explanation for the link 
between this and bone mineral density.  
 
Other investigators have suggested that the differential effects of oxidized LDL 
might also be of importance, with this molecule appearing to promote calcification 
and the osteoblastic differentiation of vascular cells in vitro, whilst inhibiting these 
processes in a bone-derived pre-osteoblast cell line (20) (68, 69).  Fetuin A is a 
circulating protein, which can exist in isolation or as a complex with matrix γ-
carboxyglutamic acid protein (MGP).  Both are powerful guardians against ectopic 
calcification and simultaneously inhibit many of the procalcific processes discussed 
above (70).  MGP needs to be both carboxylated and phosphorylated to be activated: 
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a process dependent on vitamin K. Their actions include inhibition of BMP2 and 
TGF-β, reduction of apoptosis-mediated calcification and direct prevention of 
calcification by binding to calcium crystals. Indeed there is speculation that use of 
the vitamin K antagonists such as coumarins, may be associated with increased 
vascular calcification (71). Additionally, reduced circulating levels of Fetuin-A and 
MGP are thought to explain the vascular calcification seen with end stage renal 
failure. Moreover plasma Fetuin-A concentrations are decreased in aortic stenosis 
and inversely associated with rate of disease progression (72, 73). Interestingly this 
association was seen only in older patients (>70 years) (74). Conversely, increased 
plasma dephosphorylated (inactive) MGP was a strong independent predictor of 
faster stenosis progression, but only in younger patients (≤ 57 years old) (75).  
1.4.8 Why does calcium beget calcium? 
Once calcification is established in the valve it would appear to initiate further 
calcium formation. Indeed it is this self-perpetuating cycle of calcification and valve 
injury that appears to the central driver of disease progression and the propagation 
phase of aortic stenosis. The mechanism for this may in part relate to the compliance 
mismatch caused by calcific deposits in the leaflets that result in increased 
mechanical stress, injury-induced activation of the Wnt/catenin pathway and further 
osteoblast differentiation.   
 
In bone, the mineralization process is regulated by matrix vesicles which are small 
membranous structures (30-300 nm in diameter).  They are formed as blebs off 
osteoblasts and chondrocytes and contain the prerequisite components for calcium 
crystal deposition.  They facilitate the formation of needle-like crystals of 
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hydroxyapatite (20, 76) and as these hydroxyapatite crystals expand, they pierce the 
outer membrane of the vesicle and become exposed to the extracellular environment, 
thereby forming nucleation sites for further calcium deposition.  Structures with a 
similar morphology to matrix vesicles, termed extra-cellular vesicles, have been 
identified at sites of ectopic calcification in the vasculature including calcified valves 
(77, 78).  They were initially considered to propagate pro-calcific processes in an 
analogous manner to that seen in bone however this is now recognized to be an 
oversimplification of their diverse roles. (77).  In atherosclerotic plaques they are 
thought to originate from osteogenic-transformed vascular smooth muscles cells and 
macrophages.  Under normal circumstances they have an important physiological 
role as intercellular communicators and are loaded with calcification inhibitors 
including anti-calcific microRNA and Fetuin A (79, 80).  Under pro-calcifying 
conditions however it is possible that they become trapped in the extracellular matrix 
thus propagating calcification by direct nucleation in a manner similar to that seen 
with apopotic bodies.  Failure to reach target cells may cause dysregulated gene 
expression patterns promoting osteogenic differentiation (80).  Conversely under 
pathological states they may become loaded with pro-calcific agents and induce 
further osteogenesis (81).  
  
Membrane- bound ectonucleotidases are produced by VICs and regulate the 
extracellular production of inorganic phosphate (a promoter of calcification) and 
inorganic pyrophosphate (PPi) an inhibitor of pyrophosphate.  Ectonucleotide 
pyrophosphate 1 (ENPP1) is highly up regulated in calcific aortic valve disease, with 
a polymorphism associated with increased transcripts of ENPP1 identified in stenotic 
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valves (82).  Hydrolysis of extracellular ATP by ENPP1 produces a net increase in 
inorganic phosphate thus favouring calcification and promoting the production of 
further ENPP1 in a positive feedback loop (82).  Moreover because ATP acts as a 
cell survival signal for VICs via the P2Y2 receptor, its depletion also triggers 
apoptosis of these cells, providing a further key stimulus to calcification (82). Finally 
loss of P2Y2 signalling increases the secretion of interleukin-6 (IL-6), a cytokine that 
promotes further osteogenic differentiation of VICs via the actions of BMP (83). 
Thus, via these multiple mechanisms, the ectonucleotidase pathway appears to have 
a central role in amplifying pro-calcific processes within the valve during the 
propagation phase of aortic stenosis.  
 
In summary the pathophysiology of aortic stenosis is far more sophisticated 
than originally perceived. It is likely to be initiated by valvular endothelial 
injury and in the early stages, is similar to atherosclerosis (initiation phase). 
Valvular inflammation creates a pro-calcific environment via several potential 
pathways including the osteogenic differentiation of valvular interstitial cells. 
Once the process of active calcification has become established within the valve, 
this becomes a self-perpetuating cycle driving disease progression (propagation 
phase). For reasons that are not understood, the natural history of this disease is 
extremely variable between individual patients, with some experiencing a rapid 
clinical course and others never progressing beyond aortic sclerosis.  
  
                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
 33 
1.5 BICUSPID AORTIC VALVES 
The bicuspid valve is the commonest congenital heart defect in which the aortic 
valve consists of 2 leaflets instead of 3. With a male preponderance it is estimated to 
affect 0.9-1.3% of live births (84-87). These patients are predisposed to a variety of 
pathologies of which aortic stenosis is the most common and presents approximately 
5-10 years earlier than in tri-leaflet valves. Whilst this implies an accelerated clinical 
course, there is no longitudinal data to confirm this (89). Despite representing a 
relatively small proportion of the total aortic stenosis population, bicuspid patients 
constitute approximately 30% of those undergoing surgical aortic valve replacement 
(85). One study, which included patients with no complications related to bicuspid 
valves at baseline, showed that over 15 years of follow-up, 26 out of 212 patients 
(12.3%) underwent surgical aortic valve replacement for severe aortic stenosis (88).  
 
Bicuspid valves occur within a wide range of clinical phenotypes from complex 
congenital heart disease (89), to normally functioning valves, a heterogeneity which 
is further reflected in the variability of valvular morphology. The majority of 
bicuspid valves retain the crown-like structure characteristic of the tri-leaflet valves 
with incomplete separation of the commisures producing two leaflets of differing 
size (Figure 1.3 (90). Less commonly, these valves can also manifest as a truly 
bileaflet structure consisting of two equally sized leaflets with no visible raphe. 
There is currently no agreement as to how valvular morphology influences the 
clinical sequelae in these patients. 
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CTA images of bicuspid aortic valves (B, C, D and E) are shown in addition to tri-leaflet valve 
(A) for comparison. In examples B and C, the right and left coronary cusps are fused with (B) 
and without (C) a visible raphe. Examples D and E exhibit more distorted geometry, these 
valves are elliptical in shape with equally sized leaflets. Calcification can be seen affecting 
the leaflet tips (B and E), commissures (D) and the raphe (B). 
 
The pathobiology of aortic stenosis of the bicuspid valve is likely to share many 
common pathways with that of the tri-leaflet valve, again representing a complex 
interplay of environmental and genetic factors. However the evidence for a genetic 
basis is more compelling.  Approximately 30% of first-degree relatives of subjects 
with a bicuspid valve will themselves have a bicuspid valve or a thoracic aortic 
aneurysm (a commonly associated pathology, (91, 92). The underlying genetic basis 
for this is under continued investigation however mutations in the genes encoding the 
NOTCH1 receptor (93) and fibrillin 1 (94) have been identified in association with 
bicuspid aortic valves. Fibrillin mutations are thought to increase signalling through 
TGFβ pathway and in support of this, bicuspid valves have reduced fibrillin 
expression in association with higher levels of TGFβ (95, 96). Mutations involving 
constituents of the extracellular matrix such as matrix metalloprotein 12 have been 
associated with aortic stenosis, although not bicuspid valves specifically (7). 
However excised bicuspid valves from paediatric patients were characterised by 
excessive extracellular matrix production, disorganization and VIC disarray (97). 
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The abnormal valve morphology increases the mechanical stress imposed on the 
valve tissues and creates turbulent blood flow patterns, which may represent the 
initiating mechanism by which endothelial cell damage occurs (98, 99). Interestingly 
the subsequent inflammatory response in bicuspid valves is more aggressive, with 
increased macrophage infiltration and neovascularization compared with that seen in 
tri-leaflet valves (100). Additionally altered mechanical forces can directly induce 
VICs to increase collagen synthesis and upregulate both TGF‐β and BMP‐4, offering 
a mechanistic link between the enhanced mechanical stress and calcification (101-
103).  
 
In summary therefore, the bicuspid population is a heterogenous subgroup in 
whom the predilection to aortic stenosis is likely to reflect the consequence of 
genetic susceptibility in combination with increased mechanical stress.  
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1.6 CLINICAL IMAGING OF AORTIC VALVE CALCIFICATION 
The burden and activity of aortic valve calcification can be measured using non-
invasive imaging. In particular positron emission tomography PET, computed 
tomography (CT) and echocardiography can all be employed to provide assessments 
of the calcific processes occurring at different stages of the disease process (Figure 
1.4). Indeed these techniques have not only informed our understanding as to the 
importance of calcification in aortic stenosis but have also aided our ability to assess 
disease severity, and to predict progression and adverse cardiovascular outcomes. 
The latter is of particular importance. As discussed aortic stenosis progression 
frequently does not occur in a linear or predictable manner making estimation as to 
when valve replacement will be required challenging. Annual or biannual clinical 
review is generally required with serial echocardiography performed in order to track 
progressive valve narrowing. The development of a non-invasive method capable of 
predicting the future natural history of aortic stenosis and the likely timing of valve 
surgery would represent a major advance and help streamline patient care. Given the 
central role that mineralization plays in disease progression, it is perhaps not 
surprising that assessments of aortic valve calcification have to date provided the 
best prediction (15, 17).  
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Short axis of a calcified aortic valve from the same subject imaged using two-dimensional 
echocardiography (A), computed tomography calcium scoring (B)  Computed Tomography 




Pawade et al. JACC. 2014 (29) 
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1.7 MICROCALCIFICATION 
1.7.1 18F-Fluoride Positron Emission Tomography 
Positron emission tomography (PET) is a non-invasive imaging technique that allows 
the activity of specific biological processes to be measured in vivo within specific 
structures including the aortic valve. In principle, any disease process can be 
evaluated dependent on the availability of a suitable tracer. To date studies in aortic 
stenosis have largely investigated tracers targeted to inflammation (18F-
fluorodeoxyglucose) and calcification (18F-fluoride), aiming to establish the relative 
contributions of these processes to disease development and progression (104-106).  
 
1.7.2 Inflammation 
The PET radiotracer 18F-fluorodeoxyglucose (18F-FDG) is a glucose analogue 
taken up by metabolically active cells. Because it is unable to proceed through the 
glycolytic pathway, it accumulates within these cells without further metabolism. 
Vascular macrophages have higher metabolic requirements than surrounding tissue 
so that 18F-FDG has emerged as a useful tool for the identification of vascular 
inflammation, demonstrating that uptake in regions of carotid atheroma correlates 
well with macrophage density (mean percentage staining of CD68 positive cells, r = 
0.85; P<0.0001) (107, 108) and is modifiable with statin therapy (109). 
 
In order to determine the contribution of inflammation to the pathogenesis of calcific 
aortic stenosis, PET imaging of the aortic valve was performed of the aortic valve 
using 18F-FDG in a prospective cohort of 121 patients with the full spectrum of 
calcific aortic valve disease (including 20 patients with aortic sclerosis and 20 
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control subjects) (104).  18F-FDG activity was increased in patients with aortic 
stenosis compared to controls (1.58±0.21 versus 1.30±0.13; P<0.001) and this 
correlated with disease severity (104). However unlike previous work on carotid 
atheroma, the 18F-FDG signal did not correlate with macrophage (CD68) staining 
raising the possibility that in the calcifying aortic valve, 18F-FDG may not be acting 
as a marker of macrophage driven inflammation, but instead might reflect glucose 
utilization by other metabolically active cells such as valvular interstitial cells, 
myofibroblasts, or differentiated osteogenic cells (110).  
1.7.3 Calcification 
18F-Fluoride has been used as a bone tracer for more than 40 years, exchanging with 
hydroxyl groups in hydroxyapatite to form fluoroapatite. Similar hydroxyl bonds are 
also present in the different forms of calcium in the vasculature (including 
hydroxyapatite and amorphous calcium) so that 18F-fluoride binding acts as a 
marker of vascular calcification. In particular the binding of 18-fluoride to calcium 
appears critically dependent upon the surface area of calcium orthophosphate 
available for incorporation. 18F-fluoride therefore preferentially binds regions of 
newly developing microcalcification (beyond the resolution of CT), which have a 
nano-crystalline structure and very high surface area rather than large, established, 
macroscopic deposits where much of the calcium is internalized and therefore not 
available for binding (111).  On this basis, increased 18F-fluoride uptake is observed 
in regions of actively developing calcification, demonstrating a close association 
with alkaline phosphatase staining (r=0.65, P=0.04) on excised aortic valve tissue 
removed at the time of surgery (110).  
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When the same cohort of 121 patients was imaged with 18F-fluoride, the observed 
PET signal in the aortic valve was stronger and more clearly demarcated than was 
seen with 18F-fluorodeoxyglucose (Figure 1.5). Moreover the spatial distribution of 
the 18F-fluoride signal was often discrete from the macroscopic calcium deposits 
identified by CT, indicating that 18F-fluoride uptake does indeed provide distinct but  
complementary information to CT alone.   Uptake was increased in patients with 
aortic stenosis compared to healthy controls (2.87±0.82 versus 1.55±0.17, P<0.001) 
and correlated with disease severity (r=0.73, P<0.001) (104). Indeed the highest 
calcification activity, as measured using this tracer, was observed in patients with the 
most advanced disease (Figure 1.5).  Again this supports the hypothesis that 
calcification begets calcification in aortic stenosis and would explain the rapid rates 
of disease progression in those at the severe end of the spectrum.  
 
When patients were recalled for repeat CT calcium scoring of the valve at 1 and 2 
years, new calcium could be observed in the areas of increased 18F-fluoride activity 
seen on the baseline scan (Figure 1.5).  As a consequence, a close correlation was 
observed between the baseline valvular 18F-fluoride uptake and the progression of 
the aortic valve CT calcium score (r=0.80 [0.69-0.87]; P<0.001), with PET appearing 
to offer some additional predictive information over and above the baseline calcium 
score. Moreover this translated into an ability to predict valve hemodynamic 
progression with moderate correlations also observed between 18F-fluoride activity 
and the mean (r=0.32 [0.13-0.50], P=0.001) and peak (r=0.32 [0.12-0.49], P=0.002) 
aortic valve gradients. (112). Finally after a median of 1526 days of follow up, 18F-
fluoride emerged as a prognostic marker serving as an independent predictor of the 
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combined end-point of aortic valve replacement and cardiovascular mortality (HR 
(hazard ratio):1.55 [95% confidence interval, 1.33-1.81], after adjusting for age and 
sex; P<0.001) 
 
In summary, these data highlight the potential application for 18F-fluoride as 
an immediate, non-invasive measure of disease activity in aortic stenosis with 
the ability to predict its natural history. Identifying patients with mild aortic 
stenosis who will progress to clinically severe stenosis would represent a major 
clinical advance. Additionally, the instantaneous rapid read-out of disease 
activity holds particular promise in assessing the early efficacy of novel 
therapeutic agents, in which treatment effects are likely to be discernible over a 
much shorter time period than could be resolved using clinical end-points or 
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Studies using Positron Emission Tomography have demonstrated that calcification activity in 
the valve (as measured using 18F-Fluoride) steadily increases with disease severity. As a 
consequence activity is highest in those with the most advanced disease and a good 











Baseline Computed Tomography Calcium Scores (left) for patients 1 and 2 (top and bottom).  
Fused co-axial 18F-Fluoride PET CT Scans (middle) shows Fluoride uptake in red and 
yellow.  One year follow up (right) suggests that baseline PET signal predicts spatial 
distribution of subsequent macrocalcification (110).  
 
Pawade et al. JACC. 2014 (29) 
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1.8 MACROCALCIFICATION  
1.8.1 Echocardiography 
Echocardiography is a cheap, safe and widely used method of assessing aortic 
stenosis severity in the clinical setting.  Indeed international guidelines recommend 
grading aortic stenosis severity using the following hemodynamic echocardiographic 
assessments: the peak velocity, the mean gradient and the aortic valve area (113). 
However echocardiography can also be used to categorize valves according to their 
degree of valvular calcification into those with none, mild, moderate and severe 
calcification. Indeed in a series of 128 patients with severe, asymptomatic aortic 
stenosis, this semi-quantitative assessment provided powerful prognostic 
information, acting as a strong independent predictor of death or aortic valve 
replacement that out performed the more conventional hemodynamic measures 
(114). Whilst this observation has been confirmed in another study of 141 
asymptomatic patients (115), the clinical utility of this approach has been limited by 
disappointing inter-observer agreement in grading the calcification (112, 116).  
1.8.2 Computed Tomography Calcium Scoring 
Computed tomography (CT) provides detailed, reproducible and accurate assessment 
of the calcific burden in the aortic valve (116). Using the same protocols employed 
for coronary calcium scoring, electrocardiography-gated non-contrast CT can 
provide information with respect to the density, volume and mass of macroscopic 
calcium deposits within the valve (116). However as in the coronary arteries, the 
aortic valve calcium burden is generally described using Agatston Units (AU), which 
takes account of both the radiodensity and volume of calcium.  In a series of 
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explanted aortic valves, a score of 500, 1100 and 2000 AU approximated to 300, 
1100 and 1200 mg of aortic valve calcium respectively (116).  
 
Early studies demonstrated that CT calcium scoring of the aortic valve can be used as 
an alternative marker of stenosis severity, demonstrating a good relationship with 
hemodynamic echocardiographic assessments (116-118). However until recently we 
lacked appropriate thresholds that might differentiate patients with and without 
severe aortic stenosis thereby limiting its utility (Table 1.1, (119) . Thresholds have 
been proposed as a consequence of a landmark series of papers published by Clavel 
and colleagues. Across three sites in Europe and North America they performed both 
echocardiography and CT calcium scoring in 646 patients with moderate or severe 
aortic stenosis and good left ventricular function. In those subjects in whom the 
severity of stenosis was not in doubt on echocardiography (n=460), the authors 
examined the optimal CT calcium score for differentiating moderate from severe 
aortic stenosis. Interestingly females required less calcium to develop severe 
hemodynamic stenosis than males (even after correcting for body surface area and 
the LVOT area calculated by echocardiography), so that the optimal thresholds were 
found to be 1275 AU in women and 2065 AU in men. These thresholds then 
appeared to serve as an ‘umpire test’ by independently adjudicating the severity of 
the stenosis when echocardiographic markers were discordant (42).  
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Table 1.1.  Studies attempting to define computed tomography calcium scoring 
thresholds for the diagnosis of severe aortic stenosis 
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AVA <1 cm  
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Abbreviations; CT-AVC, computed tomography aortic valve calcium score; Vmax, 
peak velocity; AVA, aortic valve area; MG, mean gradient; Sens, sensitivity; Spec, 
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Table 1.2  Studies using aortic valve computed tomography calcium scoring to predict 
outcomes.  
 
Pawade et al. JACC. 2014 (29)




Endpoint       Key Findings 











failure, or need 
for surgery 
• AVC independently predicted 
event-free survival, adjusted 
relative risk (RR) of 1.06 
(95% CI 1.02 to 1.10) per 
100-AU increment (P<0.001). 
• 5-year event free survival rate 
of 90±4% if AVC <500 AU 
versus 29±14%  if AVC ≥500 
AU (P<0.0001). 
 











• AVC strongest predictor of a 
major adverse clinical event 
(p < 0.001) among all 
parameters assessed (1,928 
+/- 789 versus 5,111 +/- 
2,409 Agatston units).  












• AVC predicted cardiac events  
(HR: 1.09, 95% CI: 1.04-1.15) 
per 100-AU increment  
• AVC Score ≥ median value of 
723 AU had associated with 
worse outcomes (p<0.0001). 





Mortality • Severe AVC defined as 
≥1,274 AU in women 
and ≥2,065 AU in men) was 
independent predictor of 
overall mortality ( HR: ≥1.58; 
p ≤ 0.04) p,0.0001) 
Abbreviations: AVR, aortic valve replacement; MI, myocardial infarction; AVC, aortic valve 
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More importantly the authors went on to demonstrate that, in a population of 794 
patients, these thresholds predicted all-cause mortality independent of all other 
markers of an adverse prognosis (120, 121). This included the standard 
haemodynamic parameters on echocardiography suggesting that CT can provide 
additional, complementary information to that obtained during routine clinical care, 
as had previously been hinted at by earlier studies (Table 1.2) (116, 122-124). An 
expanding body of literature has also demonstrated the ability of CT calcium scoring 
to predict disease progression in aortic stenosis.  Initial studies indicated that the 
aortic valve CT calcium score progresses fastest in patients with the highest baseline 
calcium burden (Figure 1.6) (125). Whilst the employment of CT calcium scoring in 
this way, holds great promise as a clinical tool, an important consideration is that 
these thresholds were derived from 3 expert aortic stenosis centres. Therefore their 
generalizability to a more heterogeneous population remains to be established. 
 








Increased calcium burden appears to translate in to more rapid disease progression as 
measured using computed tomography calcium scoring in patients with the most advanced 
forms of aortic stenosis (126). 
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1.8.3 Bicuspid Aortic Valves 
Before CT calcium scoring can be adopted into widespread clinical use, it is essential 
that its applicability within aortic stenosis subpopulations is understood. Shen et al 
demonstrated that whilst good correlations between CT calcium scores and mean 
aortic gradient were observed in patients with tricuspid valves (r=0.61, p<0.0001) 
this observed correlations were weaker in those aged ≥51 years with bicuspid aortic 
valves (r=0.55, p=0.009) and non-existant in those aged <51 with a bicuspid valve 
(127). Potential explanations for this are speculative and related to altered 
pathobiology. These findings warrant further investigation (128).  
 
In summary CT calcium scoring would appear to be a useful method for 
grading disease severity in aortic stenosis, offering powerful prediction of both 
disease progression and adverse clinical events. It is potentially complementary 
to standard echocardiographic assessments and may have some advantages, 
most notably that it is not dependent on cardiac loading conditions, geometric 
assumptions nor the presence of other cardiovascular conditions such as mitral 
regurgitation and hypertension. This technique needs to be validated prior to 
clinical application, with a better understanding of its utility in aortic 
subpopulations. 
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1.9 POTENTIAL NOVEL DISEASE MODIFYING THERAPIES 
As our understanding of the pathophysiology of aortic stenosis has improved, the key role 
that calcification plays in driving disease progression has led us away from targeting 
inflammation and lipid deposition, and towards therapies capable of directly halting valve 
calcification (129). How might this be achieved? The close association between disorders of 
skeletal bone metabolism and increased calcification in the vasculature offers a potential 
starting point. Indeed a growing body of pre-clinical and clinical data indicates that 
treatments for osteoporosis, such as bisphosphonates and denosumab, can reduce vascular 
calcification and that these agents hold considerable promise as novel therapies for aortic 
stenosis (130).  
1.9.1 Bisphosphonates 
Bisphosphonates are inhibitors of osteoclast-mediated bone resorption, are well tolerated in 
the elderly and have been widely used for the treatment of osteoporosis (131). Interestingly 
bisphosphonates also have important cardiovascular effects, demonstrating a consistent 
reduction in calcification of the vasculature and the aortic valve (130, 132, 133). This in part 
appears to be a consequence of their inhibition of bone resorption, which results in reduced 
release of calcium and phosphate into the circulation and therefore the systemic availability 
of these pro-calcific substances (130). However bisphosphonates also appear to exert direct 
anti-calcific effects on the aortic valve tissue itself.  For example, they reduce the production 
of interleukin-1β, interleukin-6 and tumour necrosis factor-α (key inflammatory cytokines 
implicated in the early stages of aortic stenosis (134)) and inhibit the secretion of matrix 
metalloproteinases 2 and 9, which remodel the valve as aortic stenosis progresses (135, 136). 
Moreover nitrogen containing bisphosphonates act as inorganic pyrophosphate (PPi) 
analogues (62), which as discussed have powerful anti-calcific properties in the vasculature. 
Finally bisphosphonates attenuate the differentiation of aortic valve myofibroblasts into cells 
with an osteogenic phenotype (137), the key step in triggering the propagation phase of 
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aortic stenosis (129). In combination, these data offer support for bisphosphonates as a 
treatment strategy for aortic stenosis that is increasingly being supported by observational 
clinical data. A recent analysis of 3,710 women in the Multi-Ethnic Study of Atherosclerosis 
(MESA) indicated that bisphosphonate use was associated with less valvular and vascular 
calcification in older women  (users versus non-users: aortic valve ring calcium 38 versus 
59%, P<0.0001) (138). Other studies appear to support these findings with a direct beneficial 
effect of these drugs on echocardiographic measures of aortic stenosis progression (139-141) 
as well as reducing valvular calcification in patients with renal failure and amongst those 
with bioprosthetic valves (130, 142). Whilst encouraging, such retrospective, observational 
studies are prone to bias, cannot assess cause-and-effect, have provided conflicting results 
(143) and are confounded by the underlying effects of the osteoporosis for which these 
agents were prescribed. Indeed the true impact of bisphosphonates in aortic stenosis will 
only become clear within the context of a randomised controlled trial (144).  
1.9.2 Denosumab 
As discussed the OPG/RANK/RANKL axis appears to play a pivotal role in aortic valve 
calcification and may provide an explanation for the link between osteoporosis and increased 
vascular calcification. It therefore represents an attractive therapeutic target for reducing 
vascular calcification. Denosumab is a human monoclonal antibody to RANKL that prevents 
its binding to RANK thereby recapitulating the actions of OPG. In a trial of 7,868 post-
menopausal women with osteoporosis, denosumab increased bone mineral density and 
reduced vertebral fracture rates by 68% over a 3-year period (145). Importantly, denosumab 
was extremely well tolerated with very few adverse side effects and no major excess in 
adverse events. Given the central regulatory role that the OPG/RANK/RANKL system has 
in vascular and aortic valve calcification, denosumab also holds considerable promise as a 
novel treatment for aortic stenosis. Again this is supported by pre-clinical data, with 
denosumab halving the aortic calcification observed in a murine model of osteoporosis 
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(146). Interestingly in the same study, this reduction was closely associated with inhibited 
bone resorption from the skeleton, indicating that the cardiovascular effects of denosumab 
are, like bisphosphonates, in part related to reduced calcium and phosphate release from 
bone into the circulation.  
1.10 CONCLUSION 
Aortic stenosis is a common condition that is set to become an increasing health care burden.  
We lack effective medical therapies capable of slowing its relentless progression towards 
major surgery or adverse events. Recent insights into the pathophysiology of aortic stenosis 
have indicated that whilst lipid and inflammation may be important in establishing the 
disease (initiation phase), it is the self-perpetuating processes of calcification that are 
predominantly responsible for driving disease progression (propagation phase). On this 
basis, imaging modalities capable of quantifying aortic valve calcification will be best placed 
to predict its natural history, whilst novel anti-calcific therapies hold major promise as 
methods of treatment. Randomised controlled trials of such agents, perhaps using imaging 
end-points such as CT calcium scoring and 18F-fluoride PET activity, are required to 
establish their early efficacy.  
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The pathogenesis of aortic stenosis can be thought of in two stages: initiation and 
propagation. These can be imaged using 18F-Fluoride PET (newly developing micro-
calcification) and CT calcium scoring (macroscopic calcific deposits). Given the central role 
of calcification in the propagation phase of aortic stenosis it is perhaps unsurprising that 
these provide important information with respect to prognosis and disease progression. 
Moreover calcification represents an important potential therapeutic target using drugs such 
as denosumab and bisphosphonates to interrupt the vicious cycle of calcification that drives 
progressive narrowing of the valve.  
 
 
Pawade et al. JACC. 2014 (29)
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1.11 AIMS AND OBJECTIVES 
The overarching aim of this thesis was to evaluate and optimise the use of 
complementary calcification imaging techniques for the study and management of 
aortic stenosis.  
 
In particular I sought to achieve the following aims: 
 
1. Refine current methods of 18F-fluoride PET-CT image acquisition and analysis 
in the study of aortic stenosis to improve image quality and scan reproducibility. 
Chapter 3 
2. Determine the reproducibility of CT calcium scoring of the aortic valve. 
Chapter 4 
3. Describe the relationship between CT-AVC measurements and 
echocardiographic measurements of disease severity. 
Chapters 4 and 5 
4. Determine the ability of CT-AVC measurements to predict disease progression. 
Chapter 4 
5. Derive our own optimum sex-specific CT-AVC thresholds and examine their 
clinical performance in comparison to those previously published. 
Chapter 5 
6. Determine the accuracy and clinical significance of CT-AVC measurements and 
continuity equation-derived estimates of disease severity in patients with 
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1.12 HYPOTHESES 
I sought to address the following hypotheses 
1. Current techniques of 18F-fluoride PET imaging of the calcific aortic valve 
can be modified to enhance image quality whilst improving scan 
reproducibility. 
2. The scan reproducibility of CT calcium scoring will be within acceptable 
limits for clinical application. 
3. Baseline CT-AVC measurements will correlate with disease severity, predict 
disease progression and clinical events. 
4. Sex-specific CT-AVC thresholds can be used as an umpire test to arbitrate 
disease severity in patients with discordant echocardiographic measurements. 
5. In patients with bicuspid aortic valves, CT-AVC scoring may not be a 
suitable umpire test. 
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Chapter 2: METHODS 
2. 1 STUDY POPULATIONS 
Study populations are described in detail in their respective chapters but 
predominantly consisted of patients recruited into two aortic stenosis clinical studies 
conducted at the Edinburgh heart centre; Saltire 2 and the Ring of Fire.  
 
Saltire 2 is a prospective, double-blinded, randomised, placebo-controlled clinical 
trial investigating the ability of the calcium modulators denosumab and alendronic 
acid to modify disease progression in aortic stenosis (Appendix 1). I am the principle 
investigator and was therefore responsible for writing the protocol, acquiring 
appropriate authorisations, recruiting patients, organising and conducting study 
visits, collecting data and performing image analysis (with the exception of the 
echocardiograms). The primary endpoint is the computed tomography aortic valve 
calcium score (CT-AVC) at 2 years and an exploratory secondary endpoint is 18F-
Fluoride positron emission tomography CT (PET-CT) uptake of the aortic valve at 1 
year. Before 18F-Fluoride PET could be reliably employed as an imaging endpoint, a 
substudy was first performed to optimise and assess scan reproducibility in aortic 
stenosis (chapter 3).  
 
The Ring of Fire is a prospective clinical study which was conducted by Dr Marc 
Dweck and Dr William Jenkins. It investigated the ability of 18F-Fluoride PET-CT 
and CT-AVC scoring to measure disease severity, predict disease progression and 
adverse clinical events. The data on 18F-Fluoride PET has been published and is 
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therefore not explored further (147, 148). Instead however, within chapter 4 of this 
thesis, the calcium scoring data is examined in detail. Baseline data from both trials 
(subject to inclusion criteria) were pooled with that from other international centres 
to create the aortic stenosis registries used for chapters 5 and 6. The conduct of the 
baseline visits for both studies are identical and detailed below. 
2.1.1 Ethical Considerations 
Both studies were approved by the research and development department at the 
University of Edinburgh, the South-East Scotland ethics committee and the 
Administration of Radioactive Substances Advisory Committee (ARSAC). Saltire 2 
is a clinical trial of an investigative medicinal product (CTIMP) and was therefore 
also approved by the Medicines Healthcare products and Regulatory Authority 
(MHRA). Both studies are also registered on the clinicaltrials.gov website (Saltire 2, 
NCT01358513; Ring of Fire, NCT02132026). Study conduct was overseen by the 
sponsors at the university of Edinburgh. 
2.1.2 Recruitment 
Patients with aortic stenosis who attended the cardiology outpatients at the 
Edinburgh Royal Infirmary were first approached by their usual care team. Those 
who agreed to be contacted by the research team were issued with an approved 
patient information sheet prior to their first study visit.  
2.1.3 Study Visits 
All visits were performed at the clinical research facility (CRF) at the University of 
Edinburgh. Patients were first required to sign a consent form. Anonymised patient 
data was entered into case record forms and study visits were also documented in the 
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clinical notes. Demographics, specifically the date of birth, gender and ethnicity were 
first recorded. Patients were then asked about symptoms of breathlessness, exertional 
chest pains and syncope. Breathlessness and angina were graded using the New York 
Heart Association (NYHA) and Canadian Cardiovascular Society scores 
respectively. The past medical history was documented using a combination of 
patient interview, electronic records and clinical notes. Comorbidities of particular 
interest included a confirmed diagnosis of hypertension, hypercholesterolaemia, 
diabetes, renal disease, angina, previous coronary artery bypass grafting, previous 
percutaneous coronary intervention, smoking status, cerebrovascular disease and 
current or past malignancies. All of the current medications including indication, 
dose, method of administration and start dates were also recorded.  
2.1.4 Clinical Examination 
The height and weight were recorded for each patient, from which the body mass 
index and body surface area were calculated. Sphygmanometry was used to 
determine the blood pressure and heart rate. All patients underwent a standardized 
cardiovascular examination in a semi-recumbent position, with the torso at 45 
degrees. Specific examination was made of the pulse rate and rhythm, the jugular 
venous pressure and fluid status. The heart sounds were auscultated for murmurs and 
lung fields for inspiratory crackles.  
2.1.5 Electrocardiogram 
All patients underwent a 12-lead electrocardiogram (ECG) which was examined 
immediately for features of ischaemia, arrhythmia, conduction disease, left 
ventricular hypertrophy and strain. Left ventricular hypertrophy was diagnosed using 
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two criteria; the Sokolow-Lyon criteria (the sum of the S wave in V1 and R wave in 
V5 or V6 ≥35mm) or the Modified Cornell Criteria (R wave in aVL ≥12 mm). Left 
ventricular strain was defined as asymmetric T wave inversion and ST segment 
depression in the anterolateral leads (149).  
2.1.6 Venesection 
At each visit, a cannula was inserted if required and up to 40 mL of blood was 
subsequently withdrawn. These were routinely tested for full blood count, renal and 
liver function, electrolytes, glucose and cholesterol. Serum and plasma samples were 
also spun and stored for future use. 
2.2 ECHOCARDIOGRAPHY 
Echocardiography employs ultrasound technology to obtain detailed information 
about cardiac structure and function. It was first pioneered by the Swedish physician 
Dr Edler in 1953 and after substantial refinement, is now the cornerstone of cardiac 
imaging and the gold-standard clinical tool for the diagnosis, grading and monitoring 
of aortic stenosis (150, 151). 
2.2.1 Image acquisition and Analysis  
Echocardiography was performed by a single experienced echocardiographer 
(Audrey White) using a pre-specified protocol according to European Society of 
Echocardiography guidelines (151). For each study the same machine (Phillips 
Affinity 70 Ultrasound System), room and bed were used to ensure consistency of 
approach. Patients were asked to undress from the waist up and issued with a gown if 
necessary. Scans were performed with patients in the left lateral and supine positions. 
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For each patient, images were acquired in the parasternal long and short-axis views, 
apical 4 and 5-chamber views, subcostal and suprasternal views. Measurements were 
made of left and right ventricular dimensions, atrial size, left ventricular outflow tract 
diameter and aortic root dimensions. Right ventricular size was assessed visually in 
respect to the left ventricle and function was assessed using tricuspid annular plane 
systolic excursion (TAPSE).  Left ventricular function was estimated using a 
combination of visual assessment and where possible confirmed using Simpson’s 
biplane measurements. Detailed diastolic assessments were also performed using 
mitral valve pulsed wave and tissue doppler. All valves were examined by using a 
combination of visual assessment, colour flow, continuous wave and pulsed wave 
Doppler. If possible an assessment was made of pulmonary artery systolic pressure 
and any additional abnormalities including pericardial effusions. 
 
Aortic stenosis severity was assessed based on the European Society of 
Echocardiography Guidelines (152)Figure 2.1). A semi-quantitative calcification 
score was assigned as previously published by Rosenhek at al; 1, no calcification;  2, 
mildly calcified with small isolated spots; 3,  moderate calcified with multiple larger 
spots and 4, heavily calcified with extensive thickening and calcification of all cusps 
(15). Pulsed wave and continuous wave doppler were used to determine aortic 
stenosis severity with measurements taken of the peak transvalvular velocity and 
mean gradient. The aortic valve area was calculated using the continuity equation. 
The continuous wave doppler measurements were then subsequently repeated using 
the pencil probe at the apex, suprasternal notch and right sternal edge. For patients in 
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sinus rhythm the average of 3 measurements were then used, this was increased to 5 
for those in atrial fibrillation.  
 
With respect to discerning aortic valve severity, echocardiography was previously 
shown to have good scan-rescan reproducibility (153) in 20 patients (mean peak 
velocity 3.47±0.78 m/s) who underwent repeated echocardiography at 3 weeks 
(mean difference = 0±0.28 m/s, reproducibility coefficient = 0.56, (153). 



























Aortic valve structure, function and calcification score were assessed in the parasternal long 
(top left) and short axis (bottom left) views. Doppler studies (right) facilitate automated 
calculation of the peak velocity (Vmax), mean pressure gradient (Mean PG) and peak 
pressure gradient (Max PG).   
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2.3 POSITRON EMISSION TOMOGRAPHY 
 
Positron emission tomography (PET) refers to the creation of digital images that 
depict the bodily distribution of a positron emitting radiotracer. PET is used to study 
the activity of biological processes and is usually performed in combination with 
imaging modalities capable of providing anatomical detail. Subject to the availability 
of a suitable radiotracer, any biological process can theoretically be studied in vivo 
using this technique. All patients recruited into Saltire 2 or the Ring of Fire studies 
underwent 18F-fluoride PET-CT scanning. 
 
18F-Fluoride is a bone-seeking radionuclide with a half-life of 110 minutes, which is 
created within a cyclotron by the bombardment of 18-Oxygen enriched water with 
protons. After coming into contact with the calcifying aortic valve, 18F-fluoride 
rapidly exchanges for OH on the surface of the hydroxyapatite matrix 
(Ca10(PO4)6OH2) to form fluoroapatite (Ca10(PO4)6F2) (154). In this way it can 
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The nucleus of the fluoride ion decays by emitting a positron (1), a subatomic particle which 
has the same mass as an electron but an opposite charge. Within tissues, an emitted 
positron collides with an electron resulting in an annihilation reaction (2), the by-product of 
which is two photons. These emitted photons then travel with an energy of 511 keV at 
exactly 180 degrees of each other (3). This coincident activity is sensed by pair of PET 
detectors which convert the light signal into an electronic signal. Two electronic pulses 
detected in coincidence confirms the presence of an annihilation signal somewhere along 
the line of response. This data is converted into a series of sinograms for each projection 
angle (4). Iterative reconstruction algorithms are then applied, to reduce the signal to noise 
ratio and facilitate the calculation of standardised uptake values for each voxel as follows 
standardized uptake value = radioactivity concentration/(injected dose/body mass). Digital 
PET images are created (5) which are subsequently fused with the co-acquired computer 
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2.3.1 Image acquisition 
The radiotracer 18F-Fluoride was synthesised by the radiochemistry department at 
the Clinical Research Imaging Centre (CRIC) at the University of Edinburgh on the 
morning of scan days and underwent immediate quality assurance checks. Patients 
were transferred to lead lined uptake rooms and given 25-50 mg of oral metoprolol if 
their resting heart rate was >65 beats/min provided there were no contra-indications. 
Patients were administered 125 MBq of 18F-fluoride flushed with 10 mL of normal 
saline intravenously, before being required to rest for 60 minutes. Dynamic imaging 
has previously confirmed that 60 minutes after injection is time point at which 
optimal contrast between plasma and vascular tissues is observed (155). Prior to the 
scan all patients were requested to empty their bladder. 
 
Imaging was performed using a hybrid PET and CT scanner (128-multidetector 
scanner (Biograph mCT Siemens). Images were acquired with patients lying supine 
and where possible with arms raised. ECG electrodes were attached to the patients to 
facilitate gating. Attenuation-correction CT scans were first performed (non-
enhanced, 120 kV and 50 mA, slice thickness 5mm, increment 3mm). Acquisition of 
PET data was then performed with in list mode using a single 30-min bed position 
centred on the valve in three-dimensional mode.  
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2.3.2 Image analysis 
 
PET-CT analysis was performed using an OsiriX workstation (OsiriX version 3.5.1 
64-bit; OsiriX Imaging Software, Geneva, Switzerland).  Non-contrast CT images of 
the aortic valve were first re-orientated and reconstructed to create planar images of 
the valve at 3 mm slice thickness (Figure 2.3).  



















Non-contrast computer tomography images were reoriented in the coronal (far left) and 
sagittal (far right) planes to create planar view of the aortic valve (centre). These were then 
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Regions of interest were drawn around the perimeter of the valve on the fused non-
gated PET and non-contrast CT images (104) Figure 2.4). These generated mean and 
maximum standard uptake values (SUV) for each slice. Averaging these values 
across the entire valve produced whole-valve SUVmean and SUVmax values 
respectively. These SUV values were then corrected for blood pool activity to 
generate respective tissue-to-background ratios (TBR): whole-valve TBRmean and 
whole-vale TBRmax. The blood pool uptake was determined using SUVmean values 
averaged from across ROIs drawn on 5 contiguous slices in the brachiocephalic vein. 
For consistency the most caudal ROI was positioned at the point where the 
innominate vein joined the brachiocephalic vein (104). The scan-rescan 
reproducibility of 18F-fluoride PET in the aortic forms the subject matter of chapter 
3. 18F-Fluorodeoxyglucose in the study of macrophage driven inflammation of 
carotid plaques has been shown to have excellent scan-rescan reproducibility with 
intraclass correlation coefficients of 0.9 (0.7-0.97) (156). 
Figure 2.4 18F-Fluoride positron emission tomography computed tomography 
analysis.  
 
Reconstructed, planar non-contrast images of aortic valve (A)  were fused with the ungated 
PET (B). Regions of interest were drawn around the perimeter of the valve (C), which 
automatically generated mean and maximum standard uptake values (SUV). This was 
repeated for each slice for the length of the valve. 
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2.4 COMPUTER TOMOGRAPHY AORTIC VALVE CALCIUM SCORING  
CT creates cross-sectional images of the body and works on the principle that 
different tissues can be distinguished by their relative ability to absorb photons 
(attenuation coefficients). Typical CT images are composed of 512 rows, each of 512 
pixels, which are multiplied by the slice width to create voxels. Calculating the 
attenuation coefficient for each voxel facilitates the creation of digital images. 
Attenuation coefficients are converted to the Hounsfield scale, expressed in 
Hounsfield units (HU). Calcification is defined on this scale as a hyperattenuated 
lesion of ≥130 HU with an area of 3-4 adjacent pixels. This can be quantified by 
applying an arbitrary weighted density score to calcification as follows; 1 = 130 to 
199 HU; 2 = 200 to 299 HU; 3 = 300 to 399 HU and 4 ≥ 400 HU. The density factor 
is multiplied by the area (mm3) to generate a calcium score in Agatston units (AU). 
2.4.1 Image acquisition 
All patients underwent an ECG-gated, non-contrast CT scans gated from 75% to 
80% of the R-R during held expiration using a, 40 mA/rot [CareDose], 120 kV). 
Images were reconstructed in the axial plane with 3 mm slice width and 1.5 mm 
increment. In the Saltire 2 study, ECG-gated contrast-enhanced CT angiography 
were also performed in diastole and in held expiration. Patients were then observed 
for 5 minutes to ensure that there were no contrast reactions before their cannula was 
removed and they were shown out of the department. 
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2.4.2 Image analysis  
Valvular calcification was quantified using dedicated analysis software (Vitrea 
Advanced, Vital Images, Minnetonka, USA, Supplementary) in the axial plane 
starting at the base of the valve (Figure 2.5).  Care was taken to exclude calcium 
from extra-valvular structures such as the mitral valve annulus and coronary arteries. 
When confluent calcium extended into the ascending aorta, the origin of the left 
coronary artery was set as the most rostral slice beyond which further calcium was 
excluded.  The aortic valve calcium burden was expressed as the CT-AVC (Agatston 
Units, AU), corrected for the LVOT area (as measured using echocardiography) to 
generate the CT-AVC density (CT AVCd, AU/cm2) and the body surface area to 
create the CT-AVC index (CT AVCi, AU/m2). The CT calcium volume was also 
recorded. 
 
The scan-rescan reproducibility of CT-AVC measurement using the Agatston score 
is unknown, however reproducibility of the calcium volume technique is excellent 
(correlation coefficient r=0.99, median interscan variability 7.9%, repeatability 
coefficient 237.8 mm3, limits of agreement −393 to 559 mm3).  Proportional bias is 
evident whereby higher calcium scores have worse rescan differences (157). 
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Figure 2.5 Computed tomography aortic valve calcium scoring.  
 
 
Computed Tomography calcium scoring performed on contiguous slices of the aortic valve in 
the axial plane.  Examples from patients with mild (A) and severe (B) aortic stenosis are 
shown.  All calcium is highlighted in pink.  Contours are then drawn around calcium in the 
aortic valve, which then turns yellow once selected.  Automated software calculates the 
density factor for each pixel before multiplying by the area (mm3) to generate an overall 
score in Agatston Units. A calcium volume (mm3) is also given. 
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2.4.3. Safety issues. 
All CT scans were supervised by a medical practitioner. Where possible, CT 
angiography images were acquired with prospective gating to minimise radiation 
exposure. The total dose received by a patient for a given scan (including injected 
doses, and dose-length product) were recorded and reviewed periodically by the 
medical physics department. All scans were reported by a consultant radiologist and 
incidental findings were acted upon as appropriate. 
2.5 STATISTICAL ANALYSIS. 
The majority of the statistical analyses within this thesis was performed by myself, 
using SPSS statistics (IBM, version 21) and graphpad Prism (Graphpad Software). 
Continuous variables were expressed as mean ± standard deviation or median 
[interquartile range (IQR)] as appropriate. CT-AVC data underwent square-root 
transformation to achieve normality (AU). Categorical data were presented as 
number and percentage.  Correlations between continuous variables were assessed 
with linear regression analysis and either Pearson’s r or Spearman’s Rho subject to 
the normality of the variables tested. Parametric (unpaired Student’s t-test) and non-
parametric (Mann-Whitney U) tests were used as appropriate. Reproducibility 
studies were performed using Bland-Altman analyses. Outcome variables were 
assessed using Kaplan-Meier curves and cox proportional hazards regression 
analyses. Two-sided significance was taken as p<0.05. Statistical support was also 
provided by Dr Anoop Shah and the dedicated trial statisticians for Saltire 2,  Dr 
Sharon Tuck and Dr Catriona Graham.  
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Objective  
18F-Fluoride positron emission tomography (PET) and computed tomography (CT) 
can measure disease activity and progression in aortic stenosis. Our objectives were 
to optimize the methodology, analysis and scan-rescan reproducibility of aortic valve 
18F-fluoride PET-CT imaging.  
 
Methods and Results 
Fifteen patients with aortic stenosis underwent repeated 18F-fluoride PET-CT. We 
compared non-gated PET and non-contrast CT, with a modified approach that 
incorporated contrast CT and ECG-gated PET. We explored a range of image 
analysis techniques including estimation of blood-pool activity at differing vascular 
sites and a most-diseased segment (MDS) approach.   
 
Contrast-enhanced ECG-gated PET-CT permitted localization of 18F-fluoride uptake 
to individual valve leaflets. Uptake was most commonly observed at sites of 
maximal mechanical stress: the leaflet tips and the commissures.  Scan-rescan 
reproducibility was markedly improved using enhanced analysis techniques leading 
to a reduction in percentage error from ±63% to ±10% (tissue-to-background ratio 
MDS mean of 1.55, bias -0.05, limits of agreement -0·20 to +0·11).  
 
Conclusion 
Optimized 18F-fluoride PET-CT allows reproducible localization of calcification 
activity to different regions of the aortic valve leaflet and commonly to areas of 
increased mechanical stress. This technique holds major promise in improving our 
understanding of the pathophysiology of aortic stenosis and as a biomarker end-point 
in clinical trials of novel therapies.   
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3.1 INTRODUCTION 
Aortic stenosis is the most common form of valve disease in the western world and a 
major health care burden that is set to treble by 2050. However we currently lack any 
disease-modifying therapies. Calcification appears to be the predominant 
pathological process driving disease progression leading to major interest in novel 
treatment strategies aimed at reducing calcification activity in the valve (29). 
However assessing the efficacy of new therapies requires large trials with prolonged 
follow-up to demonstrate an impact on disease progression and clinical end-points 
(11). A non-invasive imaging technique capable of measuring calcification activity 
in the valve would be highly desirable to assess treatment efficacy in phase 2 clinical 
trials.  
 
18F-Fluoride is a positron-emitting radiotracer that binds to regions of newly 
developing microcalcification beyond the resolution of computed tomography (155).  
18F-Fluoride is readily taken up by the valves of patients with aortic stenosis and on 
histology, correlates with markers of calcification activity (147). Importantly this 
technique predicts disease progression both with respect to echocardiography and CT 
calcium scoring as well as adverse cardiovascular events (104, 110, 112).  18F-
Fluoride positron emission tomography (PET) imaging therefore holds major 
promise as a marker of calcification activity in aortic stenosis and is an exploratory 
secondary end-point in the on-going Saltire 2 clinical trial. 
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Here, we sought to optimize 18F-fluoride PET scanning of the aortic valve, reduce 
the effects of cardiac motion and assess the scan-rescan reproducibility of this 
technique to assess its future application as a novel biomarker of calcification 
activity in clinical trials.  
3.2 METHODS 
3.2.1 Study Population 
Patients aged over 50 years with mild, moderate and severe calcific aortic stenosis 
were recruited prospectively from outpatient clinics at the Edinburgh Heart Centre.  
Aortic stenosis severity was determined by clinical echocardiograms and graded 
according to according to European Society of Cardiology guidelines (152). Since 
this is a sub-study of the ongoing Saltire 2 clinical trial, patients were required to 
fulfil the same inclusion and exclusion criteria as those entering the main trial.  
These included renal failure and women of childbearing potential (full list in 
Appendix 1).   
3.2.3 Initial Image acquisition  
Each patient underwent 18F-fluoride positron emission tomography (PET) and 
computed tomography (CT) scanning on two occasions.  The imaging protocol is 
described in chapter 2. 
3.2.4 Initial image analysis 
This was performed as described in Chapter 2. To optimize the spatial localization 
and scan-rescan reproducibility of 18F-fluoride PET-CT imaging, we assessed 
different approaches to both image acquisition and image analysis.  
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3.2.5 Optimisation of 18F-Fluoride PET image acquisition: Contrast CT  
Our original technique required the reorientation and co-registration of non-contrast 
CT images of the aortic valve (Figures 2.3 and 2.4). This technique posed several 
challenges, particularly with respect to aligning with the true plane of the valve and 
accurately defining its perimeter. Moreover the structure of individual leaflets was 
not visible on these scans precluding more detailed localization of 18F-fluoride 
uptake. Contrast CT offered potential solutions to these challenges given its superior 
anatomical detail and the well-established methodology for finding the true plane of 
the valve (158) Figure 3.1). 
3.2.6 Optimisation of 18F-Fluoride PET image acquisition: ECG-Gated PET Data 
PET is susceptible to motion, limiting accurate co-registration and the spatial 
assessment of PET activity within the valve. As a solution, we employed 
electrocardiogram (ECG) gating of list mode PET data. These data were 
reconstructed into 4 gates at 25% intervals of the cardiac cycle. Only data acquired 
between 50 and 75% of the RR interval were assessed because this period 
corresponds with diastole when cardiac motion is at a minimum. Given that three 
quarters of the PET data are therefore discarded, the bedtime was increased to 30 
min in order to preserve signal-to-noise.  
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Figure 3.1 Creation of co-registered planar images of the aortic valve 
  
 
Creation of planar en-face valve images using CT angiography was achieved as follows. 
First, the CT angiogram is re-orientated to get into the approximate plane of the aortic valve 
by lining up the axial cross hair (purple in this example) using the images in the coronal (a) 
and sagittal planes (c).  This creates an approximate cross sectional image of the aortic 
valve in the axial frame (b).  Scrolling down in the axial frame, the centre of the crosshairs is 
then placed over the exact point at which the right coronary cusp disappears, identifying the 
base of that leaflet (d). Similarly the base of the non-coronary cusp is identified and 
orthogonal planes adjusted so that the purple plane goes through the base of both these two 
cusps (d). Finally the base of the left coronary cusp is found by rotation of the axial cross 
hairs so that first the cusp comes into view. The image is then slowly rotated in the opposite 
direction until the point where the leaflet first disappears (the base) is again found (f). This 
produces an en face image of the valve aligned with the base of all three leaflets (g). 
Adjacent 3-mm slices are then created in that plane and used for subsequent assessment. 
These slices are fused with the 18F-Fluoride PET images (h) and careful co-registration 
performed in 3-dimensions to ensure accurate alignment between the PET and CT images 
(i). 
                Pawade et al.Circ Cardiovas Imaging. 2016 (159) 
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3.2.7 Optimisation of 18F-fluoride PET image analysis: Measurement Of Blood 
Pool Activity 
The stability of blood pool measurements in the SVC for 18F-fluoride based tracers 
has recently been questioned (160) and we were concerned about variation in the 
measured blood-pool activity at different levels of the brachiocephalic vein.  We 
reasoned that this may be explained by the relatively small diameter of this vein 
rendering it susceptible to partial volume effects, amplified by the very low PET 
signal in surrounding lung tissue (especially in the cranial aspects of the 
brachocephalic vein). We hypothesized that sampling blood-pool activity from the 
center of the right atrium (a much larger structure) may improve the ease and 
accuracy with which these measurements could be made and the consequent scan-
rescan reproducibility. Using the same co-registered PET and CT images of the 
heart, re-orientated to the plane of the valve, a 2-cm2 ROI was drawn in the center of 
the right atrium at the level of the right coronary ostium and again in the same 
position one slice superiorly.  Averaging the mean SUV for these two slices gave an 
alternative measure of blood-pool activity, which was used to correct valvular uptake 
measurements using two different approaches. First we used the conventional 
method of dividing aortic valve SUV measurements by the blood-pool to generate 
TBR values. Secondly we subtracted the blood-pool value from the valvular uptake, 
to generate the corrected aortic valve SUV (cSUV) as described recently (160).  
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3.2.8 Optimisation of 18F-fluoride PET image analysis: Most -diseased Segment 
and Whole Valve Approach 
One of the biggest difficulties in quantifying uptake in the valve is defining its limits 
in the z-plane. To overcome this challenge, our original whole valve technique was 
compared to a ‘most-diseased segment’ (MDS) approach where the two contiguous 
slices with the highest SUV values (frequently in the center of the valve) were 
averaged to generate SUVMDSmean, SUVMDSmax and corresponding TBR values. This 
is similar to the approach previously used for quantifying 18F-fluorodoexyglucose 
uptake in carotid and aortic atheroma (161)  
3.2.9 Scan-rescan reproducibility 
Scan-rescan repeatability and intra-and inter-observer reproducibility of valvular 
18F-fluoride PET quantification was assessed for each of the established and novel 
image analysis approaches described above. Two experienced operators (Tania 
Pawade and Timothy Cartlidge) quantified uptake values on each of the scan-pairs, 
on two occasions separated by a 2-week interval to avoid recall bias.  Observers were 
blinded to both their own previous measurements and those of the other operator.  
3.2.10 Spatial localisation 
The effect of our modifications on spatial resolution and scan-rescan reproducibility 
were then assessed in comparison with the original approach. First we assessed the 
ability of the technique to localize increased 18F-fluoride activity to individual valve 
leaflets and their different regions. Windowing of the fused PET/CT images was 
performed largely visually although a standardized method incorporated using 2 
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standard deviations of the blood pool activity in RA as the minimum. Scan-rescan 
and observer agreements were assessed.  
3.2.11 Statistical Analysis 
Continuous variables were expressed as mean ± standard deviation and categorical 
variables were expressed as total and percentage.  Kappa statistics (with 95% 
confidence intervals) were used to measure the intra-observer and scan-rescan 
agreement in presence or absence of 18F-fluoride uptake across coronary cusps.  The 
kappa values were interpreted as follows: poor <0.20, fair 0.21-0.4, moderate 0.41-
0.60, good 0.61-0.80 and very good >0.81. 
 
Intra-observer, inter-observer and scan-rescan reproducibility of several 18F-fluoride 
PET uptake approaches were analysed and presented using Bland-Altman analysis 
and percentage error (162).  Variability in the different techniques was expressed 
using the width of the 95% limits of agreement (LOA) from Bland-Altman analyses.  
For the final approach, we considered the scan re-scan reproducibility to be good and 
acceptable for use in our future trial if the width of the 95% LOA were within ±0.2 
for the TBRMDSmean measurements. Percentage errors for the mean bias were 
calculated using twice the standard deviation of the difference divided by the overall 
mean measurements. The intraclass correlation coefficient (ICC) was used to 
examine the reliability for both intra and inter-observer variability. Statistical 
analysis was performed using SAS for Windows version 9.4. Graphs were produced 
using PRISM version 6.0 for Mac. 
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3.3 RESULTS 
3.3.1 Patient Characteristics 
Fifteen patients (73±7 years, 67% male) had 2 scans (Table 3.1), 3.9 ±3.3 weeks 
apart between November 2014 and May 2015.  Seven patients had mild aortic 
stenosis, 4 had moderate and 4 had severe aortic stenosis. In three participants, the 
between scan interval exceeded 4 weeks (5 weeks, 8 weeks and 14 weeks). The dose 
of 18F-fluoride was similar on each visit (123±8 and 125±4 MBq, P=0·49). The 
mean total dose was 29 mSv (range of 12.4 – 47.6 mSv).  
  
                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
80 
Table 3.1 Patient Characteristics 
   
DEMOGRAPHICS Age (years) 73.3 ± 7.4 
 Male 10 (67 %) 
VITAL SIGNS Body Mass Index (kg/m2)*    29.7 ± 5.6 
 Pulse (beats/min)* 67.7 ± 15.5 
 Body Surface Area (m2)* 1.9 ± 0.2 
 Mean Arterial Pressure (mmHg)* 100.1 ± 9.3 
 Current Smoker                  1 (7%) 
 Ex smoker 5 (33%) 
SYMPTOMS Chest Pain 4 (27%) 
 Breathlessness 7 (47%) 
 Syncope 2 (13%) 
RELEVANT MEDICAL HISTORY Hypertension 11 (73%) 
 Previous CABG 2 (13%) 
 Previous PCI 4 (27%) 
 Liver Disease 1 (7%) 
 Rheumatic Fever 0 (0%) 
 Previous myocardial infarction 3 (20%) 
 Hypercholesterolemia  10 (67%) 
 Diabetes 4 (27%) 
 Renal Disease  0 (0%) 
 Cerebrovascular disease  2 (13%) 
CONCOMITANT MEDICATIONS Angiotensin Converting Enzyme 
Inhibitor 
6 (40%) 
 ARIIB 3 (20%) 
 Beta Blocker 7 (47%) 
 Statin 9 (60%) 
SCAN INTERVAL Weeks 3.9 ± 3.3 
Abbreviations: CABG, coronary artery bypass grafting; PCI, percutaneous coronary 
intervention; eGFR, estimated glomerular filtration rate; ARIIB, Angiotensin two 
receptor blocker. 
 
Pawade et al.Circ Cardiovas Imaging. 2016 (159) 
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3.3.2 Altered PET acquisition and Image Quality. 
Good image quality allowing complete image analysis was achieved on all 15 scan-
pairs.  The prolonged bed-times of 30 min did not result in increased patient motion 
during the 18F-Fluoride PET scans.  The impact of each stepwise change in the 
acquisition and analysis protocol on scan-rescan reproducibility is summarized in 
Table 3.2.  
 
On visual assessment contrast CT imaging of the valve provided much clearer 
anatomical detail of the leaflets and valve structure compared to non-contrast CT 
This made it technically easier to get into the true plane of the valve and allowed 
more accurate regions of interest to be drawn around its perimeter.  Co-registration 
with ECG-gated PET data then allowed localization of 18F-fluoride uptake to 
individual leaflets and their different regions. This was previously impossible using 
non-contrast CT and non-gated PET (Figure 3.3). 
 
Activity was most frequently observed at the valve commissures: the point where the 
valve cusps meet the aortic ring [n=10] and at the tips where the leaflets coapt during 
diastole (n=8). When examining intra-observer reproducibility for detecting the 
presence or absence of 18F-fluoride uptake on individual valve leaflets, this was 
‘very good’ for the right coronary cusp (kappa=1.00), ‘good’ for the non coronary 
cusp (kappa=0.63) and ‘moderate’ for the left (kappa=0.58) coronary cusps. The 
scan-rescan agreement was ‘good’ for the right (kappa=0.76), ‘good’ for the non  
(kappa=0.63) and ‘very good’ for the left (kappa=0.81) coronary cusps (Tables 3.3 
and 3.4).  
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Table 3.2. Bland-Altman values and percentage errors for each stepwise change to the 
image acquisition and analysis technique            
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ORIGINAL APPROACH  











1.44±0.45 0.05 -0.84, 0.93 63 1.87±0.61 0.15 
-1.05, 
1.35 65 








(dividing RA)  
1.42±0.09 0.00 -0.17,  0.17 12 1.84±0.20 0.06 
-0.33, 
0.46 22 










1.55±0.08 0.01 -0.15, 0.14 10 2.01±0.15 0.11 
-0.17, 
0.39 14 
FINAL APPROACH  
RA blood pool, most diseased segment,  
gated PET, contrast CT 
    
 









0.11 -0.75, 0.97 37 
Abbreviations: Ave, average; Diff, difference; Std. Dev, standard deviation; LOA, limits of 
agreement; SUV, standard uptake value; TBR, tissue to background ratio; PET, positron 
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Paired non-gated, non-contrast PET/CT scans (Original approach 1a-6a) and gated, 
contrast-enhanced PET/CT images (Final approach 1b-6b). Images demonstrate the typical 
distribution of the tracer uptake within the valve at sites of increased mechanical stress i.e. at 
the leaflet tips (left: 1,2 and 3) and at the commissures (right: 4,5,6).             
 
Pawade et al.Circ Cardiovas Imaging. 2016 (159) 
  
                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
84 
Table 3.3  Scan-rescan and intraobserver reproducibility for presence or absence of 
18F-fluoride uptake.  
 
 
Right coronary Cusp Non Coronary Cusp Left Coronary Cusps 
Subject 1a 1b 2 1a 1b 2 1a 1b 2 
1 + + + + + + + + - 
2 + + + + + + + + + 
3 + + + - + + - + - 
4 + + + + + + + + + 
5 + + + + + + + + + 
6 + + + - - - - - - 
7 + + + + + + + + + 
8 - - - + + + + + + 
9 + + + + + + + + + 
10 + + + + + + + + + 
11 - - - + + + + + + 
12 + + - + + + - - - 
13 + + + + + + + + + 
14 + + + + + + + - + 
15 + + + + + + + + + 
 
Presence or absence of 18F-Fluoride PET signal is denoted (+ and – respectively) for each 
individual valve leaflet.  The distribution of 18-Fluoride signal on scan 1 images (1a) were 
reassessed (1b) to assess intraobserver reproducibility and compared to scan 2 (2) to 
determine scan-rescan reproducibility. 
 Pawade et al.Circ Cardiovas Imaging. 2016 (159)
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Table 3.4  Kappa Statistics for Interobserver and Scan-rescan agreement for 18F-
Fluoride PET signal distribution. 
 
a) Right Coronary Cusp 
 
Scan 1 (Reading 2)  
 
Scan 2 
Absence Presence  Absence Presence 
Scan 1  
(1st 
Reading) 
Absence 2 0  Scan 1  
(1st 
Reading) 
Absence 2 0 
Presence 0 13  Presence 1 12 
Intra-observer 
agreement 1.00, 95% CI ( -, - ) 
 Scan/Rescan 
agreement 
0.76, 95% CI (0.32, 
1.00) 
 
b) Non Coronary Cusp 
 
Scan 1 (Reading 2)  
 
Scan 2 
Absence Presence  Absence Presence 
Scan 1  
(1st 
Reading) 
Absence 1 1  Scan 1  
(1st 
Reading) 
Absence 1 1 
Presence 0 13  Presence 0 13 
Intra-observer 
agreement 




0.63, 95% CI (-0.01, 
1.00) 
 
c) Left Coronary Cusp 
 
Scan 1 (Reading 2)  
 
Scan 2 
Absence Presence  Absence Presence 
Scan 1  
(1st 
Reading) 
Absence 2 1  Scan 1  
(1st 
Reading) 
Absence 3 0 
Presence 1 11  Presence 1 11 
Intra-observer 
agreement 




0.81, 95% CI (0.47, 
1.00) 
 
The numbers of presence or absence of 18F-Fluoride for right (a), non (b) and left (c) 
coronary cusps are provided.  Kappa statistics and 95% confidence intervals for intra-
observer [i.e. Scan 1 (1st Reading) vs. Scan 1 (2nd Reading)] and scan/rescan [i.e. Scan 1 
(1st Reading) vs. Scan 2] agreement are also shown.             
 
Pawade et al.Circ Cardiovas Imaging. 2016 (159)
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3.3.3 Effect of Altered Image Analysis on PET reproducibility. 
Interobserver and intra-observer reproducibility was good using both the original and 
modified approaches as previously reported. ICC values for intra and inter-observer 
reproducibility were 0.88 and 0.80 respectively (Table 3.5). However the scan-rescan 
reproducibility of our original approach produced percentage errors of ±26% and 
±27% for the mean and maximum SUV measurements respectively (Table 3.2).  
Scan re-scan reproducibility for TBR measurements were disappointing with 
percentage errors of ±63% and ±65%.  
3.3.4 Blood pool measurements  
The percentage error of our original TBR values was double that of the SUV values 
suggesting a problem with our blood-pool measurements. Interestingly a step-wise 
and non-physiological reduction in our original brachio-cephalic vein measurements 
was observed on moving cranially up the axial slices away from the heart and into 
the lung. On average a 20% difference in values was observed between the top and 
bottom slices but this difference could be as high as 66%. By comparison, blood-
pool sampling from the right atrium was easier to perform, allowed larger regions of 
interest to be drawn and was consistent, demonstrating a <1% difference in 
measurements acquired on adjacent slices (Figure 3.3).  
 
Sampling the blood pool in the right atrium led to a substantial improvement in the 
scan-rescan reproducibility of all our TBR measurements. Indeed after implementing 
this approach, the reproducibility of our TBR values consistently outperformed those 
for SUV values with percentage errors of between ±12% and ±22% for mean and 
maximum values respectively. In contrast, the approach of subtracting the blood pool 
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uptake from the tissue SUV to produce cSUV measures did not greatly improve 
reproducibility resulting in percentage errors of ±43% and ±39% for mean and 
maximum measurements respectively despite similar limits of agreement. 
Considerable variation was observed in 18F-fluoride blood pool PET activity across 
our population (blood pool SUV 1.10±0.35) and even between different scans on the 
same patients. This is likely to reflect physiological variations in tracer distribution. 
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Regions of interest for measuring blood pool activity in the brachiocephalic vein (top) and 
right atrium (bottom) are shown in the en-face of the valve (left) and coronal (right) planes. 
Note that the right atrium is a much larger structure allowing for larger regions of interest with 
less potential for partial volume artifact problems related to poor registration. Tukey plot 
demonstrates mean SUV values for 5 contiguous slices from brachiocephalic (blue) and 2 
from the right atrium (purple).  Note the variation in brachocephalic vein measurements 
between those taken most caudally versus those taken most cranially.  
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3.3.5 MDS Approach  
The MDS technique improved the technical ease of image analysis, removing the 
difficulty in deciding upon the upper and lower limits of the valve in the z-plane. 
This translated into further improvements in scan-rescan reproducibility for mean 
TBR values with the percentage error for TBRMDSmean measurements reduced to 
±10%. Similarly maximum TBR values were optimized upon addition of the MDS 
approach (percentage error TBRMDSmax ±14%) as were the SUV measurements 
(percentage errors: SUVMDSmean ±25%, SUVMDSmax ±25%; Table 3.2).  
3.3.6 Final Approach: Addition of Contrast-CT and ECG-gated PET  
The addition of contrast CT and ECG-gated PET data, whilst markedly improving 
image quality as described above, did not have a major affect on scan-rescan 
reproducibility. Reproducibility of our final approach however, remained good with 
a percentage error of ±10% for TBRMDSmean measurements (Figure 3.4 and 3.5). This, 
combined with its ability to localise PET uptake to individual leaflets, made the final 
approach our preferred strategy.  TBRMDSmean values using the final approach did not 
show any proportional bias with disease severity and were again superior to the 
equivalent SUVMDSmean values (percentage error ±35%) and to measurements 
quantifying maximum valvular 18F-fluoride uptake, which were less reproducible 
after the addition of gated-PET and contrast-CT (percentage errors: SUVMDSmax 
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Figure 3.4   Final Approach 
 
 
The original technique (A) underwent a series of modifications. Contrast computed 
tomographic angiographic are reorientated (B and C) to obtain planar views of the aortic 
valve (D). These are co-registered with the gated PET in multiple views (E and F) to ensure 
optimal allignment (G). Mean standard uptake values from the most diseased segment (H) 
are divided by the blood pool which is sampled from the right atrium blood pool (I) to 
generated the TBRMDSmean.  
                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
91 
 
Figure 3.5 Scan-rescan reproducibility for quantification of 18F-Fluoride positron 





Bland Altman plots of scan-rescan reproducibility for TBRMDSmean measurements using the 
original image analysis and acquisition methods (left) and then using final method (right).  
Percentage error for the final method is less than ±10 
 
Table 3.5 Intra/Inter-observer variability of 18F-Fluoride PET Uptake (expressed as a 
continuous variable) 
 
 Difference  95% limits of 
agreement ICC Mean Standard Deviation 
Intra-observer1 0.053 0.12 -0.19, 0.30 0.88 
Intra-observer2 0.028 0.08 -0.13, 0.19 0.98 
Inter-observer3 -0.092 0.17 -0.42, 0.23 0.80 
Abbreviations: ICC, intra class correlation coefficient. 
 
1. Rater 1 Scan 1 (1st Reading) vs. Rater 1 Scan 1 (2nd Reading)  
2. Rater 2 Scan 1 (1st Reading) vs Rater 2 Scan 1 (2nd Reading) 
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3.4 DISCUSSION 
In this study, we have systematically investigated the acquisition and analysis of 
18F-fluoride PET imaging of the aortic valve. First we have improved the spatial 
localization of tracer uptake using ECG-gated PET data and contrast CT imaging, so 
that activity can now be localized to individual leaflets and regions within those 
leaflets. This has demonstrated that calcification activity is most commonly observed 
at sites of maximal mechanical stress: in particular in regions of leaflet coaptation 
and at the commissures. Second we have improved the scan-rescan reproducibility 
ultimately demonstrating good agreement for repeat TBRMDSmean measurements in 
the valve (percentage error ±10%). This has important implications for application to 
future clinical trials, indicating that 18F-fluoride might provide a useful imaging end-
point of drug efficacy. 
 
In this study we have modified our previous image acquisition protocol to include 
contrast-enhanced CT imaging of the aortic valve, thereby providing greater 
definition of the individual valve leaflets and their components. Moreover we have 
included ECG-gated PET data to reduce the effects of cardiac motion and more 
accurately localize the pattern of activity on to the valve. The combined effect of 
these changes has been to improve the spatial localization of PET activity within the 
valve, which after accurate 3D co-registration, is now possible within specific 
regions of individual leaflets. This has demonstrated that 18F-fluoride activity 
predominantly localizes to sites of increased mechanical stress within the valve, 
supporting mechanical injury as a key driver to the disease process. For example 
18F-fluoride activity was observed at the edges of the valve leaflets exactly at the 
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sites of leaflet impact during valve closure. Additionally uptake was observed at the 
valve commissures where mechanical stress is concentrated before being transferred 
to the aortic wall (101, 163).  Whilst these findings need to be confirmed in larger 
studies with further refinement of thresholding techniques, they here provide key 
insight into the triggers to calcification activity in aortic stenosis and the importance 
of mechanical injury. Recent data have indicated that the relationship between the 
valve calcium burden and hemodynamic obstruction is not perfect (121, 164). The 
ability of PET to accurately localize calcification activity may be useful in trying to 
understand whether calcium formation at different sites of the valve has different 
hemodynamic impacts.   
 
We have modified our image analysis protocol, optimizing the scan-rescan 
reproducibility of 18F-fluoride imaging in the aortic valve using several different 
approaches. To date, it has been standard practice for 18F-fluorodeoxyglucose PET 
to measure the blood pool SUV in the brachiocephalic vein (165). This has the 
benefit of avoiding contamination of myocardial 18F-fluorodeoxyglucose uptake that 
would overestimate the blood pool activity if measured in the heart. However, this 
benefit does not exist for 18F-fluoride, which has no background myocardial uptake. 
We therefore measured blood pool activity in both the right atrium and the 
brachiocephalic vein. Measurements in the right atrium are easily performed on the 
en face (short-axis) images of the valve and resulted in much more consistent blood-
pool measurements. Moreover this approach led to a dramatic improvement in the 
scan-rescan reproducibility of our TBR measurements such that they then 
outperformed equivalent SUV measures. We believe that sampling the blood-pool 
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activity in the right atrium improved reproducibility because these measurements are 
less susceptible to the partial volume effects of adjacent lung tissue and because any 
minor inaccuracies in co-registration with the PET signal will not have a great 
impact.  Furthermore it appears important to correct for variations in background 
blood pool activity that can occur between scans perhaps due to minor changes in 
renal function, tracer dose and pharmacokinetic distribution. Chen et al recently 
surmised that subtracting the blood pool from tissue SUV would improve accuracy 
(160).  However our study findings did not support this and their approach produced 
lower TBR values thereby increasing the percentage error of our repeat 
measurements.  
 
Another major improvement in reproducibility was obtained using the most diseased 
segment (MDS) approach: measuring activity in the two hottest adjacent slices in the 
valve, rather than attempting to sample the entire valve. The major advantage of this 
technique is that it removes the considerable difficulty in deciding the limits and 
boundaries of the valve. Such uncertainty can lead to major differences in valve 
measurements because uptake is much lower at the extremes of the valve where the 
volume of tissue is small and inclusion of extraneous tissue will dilute down mean 
values.  
 
Whilst our stepwise changes to the protocol generally improved the reproducibility 
of “mean” measures of PET uptake, the effects on  “maximum” measures were more 
variable. This finding is somewhat at odds with experience in oncology where the 
maximum values are often preferred.  This may reflect the use of contrast enhanced 
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CT (not used in cancer imaging), which allowed accurate and reproducible regions of 
interest to be drawn around the perimeter of the valve facilitating reproducible 
measurement of mean PET uptake. In addition it may reflect ECG-gating of the PET 
data, which discards 75% of the counts, potentially having a greater detrimental 
impact on maximum values (which rely on counts from only a few pixels and are 
therefore particularly susceptible to noise) than mean values. It is possible that 
advanced image analysis approaches that model and correct for cardiac motion 
without discarding any PET data will improve the reproducibility of TBRMDSmax 
measurements as has recently been described for coronary 18F-fluoride activity 
(166).  
 
This is the first study to assess scan-rescan reproducibility for 18F-fluoride uptake in 
the aortic valve. We acknowledge that scan-rescan reproducibility does not necessary 
translate to accuracy and sensitivity. The value of 18F-Fluoride as an imaging 
marker of calcification activity will ultimately be determined by its ability to predict 
disease progression and to detect changes in calcification activity in response to 
novel therapies.  These aspects are both currently being studied within the Saltire 2 
clinical trial.  We have already shown that the TBRMDSmean can predict disease 
progression and clinical events in patients with aortic stenosis (148). We can now 
report TBRMDSmean measurements, made using our optimized image acquisition and 
analysis protocols, quantify valvular 18F-fluoride activity with good reproducibility 
and a 10% error. This translates directly into the requirement for low patient numbers 
for studies investigating the effects of interventions on 18F-fluoride PET uptake (as a 
marker of calcification activity), because any true effect will not be swamped by ’noise’ 
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within the measuring technique.  
3.4.1 Limitations.  
We acknowledge the small sample size, in this study however it is similar to that 
used in previous studies examining the reproducibility of vascular PET (156)and in 
part reflects attempts to minimize the radiation exposure associated with repeat 
PET/CT imaging. Moreover whilst previous studies have indicated that 18F-fluoride 
uptake correlates with histological markers of calcification activity and accurately 
predicts the progression in the CT calcium score, we currently lack data to show that 
18F-fluoride is modifiable with drug therapy. Largely this is because no drug has yet 
demonstrated an ability to reduce disease activity in aortic stenosis and we lack 
reliable animal models of this condition.  
3.5 CONCLUSION 
In conclusion, we have optimized 18F-fluoride PET-CT imaging in the aortic valve. 
Excellent localization of the PET signal within the aortic valve is now possible, with 
uptake observed in regions of maximal mechanical stress. Moreover quantification of 
valvular 18F-fluoride uptake is also now possible with good scan-rescan 
reproducibility. 18F-Fluoride PET-CT holds major promise as a method to better 
understand calcification activity in aortic stenosis and as a surrogate endpoint in 
clinical trials assessing the efficacy of potential therapeutic interventions. 
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Objective 
Quantification of aortic valve calcification (AVC) by computed tomography (CT) 
has major potential for the management of patients with aortic stenosis. We aimed to 
assess scan-rescan reproducibility, correlation with echocardiography, sex-specific 
differences and the prediction of disease progression and clinical events. 
 
Methods and Results 
Volunteers (72±8 years, 68% men) with and without aortic valve disease (20 
controls; 20 aortic sclerosis; 32 mild, 37 moderate, and 27 severe aortic stenosis) 
underwent CT and echocardiography. Fifteen patients underwent repeat CT scanning 
to assess CT-AVC reproducibility. Disease progression was assessed at 1 and 2 years 
using CT-AVC measurements and echocardiography. The primary clinical endpoint 
was a composite of death and aortic valve replacement (AVR).   
 
Baseline CT-AVC scores were reproducible and correlated strongly with 
echocardiographic measures of disease severity (r=0.87 for peak velocity, p<0.001). 
Women required less calcification than men for the same degree of stenosis (0.061 
[95% confidence intervals, 0.052-0.070] versus 0.042 [0.037-0.047] m/sec/√AU 
respectively, p<0.001). Baseline CT AVC predicted disease progression defined 
either using echocardiography (Δ Vmax r=0.32 [0.13–0.49], p<0.0012) or CT (Δ CT 
AVC, r=0.86 [0.79-0.91], p<0.0001). Sex-specific thresholds for severe CT-AVC 
independently predicted AVR and death after adjustment for age, sex and 
echocardiographic measures of disease severity (HR=5.54 [2.37-12.97], p<0.001).   
 
Conclusion 
CT-AVC scoring exhibits important sex-specific differences, correlates with disease 
severity and predicts progression. CT-AVC is a major independent determinant of 




                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
 99 
4.1 INTRODUCTION 
Aortic stenosis represents a major cause of morbidity and mortality that is set to 
increase with an ageing population. Despite its prevalence, we lack accurate methods 
of predicting disease progression and clinical events.  
Doppler and two-dimensional echocardiography are the principal techniques for 
assessing disease severity including the peak aortic valve jet velocity, the mean 
gradient and the aortic valve area (167).  However these measures of disease severity 
are discordant in up to one third of patients with moderate or severe aortic stenosis 
(121). Diagnostic uncertainty as to the true severity of the disease is therefore 
common, making decisions regarding timing of surgery challenging.  A 
complementary imaging technique capable of providing independent diagnostic and 
prognostic information to echocardiography is desirable.   
Calcification is thought to represent the central process driving progressive 
obstruction in aortic stenosis (29). Computed tomography aortic valve calcification 
(CT-AVC) scoring offers accurate quantification of the valvular calcification burden 
(116). Recent studies have demonstrated a close association between CT-AVC 
measurements and hemodynamic assessments of disease severity (121, 168, 169). 
These studies have also highlighted important sex differences.  Compared to men, 
women develop a greater degree of hemodynamic obstruction for any burden of 
valvular calcification, even when corrected for body size or the left ventricular 
outflow tract area.  Sex-specific CT-AVC diagnostic thresholds for severe aortic 
stenosis have subsequently been proposed that predict adverse cardiovascular 
outcome independently of echocardiography (121, 168).   
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These early data require rigorous external validation and evaluation before CT 
calcium scoring is ready for widespread clinical use and potential incorporation into 
international clinical guidelines.  In this study, we aimed to determine whether CT 
AVC scoring has acceptable scan-rescan reproducibility, demonstrates important sex 
differences, correlates with echocardiographic measures of disease severity, and 
predicts aortic stenosis disease progression and clinical outcomes independent of 
echocardiography. 
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4.2 METHODS 
4.2.1 Study Populations  
This chapter utilizes data from 2 cohorts, the Saltire 2 substudy and the Ring of Fire. 
4.2.2 Scan reproducibility 
The scan-rescan reproducibility of CT-AVC scoring was examined using the same 
15 patients described in Chapter 3 (Table 3.1). The scan reproducibility of CT 
calcium scoring is discussed within this chapter.  
4.2.3 Prospective clinical study 
The ability of CT-AVC measurements to correlate with disease severity, predict 
disease progression and clinical events was examined in a prospective clinical study, 
the Ring of Fire. Patients aged >50 years with aortic sclerosis and mild, moderate or 
severe aortic stenosis attending the outpatient department of the Edinburgh Heart 
Centre were recruited in addition to age- and sex-matched control subjects (104, 170, 
171).  
4.2.4 Baseline Assessment 
These participants underwent a full baseline assessment which included history, 
clinical examination, echocardiography and CT calcium scoring as described in 
Chapter 2.  
4.2.5 Assessment of Disease Progression 
Participants were invited to return for repeat clinical assessment and 
echocardiography 1 and 2 years after enrolment. The same research 
echocardiographer (Audrey White) performed each echocardiograph. These patients 
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also underwent repeat ECG-gated CT scanning for calculations of CT-AVC at either 
the 1 or 2-year time points (147).  
4.2.6 Follow-up for Clinical Events 
The primary clinical endpoint was a composite of aortic valve replacement (AVR) 
and all-cause mortality.  All deaths were captured from the General Register of 
Scotland.  All events, including AVR (either surgical or transcutaneous), were 
confirmed by independent review of each patient’s healthcare record. Patients were 
managed in a single tertiary cardiac center, reviewed at a multi-disciplinary meeting 
and only underwent AVR if they met established indications according to 
contemporary guidelines (172). 
4.2.7 Statistical Methods 
Statistical analyses were performed as outlined in Chapter 2. Annualised rates of 
progression for aortic stenosis were calculated by Dr Anoop Shah either using the 
mean over two-time points (CT AVC) or regression analysis over three time-points 
(echocardiography).  The effect of clinical, echocardiographic variables, CT-AVC 
and CT-AVCd upon reaching the primary endpoint were assessed using Cox 
proportional hazards regression analysis. This included analysis of the CT 
measurements as both continuous variables and using previously proposed sex-
specific thresholds for severe valve calcification (CT AVC, men ≥2,065 AU, women 
≥1,274; CT AVCd men 476 AU/cm2, women 292 AU/cm2(121). Statistical 
significance was defined as two-sided p<0.05.   
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4.3 RESULTS: REPRODUCIBILITY STUDY 
4.3.1 Patient Characteristics  
Fifteen patients (73±7 years, 67% male) received two ECG-gated contrast and non-
contrast cardiac scans 3.9 ±3.3 weeks apart between November 2014 and May 2015 
(Table 3.1, Chapter 3) 
4.3.2 Reproducibility 
In three participants, the scan interval exceeded the target of 4 weeks (5 weeks, 8 
weeks and 14 weeks).  Motion artefact affected 2 scans (7%), which were excluded 
from the initial analysis. Scan-rescan reproducibility for CT-AVC measurements was 
very good (median CT-AVC score 1149 AU, mean difference 2%  [limits of 
agreement 16 to -12 %] Figure 4.1). Intra-observer (median CT-AVC score 1178 
AU, mean difference 1% [limits of agreement 9 to -11%]) and inter-observer 
(median CT-AVC score 1207 AU, mean difference 0% [limits of agreement 5 to -
6%]) reproducibilities were also excellent.  
 
As a secondary analysis, we next applied the previously published sex-specific CT-
AVC thresholds to classify each scan as either severe (n=5) or non-severe (n=10). 
All scan pairs including those with significant motion artefact were included and 
demonstrated 100% agreement (kappa statistic=1).  
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Bland-Altman plots showing scan-rescan reproducibility (A) and inter-observer reproducibility 
(B). Correlation between scan-pairs (C). 
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4.4 RESULTS: PROSPECTIVE COHORT STUDY  
4.4.1 Patient Characteristics 
121 patients (20 controls, 20 with aortic sclerosis, 25 with mild, 33 with moderate 
and 23 with severe aortic stenosis) were recruited into the prospective cohort study 
((104, 170, 171). 
4.4.2 CT-AVC and Aortic Stenosis Severity 
At baseline, measurements of CT-AVC and CT-AVCd correlated strongly with all 
echocardiographic measures (Table 4.2). The closest associations were observed 
with the peak velocity (Vmax), and the weakest with the aortic valve area. Women 
required less valve calcification to develop the same degree of hemodynamic 
obstruction as men (linear regression slope of CT AVC vs. Vmax, 0.061 [95% 
confidence intervals, 0.052-0.070] versus 0.042 [95% confidence intervals, 0.037-
0.047] m/s/√AU respectively, p<0.001).  These sex differences persisted despite 
correction for LVOT size (p<0.001), and body surface area (p=0.04) (Figure 4.2). 
4.4.3 Patient Follow up 
Clinical follow-up and echocardiography was performed in 107 subjects at 1 year 
and 99 at 2 years (147). During the 2-year follow up period, (median 736 [722–760] 
days), 97 patients (78%) underwent a repeat cardiac CT (20 at 1 year and a further 77 
at 2 years).  Scans were not interpretable in 10 subjects (10%) due to motion artifact 
and were excluded. A total of 87 follow-up ECG-gated cardiac CT scans were 
therefore available for annualized progression analyses (Figure 4.3).  
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Table 4.1: Baseline Clinical Characteristics  
 
 ALL Echo FU CT FU AVR/Death 
Number 121 99 87 47 
CLINICAL     
Age (years) 72±8 72±8.5 72±8 72±10 
Male 83 (69) 66 (65) 45 (51) 32 (71) 
Body-mass Index (kg/m2) 27±4 28±4 28±6 28±4 
Systolic Blood Pressure  142±18 143±19 144±19 141±20 
COMORBIDITY     
Diabetes Mellitus 18 (15) 13 (13) 12 (14) 7(15) 
Hypertension 73 (60) 59 (60) 53 (61) 30 (65) 
Documented CAD 43 (35) 36 (36) 38 (44) 17 (37) 
Current smoker 14 (12) 11 (11) 7 (8) 8 (17) 
Serum Creatinine (mg/dL) 1.01±0.29 1.02±0.32 1.00±0.28 0.98±0.33 
MEDICATIONS     
    ACE inhibitors 47 (39) 36 (36) 36 (41) 18 (39) 
    AIIRB 13 (11) 11 (11) 10 (11) 4 (9) 
    Beta Blockers 48 (40) 41 (41) 40 (46) 19 (41) 
    Statins 65 (54) 54 (54) 54 (62) 28 (60) 
ECHOCARDIOGRAPHY     
Peak velocity (m/s) 2.8 [1.7-3.7] 2.6 [1.7-3.6] 2.6 [1.7-3.6] 3.8 (3.5-4.1) 
Mean gradient (mmHg) 16 [6-29] 14 [6-27] 14 [6-27] 34 [23-44] 







Calcium Score 1.6±0.9 1.5±0.9 1.5±0.9 2.3±0.6 
ELECTROCARDIOGRAPHY   
     LVH 28 (23) 19 (19) 17 (20) 16 (34) 
     LV Strain 13 (11) 9 (9) 8 (9) 10 (22) 
COMPUTED TOMOGRAPHY 







 TIME IN STUDY     







Abbreviations: ACE, angiotensin converting enzyme; AIIRB, angiotensin 2 receptor 
antagonists; AS, aortic stenosis; AV, aortic valve; CAD, coronary artery disease; AU, 
arbitrary unit; LV, left ventricle; LVH, left ventricular hypertrophy; FU, follow up. 
 
Baseline characteristics are shown for all patients. Subsequent columns show the patient 
characteristics for those patients who had echocardiography follow up available, computed 
tomography follow up available and for those who had met the primary endpoint of aortic 
valve replacement or death. The mean±SD, median [IQR] and number (percentage) are 
shown. 
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Table 4.2 Correlation between computed tomography aortic valve scores and 
echocardiographic indices of severity 
 





























Pearson’s correlation and respective p values are shown. 
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Figure 4.2  Correlation between computed tomography aortic valve calcium 























A. Correlation between peak aortic-jet velocity (m/s) with total aortic valve 
calcium scores (√AU) for males (blue) and females (orange).   
B. Corrected for the left ventricular outflow tract area to generate the AVC 
density (√AU/cm2) 
C. Corrected for body surface area (√AU/m2) 
 
Abbreviations: AVC, aortic valve calcium; AU, Agatston Units 
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Figure 4.3. Study protocol and CONSORT diagram. 
 








•  Baseline clinical assessment (121)  
•  Echocardiogram (121) 
•  Aortic Valve CT calcium Score (112) 
•  Echocardiogram (108) 
•  Repeat CT calcium score (20)                   
- Images degraded by artefact (2) 
•  Clinical outcome met (10) 
•  Declined 1 year follow up (3) 
 
•  Echocardiogram (99) 
•  Repeat CT calcium score (77) 
•  Images degraded by artefact (8) 
•  Clinical outcome met (18) 
•  Declined 2 year follow up (4) 
•  Declined CT follow up only (2) 
AVR (32) 
All Cause Mortality (15) 
Baseline 
     PROSPECTIVE COHORT STUDY 




4.4.4. Aortic Stenosis Progression 
Across all patients with aortic stenosis, modest progression in each 
echocardiographic measure of aortic stenosis severity was observed (Table 4.3). 
However when patients were divided in to mild, moderate and severe aortic stenosis, 
only those patients in the moderate group demonstrated clear evidence of disease 
progression on echocardiography (Figure 4.4). For CT, large annual changes in CT 
AVC score were observed across the whole aortic stenosis cohort with clear evidence 
of disease progression in all of the subgroups with mild, moderate and severe disease 
(Table 4.3, Figure 4.4). The most rapid rates of progression were observed in patients 
with the most severe aortic stenosis.  
 
Prediction of Disease Progression 
The baseline CT-AVC predicted disease progression, whether this was measured 
using CT (Δ CT-AVC, r=0.86 [95% confidence intervals, 0.79-0.91], p<0.0001; 
Figure 3) or echocardiography (Δ Vmax r=0.32 [95% confidence intervals, 0.13–
0.49], p<0.0012, Δ mean gradient , r=0.37 [95% confidence intervals, 0.19–0.53], 
p=0.0002; Table 4). The rate of progression of AVC score correlated with 
echocardiographic measures of aortic stenosis progression (Δ Vmax, r=0.40 [95% 
confidence intervals, 0.22-0.58], Δ mean gradient, r=0.45 [95% confidence intervals, 
0.26-0.61], both p<0.0001) (Table 4.4, Figure 4.5). 
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Table 4.3 Progression and outcome data. 
 














BASELINE ECHOCARDIOGRAPHY  
No. of patients 121 20 20 25 33 23 
Peak jet velocity 
(m/s) 
2.8±1.2 1.3±0.2 1.7±0.2 2.5±0.2 3.4±0.3 4.6 ±0.6 
Mean gradient 
(mmHg) 
16.2±0.49 3.6±1.0 5.9±1.4 13.2±2.7 25.2±4.1 48.6±15.4 




2.54±0.49 2.27±0.41 1.42±0.30 1.13±0.27 0.76±0.21 
FOLLOW-UP ECHOCARDIOGRAPHY 
No. of patients 99 20 17 24 26 12 




























































BASELINE COMPUTED TOMOGRAPHY 
No. of patients 112 20 20 23 30 19 
















FOLLOW-UP COMPUTED TOMOGRAPHY 
No. of patients 87 18 18 21 24 6 
Change in aortic 
valve calcium score 



































All cause mortality 15 2 2 4 2 5 
Aortic-valve 
replacement 
32 0 0 1 15 16 
Composite outcome 
(%)  
47 (39) 2 (10) 2 (10) 5 (20) 17 (21) 21 (91) 
 
Mean ± (Standard Deviation), Median [Interquartile Range] and Number (Percentages) are 
shown.   
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A&B.  Annualized disease progression across each cohort using computed tomography (CT) 
calcium scoring (A) and echocardiography (B). Relatively large annualized changes in the 
CT calcium score are observed compared to smaller changes and wide overlap in the peak 
aortic-jet velocity measurements.    
C. Absolute difference in aortic valve calcium scores between scan pairs (AU).  This 
demonstrates the proportional bias in scan-rescan reproducibility, but also that this error is 
less than the annual changes observed in panel A.  
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The baseline CT-AVC calcium score offers powerful prediction of disease progression as 
measured using computed tomography. 
 
Abbreviations; CT-AVC, computed tomography aortic valve calcium score; CI confidence 
interval 
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 Abbreviations: AV: aortic valve; AU: Agatston unit; CT-AVC, computed tomography  
 aortic valve calcium,  
 
                 



















r =0.86, 95% CI [0.79-0.90] p<0.001
r2=0.74
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4.4.5 Prediction of Adverse Clinical Outcomes 
Clinical outcomes were assessed at a median of 1,875 [1,188-1948] days after 
enrollment and 32 (26%) patients had received aortic valve replacement (AVR). 
There were 15 deaths (12%) of which 6 were cardiovascular deaths. Overall, 47/121 
(39%) subjects were adjudicated to have reached the primary clinical end-point.  
Two control subjects died: 1 cardiovascular and 1 non-cardiovascular death. 
4.4.6 Echocardiography 
On univariate cox-proportional hazards analysis, severe aortic valve calcification as 
defined by an echocardiographic calcium score (ECS) of 3 was a strong predictor of 
AVR and death (hazards ratio, 6.00 [95% confidence intervals, 3.21-11.24], 
p<0.001).  After adjustment for age and sex, it remained an independent predictor 
(hazards ratio, 6.07 [95% confidence intervals, 3.21-11.47], p≤0.001). However 
when peak velocity was included in the model, this effect was no longer significant 
(hazards ratio, 1.19 [95% confidence intervals, 0.50-2.82], p=0.690). 
4.4.7 Computed Tomography 
When examined as a continuous variable, baseline CT-AVC was a predictor of AVR 
and death (hazard ratio per unit increase in CT AVC, 1.06 [95% confidence intervals, 
1.05-1.08] /√AU, p<0.001) and remained an independent predictor after multivariate 
adjustment for age, sex and peak velocity (hazard ratio, 1.04 [95% confidence 
intervals, 1.02-1.07], p<0.001).  Similarly CT-AVCd proved to be an independent 
predictor of outcome after multivariate adjustment for age, sex and peak velocity 
(hazard ratio per unit increase in CT-AVCd, 1.07 [95% confidence intervals, 1.02-
1.12] /√AU, p=0.006). 
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We next investigated the prognostic utility of the previously proposed sex-specific 
CT-AVC thresholds for severe aortic stenosis (≥1,274 AU in females and ≥2,065 AU 
in males) as well as the equivalent CT-AVCd cut-offs (≥292 AU/cm2 in females and 
≥476 AU/cm2 in males.(121) On univariate analysis, the presence of severe CT-AVC 
was associated with a 15-fold increase in the likelihood of AVR and death (hazards 
ratio, 14.85 [95% confidence intervals, 7.49 - 29.42], p<0.001) and remained an 
independent predictor of AVR and death after adjustment for age, sex (hazards ratio, 
14.82 [95% confidence intervals, 7.40 - 29.70], p<0.001) and the peak aortic jet 
velocity (hazards ratio, 5.54 [95% confidence intervals, 2.37 - 12.97], p<0.001). 
Similarly, severe CT-AVCd provided independent prediction of death and AVR after 
adjustment for these same factors (hazards ratio, 3.10 [95% confidence intervals, 
1.33 -7.20], p=0.009; Figures 4.6 and 4.7).  
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HR 14.9 [7.49 to 29.4] p<0.001 






















HR 10.06 [5.19-19.5] p<0.001 
A B
Figure 4.6 Event-free survival using sex-specific computed tomography aortic valve 



















Event free survival using the sex-specific computed tomography (CT) thresholds for CT 
aortic valve calcium  (A) and aortic valve calcium density (B) are shown. Severe calcification 
as defined by these thresholds was associated with an adverse prognosis 
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Figure 4.7. Sex-specific computer tomography aortic valve calcium thresholds predict 






CT Calcium scoring is an independent predictor of aortic valve replacement (AVR) and 
death.  Hazards ratios (HR) with 95% confidence intervals (CI) are given for severe aortic 
valve calcification as defined using the echocardiographic calcium score (ECS) and 
thresholds for AVC and AVCd.  Hazard ratio for both the unadjusted analysis and analysis 
after adjustment for age, sex and peak aortic jet velocity are shown with their respective 
confidence intervals and p values.   
 
Abbreviations: ECS, echocardiography calcium score; AVC, aortic valve calcium score; 
AVCd, aortic valve calcium density; HR, hazard ratio; CI, confidence interval
HR 95% CI Sig 
   6.00 3.21-11.2 <0.001 
14.9 7.49-29.4 <0.001 
10.06 5.19-19.5 0.001 
1.19 0.50-2.82 0.690 
5.54 2.37-13.0 0.001 
3.10 1.33-7.20 0.009 
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4.5 DISCUSSION 
In this comprehensive, prospective, single-centre imaging study, we have confirmed 
that CT calcium scoring is reproducible, has important sex differences, and predicts 
disease severity and progression. Moreover, independent of standard risk factors and 
echocardiographic measures of disease severity, baseline scores for CT-AVC is a 
major determinant of the future risk of AVR and death in patients with aortic 
stenosis. These data are supportive of the use of CT calcium scoring in clinical 
practice as an adjunct to echocardiography, especially where echocardiographic 
findings are discordant or when attempting to assess future risk. 
 
Standard clinical follow up for patients with aortic stenosis encompasses clinical 
history, examination and Doppler echocardiography. Whilst echocardiography is a 
robust and reliable clinical tool that provides accurate assessment in the majority of 
patients, it does have some limitations.  Even in experienced hands, discordant 
echocardiographic measures of severity are seen in approximately a third of patients, 
most frequently due to conflicting aortic valve area and peak velocity or mean 
gradient measurements (173). This common discrepancy can be explained by low-
flow states in only a minority of patients, resulting in diagnostic difficulty and 
problems addressing the need for valve replacement. A complementary technique 
that can aid in assessing disease severity and improving risk stratification is therefore 
highly desirable.  Given the central role of calcification in the progression of aortic 
stenosis, direct assessments of aortic valve calcification holds major potential (29) 
and in particular, CT calcium scoring (116, 168, 169).  
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Before an imaging technique can be applied to routine clinical practice, clinicians 
need to be reassured that it is robust and reproducible. Measurement of CT-AVC is 
technically straightforward although it can be complicated by confluent calcium in 
the aortic root, left ventricular outflow tract, coronary arteries and mitral valve 
annulus.  In this study, we have demonstrated that excellent reproducibility can be 
achieved with a consistent approach to dealing with calcium from extra-valvular 
structures. Unfortunately motion artefact still occurs in approximately 5-10% of 
cases despite administration of beta-blockade and ECG-gating, hampering image 
quality and rendering these scans challenging to interpret. However, given that the 
anticipated clinical application will adopt the employment of sex-specific thresholds, 
it was reassuring these limitations did not result in reclassification for any patients 
within our reproducibility cohort.   
 
There is a strong association between CT-AVC measurements and hemodynamic AS 
severity on echocardiography. We have confirmed the findings of previous studies 
by demonstrating that, despite correction for anatomical size differences, less 
valvular calcification is required in women to produce severe haemodynamic 
obstruction (121). This supports the need for sex-specific thresholds when assessing 
severity.  The  discrepancy is unaccounted for but is thought to relate to a higher 
degree of valvular fibrosis in women (174). These findings warrant further 
exploration, as different therapeutic strategies may be required in men and women.  
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CT calcium scoring appeared to be a superior predictor of disease progression as 
measured by CT or echocardiography. Additionally progression of disease severity 
was easier to detect using CT calcium scoring compared to echocardiography at all 
stages of aortic stenosis disease severity. Indeed only CT-AVC scoring was able to 
measure disease progression in patients with mild, moderate and severe aortic 
stenosis. This in combination with its excellent reproducibility supports a role for 
CT-AVC in monitoring disease progression particularly in the context of research 
trials investigating the effects of novel therapies. We also demonstrated that 
progression in the CT-AVC score accelerates with progressive disease severity, 
consistent with a self-perpetuating cycle of injury and calcification (29). 
 
Finally we have confirmed the ability of CT-AVC to predict clinical events. A strong 
correlation was observed between baseline CT-AVC and disease progression as 
measured using both CT and echocardiography. Moreover a strong association was 
observed between baseline AVC and the future incidence of AVR and death 
independent of age, sex and standard echocardiographic measures of disease 
severity.  This was observed both when CT-AVC measurements were considered as 
continuous variables or as a dichotomous variable according to the sex-specific 
thresholds proposed by Clavel et al.(121)  
4.5.1 Study Limitations 
This was a single centre study and it therefore yet to be determined whether these 
findings apply to a wider, more heterogenous cohort. We acknowledge that while our 
prospective cohort represented the full physiological range of calcific aortic valve 
disease and allowed us to evaluate disease progression at each of these stage, this 
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resulted in a smaller proportion of patients with moderate or severe stenosis. 
Consequently only a modest event-rate was observed despite protracted follow up. In 
addition, those patients with the most severe disease underwent AVR before repeat 
echocardiography and CT could be performed at 2 years. This will have introduced 
survival bias in our estimates of disease progression by CT and especially by 
echocardiography. Therefore, our current estimates are likely to under represent the 
true extent of disease progression in this severe group of patients and perhaps 
explains apparent the fall in progression rates with echocardiography.  
4.6 CONCLUSION 
In combination with previous studies, we have demonstrated that CT-AVC scoring is 
a robust and reproducible clinical tool that can reliably assess disease severity, and 
predict disease progression and adverse clinical outcomes. We believe that this 
technique holds promise as a useful adjunctive investigation in the management of 
patients with this common and potentially life-threatening condition. This is the first 
external validation of clinical utility of sex-specific CT calcium scoring thresholds 
and supports their clinical utility in providing powerful patient risk stratification. We 
envisage that their primary clinical application would therefore be to assist with 
decision-making with regards to the confirmation of severe aortic valve disease and 
the consideration of AVR not only in patients with discordant echocardiographic 
findings but also those undergoing cardiac surgery for another indication such as 
coronary artery bypass grafting. Nonetheless, before these thresholds can be 
incorporated into widespread clinical guidelines, the ability of these thresholds to 
identify severe aortic stenosis and predict clinical outcomes within a larger, more 
heterogenous population needs to be examined.  
















To establish the clinical utility of computed tomography aortic valve calcium scoring 
(CT-AVC) in patients with aortic stenosis.  
 
Methods and Results 
Patients with aortic stenosis who had undergone electrocardiogram-gated CT-AVC 
measurements within 3 months of echocardiography were entered into a 
collaborative international multicenter observational registry. The identification of 
sex specific CT-AVC thresholds to diagnose severe aortic stenosis was determined in 
patients with concordant echocardiographic assessments in whom disease severity 
was unambiguous. In patients with prospective long-term follow up, we assessed 
whether these thresholds predict aortic valve replacement (AVR) and death. Finally 
CT-AVC thresholds were used as an ‘umpire test’ to arbitrate disease severity in 
patients with discordant echocardiographic measurements.   
 
In 918 patients recruited from 8 international centers (age 77±10, 60% male, peak 
aortic-jet velocity 3.88±0.90 m/s), 708 (77%) patients had concordant 
echocardiographic assessments, in whom optimal sex-specific CT-AVC thresholds 
(women 1377, men 2062 AU) provided excellent discrimination for severe aortic 
stenosis (c-statistic: women 0.92, men 0.88; P<0.001 for both) and were nearly 
identical to those previously reported (women 1274, men 2065 AU).  
 
Clinical outcomes were available in 237 patients over a median of 1029 [100-2,251] 
days. Sex-specific CT-AVC thresholds were independent predictors of AVR and 
death (hazards ratio, 3.02 [95% confidence intervals, 1.83-4.99], p<0.001) after 
adjustment for age, sex, peak aortic-jet velocity and aortic valve area. Among the 
210 (23%) patients with discordant echocardiographic assessments, CT-AVC 




Sex-specific CT-AVC thresholds for severe aortic stenosis are consistent across 
different patient populations and provide powerful independent prognostic 
information. CT-AVC thresholds should be used to guide clinical management 
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5.1 INTRODUCTION 
Aortic stenosis is a common and potentially fatal condition in which progressive 
fibro-calcific changes within the valve leaflets cause outflow tract obstruction. 
Severe symptomatic stenosis is an indication for aortic valve replacement  (AVR) 
and timely referral is essential to prevent adverse clinical events (2). Stenosis 
severity is determined using echocardiography and commonly graded using the peak 
velocity (Vmax), mean gradient (MG) and aortic valve area (AVA) (175). The latter 
is less flow dependent and can be indexed to body surface area (AVAi) (152). In the 
majority of patients, these measurements provide concordant assessments and the 
severity of aortic stenosis is clear. However as previously discussed, in around a 
quarter of cases, these measures are discordant, creating confusion as to the true 
severity of aortic stenosis and difficulties in clinical decision-making (121, 164). An 
independent complementary test that could be used to arbitrate the true severity of 
aortic stenosis would therefore have major clinical utility and potentially improve 
patient care (176). 
In the previous chapter we confirmed the presence of importance sex differences 
with respect to the association between computed tomographic aortic valve 
calcification (CT-AVC) measurements and hemodynamic measures of stenosis 
severity on echocardiography (177-179). We also confirmed that the recently 
proposed sex-specific CT-AVC thresholds (women 1274 AU and men 2065 AU) 
predict adverse clinical events (121, 168). There is currently great interest in using 
these thresholds as an alternative assessment of aortic stenosis severity and as an 
“umpire test” in patients with discordant echocardiographic findings (180).  However 
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before thresholds can enter routine clinical use, their widespread clinical 
applicability needs to be established.  
 
The aim of this study was to investigate the clinical utility and generalizability of 
sex-specific CT-AVC thresholds in an international multicenter registry 
incorporating a wide range of patient populations, different scanner vendors, and 
varied image analysis platforms. Specifically we sought to determine the ability of 
the thresholds to identify severe aortic stenosis in those with concordant 
echocardiographic measures, to establish the ability of this technique to predict 
clinical outcomes, and to arbitrate disease severity in patients with discordant 
echocardiographic findings. 
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5.2 METHODS 
Eight international centers were invited to contribute clinical, CT and 
echocardiography data from patients with aortic stenosis into a multicenter registry 
(Table 5.1).  Patients were required to have at least mild aortic stenosis (peak 
velocity [Vmax] >2.5 m/s or mean gradient [MG] >10 mmHg) and to have 
undergone electrocardiogram-gated CT calcium scoring within 3 months of the 
echocardiogram. Patients with other forms of valvular heart disease of at least 
moderate severity or an estimated glomerular filtration rate <30 mL/min/1.73 m2 
were excluded.   
 
Three centers contributed data from five prospective aortic stenosis clinical research 
studies: Edinburgh Heart Centre, Edinburgh, UK (NCT01358513 NCT02132026), 
Hôpital Bichat, Paris, France (NCT00338676 and NCT00647088), and Institut 
Universitaire de Cardiologie et de Pneumologie, Québec City, Québec, Canada, 
(NCT01679431).  Two centers (Paris and Quebec) had previously published CT-
AVC thresholds (121) but here provided separate distinct populations of patients that 
did not overlap with their original cohort.  The remaining 5 centers contributed data 
from patients in Europe and North America who had undergone these investigations 
for clinical indications (Table 5.1). The University of Edinburgh co-ordinated the 
study and its design was approved by the South East Scotland Research Ethics 
Committee and the Health Research Authority of the United Kingdom. Informed 
consent was obtained for those patients who had taken part in research studies. In 
patients who had undergone scans for clinical indications, patients were de-identified 
and anonymised.  
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Table 5.1 Centre List 
 
CENTRE COHORT CT SCANNER IMAGE ANALYSIS SOFTWARE 
Centre for Cardiovascular 
Science,  














Philips scanner (MX 
8000 IDT 16, Phillips 
Medical Systems, 
Andover, MA, USA) 
 
General Electric scanner 











Institut Universitaire de 
Cardiologie et de 
Pneumologie  










Guy's and St Thomas' 




Clinical Philips Brilliance ICT 
scanner 















Amiens- Picardie,  
France 
 
Clinical General Electric CT 750 
HD 
Discovery CT750 HD 
(GE Healthcare). 
- Optima CT660 (GE 
Healthcare). 
- LightSpeed VCT XT 
(GE Healthcare) 
Smartscore 4.0 (GE 
Healthcare) , work 
station = Advantage 
Workstation 4.6 (GE 
Healthcare). 
Vascular Medical 
Institute, University of 
Pittsburgh, 
United States of America 
 
Clinical GE Discovery 750HD 
 




Saint Denis,  
France 
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5.2.1 Computed Tomography Aortic Valve Calcium Scoring 
All centres performed non-contrast CT scans gated from 75% to 80% of the R-R 
interval, with a tube current of 42 to 1312 A and a voltage of 120 kV. Imaging was 
performed on a range of different scanners (Table 5.1). At the discretion of the 
attending clinician, some centres administered beta-blockade to achieve a resting 
heart rate of ≤65 beats per minute (Amiens, France and Edinburgh, United 
Kingdom).  
 
Image analysis was performed locally using a range of different software packages.  
At the initiation of the study, consensus was reached regarding the optimum method 
for calcium scoring and this was then applied at each of the centers, ensuring 
consistency of approach. In brief, CT-AVC scores were quantified on contiguous 3-
mm axial slices as described in Chapter 2, commencing at the base of the valve, with 
care taken to exclude calcium originating from extra-valvular structures such as the 
mitral valve annulus, the ascending aorta and coronary arteries. The total AVC in 
Agatston Units (AU) was calculated and subsequently indexed to the body surface 
area (AVCi (AU/m2)) or divided by the left ventricular outflow tract area to estimate 
calcium density (AVCd (AU/cm2)). In order to stratify for gender the CT-AVC 
scores were then divided by the derived sex-specific thresholds to generate a ratio 
whereby a ratio ≥1 was consistent with severe calcification on CT. 
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5.2.2 Echocardiography 
Echocardiography was performed according to the European Association of 
Cardiovascular Imaging and American Society of Echocardiography guidelines as 
described in Chapter 2 (152). Echocardiographic data were defined as concordant 
when findings from both the Vmax and AVA provided the same assessment of 
disease severity (severe AS: AVA <1.0 cm2 Vmax ≥4.0 m/s; non-severe AS: AVA 
≥1.0 cm2 Vmax <4.0 m/s). Patients in whom the Vmax and AVA gave discordant 
assessments of aortic stenosis severity were sub-categorized as having normal-flow 
or low-flow. Discordant low-flow patients were further subdivided into those with a 
low (<50%, classical low-flow severe aortic stenosis) or preserved (≥50%, 
paradoxical low-flow severe aortic stenosis) ejection fraction (152). Discordant 
normal-flow patients were further subdivided into those with Vmax ≥4.0 m/s (and 
AVA ≥1.0 cm2) versus patients with Vmax <4.0 m/s (and AVA <1.0 cm2) (175). The 
sex-specific CT-AVC thresholds were then applied to these discordant patients in 
order to arbitrate whether they had severe or non-severe disease (Figure 5.1).  
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Vmax <4 m/s 
AVA ≥1.0 cm2  
SEVERE 
Vmax ≥4 m/s 




Stroke Volume Index 
<35 mL/m2 
NORMAL FLOW 
Stroke Volume Index 
≥35 mL/m2 
 
EF <50% EF ≥50 %  AVA ≥1.0 cm2          
Vmax ≥ 4 m/s 
AVA <1.0 cm2        
Vmax < 4 m/s 
GROUPS WITH DISCORDANT Aortic Stenosis 
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5.2.3 Prediction of Outcomes 
The primary outcome was the time to first event of death or aortic valve replacement. 
Aortic valve replacement included both open surgical procedures and transcatheter 
aortic valve implantation (TAVI). Patients in whom a decision to refer for aortic 
valve replacement had already been made at the time of CT calcium scoring or who 
had CT imaging performed as part of the work up prior to TAVI or surgery were 
excluded from this analysis.   
5.2.4 Statistical Analysis 
Statistical analyses were performed as outlined in Chapter 2. Additionally, in patients 
with concordant echocardiographic data, receiver operator curves were derived to 
assess CT-AVC thresholds and to identify the optimum thresholds for severe aortic 
stenosis. Kaplan-Meier curves and cox proportional hazards regression analyses were 
used to determine the ability of CT-AVC measurements to predict adverse clinical 
events. Two-sided significance was taken as p<0.05. 
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5.3 RESULTS 
Data were collated from 918 patients across 8 international centers (age 77±10 years, 
60% male, Vmax 3.88±0.90 m/s; Table 5.2) with 431 patients undergoing imaging 
within prospective clinical research studies and 487 patients being imaged as part of 
routine clinical care. The latter group included 366 patients being considered for 
TAVI.  
 
CT-AVC measurements correlated with the different echocardiographic measures of 
aortic stenosis severity (Table 5.3). When subdivided by sex, women had lower CT-
AVC scores to achieve the same degree of hemodynamic obstruction than men even 
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Table 5.2. Patient Characteristics 
   CONCORDANT DISCORDANT  LOW FLOW 
DISCORDANT  
NORMAL FLOW 






CLINICAL  918 436 272 7 68 35 96 
        
Age years ± SD 77±10 80±9 72±10 81±7 77±11 74±11 79±8 
Males % 60 51 78 57 57 80 52 
Height cm ± SD 165±12.0 164±13 169±8 163±7 167±9 171±8 163±9 
Weight cm ± SD 78±17 75±17 82±17 69±12 84±17 84±17 72±16 
Body Surface Area m2 ± SD 1.88±0.25 1.83±.24 1.94±0.25 1.76±0.19 1.96±0.23 1.99±.0.23 1.79±0.23 
Body Mass Index kg/m2± SD 28±6 28±6 29±5 26±4 30±5 29±5 27±5 
         
Systolic Blood Pressure mmHg ± SD 136±20 134±19 139±21 124±28 139±19 137±18 137±20 
Diastolic Blood 
Pressure 
mmHg ± SD 72±12 71±12 74±13 76±19 75±10 71±10 71±11 
         
Possible Symptoms % 70 91 47 100 75 69 58 
Hypertension % 77 77 82 57 81 83 75 
Coronary Artery 
Disease 
% 45 49 37 43 50 34 44 
Ever smoked % 32 24 42 29 50 34 39 
Diabetes % 28 30 24 0 28 20 26 
Hyperlipidaemia % 65 64 59 43 68 54 68 
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Table 5.2 continued. Patient Characteristics 







 ALL SEVERE NON-SEVERE EF<50 % EF≥50 % 





 ECHOCARDIOGRAPHY  918 436 272 7 68 35 96 
Peak velocity mmHg ± SD 3.88±0.90 4.61±0.50 2.9±0.50 3.21±0.44 3.47±0.36 4.30±0.33 3.51±0.33 
Percentage ≥4 m/s % 51 100 0 0 0 100 0 
Mean Gradient m/s ± SD 38±19 54±14 19±7 26±8 30±7 44±8 30±7 
Percentage ≥40 mmHg % 48 91 5.3 0 12 69 8 
Aortic Valve Area cm2 ± SD 0.90±0.35 0.66±0.15 1.33±0.28 0.66±0.21 0.72±0.15 1.16±0.17 0.83±0.11 
Percentage ≤ 1.0 cm2 % 67 100 0 100 100 0 100 
Aortic Valve Area Index cm2/m2 ± SD 0.48±0.18 0.36±0.08 0.69±0.15 0.37±0.11 0.37±0.08 0.59±0.13 0.47±0.07 
Percentage ≤ 0.6  cm2 % 77 99 0 100 100 66 100 
Bicuspid % 7 4 12 0 3 23 4 
         
Ejection Fraction % ± SD 61±8.5 61±8 60±9 31±5 58±8 61±10 61±8 
COMPUTED TOMOGRAPHY       
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Table 5.3. Correlations between Echocardiography measurements and Computed 










ALL PATIENTS     
      
AVC Correlation 0.66 0.64 -0.49 -0.54 
 Sig. p<0.001 p<0.001 p<0.001 p<0.001 
 N 918 918 918 915 
AVCi Correlation 0.68 0.67 -0.54 -0.54 
 Sig.  p<0.001 p<0.001 p<0.001 p<0.001 
 N 915 915 915 915 
AVCd Correlation 0.69 0.66 -0.59 -0.62 
 Sig. p<0.001 p<0.001 p<0.001 p<0.001 




     
      
AVC Correlation 0.70 0.67 -0.54 -0.56 
 Sig. p<0.001 p<0.001 p<0.001 p<0.001 
 N 548 548 548 547 
AVCi Correlation 0.71 0.69 -0.57 -0.55 
 Sig.  p<0.001 p<0.001 p<0.001 p<0.001 
 N 547 547 547 547 
AVCd Correlation 0.72 0.69 -0.62 -0.63 
 Sig.  p<0.001 p<0.001 p<0.001 p<0.001 
 N 547 547 545 547 
WOMEN      
      
AVC Correlation 0.66 0.67 -0.56 -0.58 
 Sig. p<0.001 p<0.001 p<0.001 p<0.001 
 N 370 370 370 368 
AVCi Correlation 0.67 0.67 -0.58 -0.56 
 Sig.  <0.001 <0.001 <0.001 <0.001 
 N 368 368 368 368 
AVCd Correlation 0.65 0.65 -0.63 -0.63 
 Sig. (2-
tailed) 
<0.001 <0.001 <0.001 <0.001 
 N 369 369 369 367 
Abbreviations: Vmax, peak velocity; AVA, aortic valve area; AVAi, indexed aortic valve area; 
AVC, aortic valve calcium score; AVCi, indexed aortic valve calcium score; AVCd, aortic valve 
calcium density; sig, significance. 
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5.4 Patients with Concordant Echocardiography 
5.4.1 Performance of CT-AVC Thresholds 
Overall 708 (77%) patients had concordant echocardiographic assessments of their 
disease severity (defined using the Vmax and AVA). Patients with concordant-severe 
disease (n=436) had AVC scores that were more than double patients with 
concordant non-severe disease (n=272) (p<0.0001). In these concordant patients, we 
determined that the optimum CT-AVC thresholds for severe aortic stenosis were 
1377 AU for women and 2062 AU for men (Figure 5.2). These thresholds had a 
sensitivity of 87% and specificity 84% in women and a sensitivity of 80% and a 
specificity of 85% in men with a c-statistic of 0.92 and 0.88 respectively (Table 5.4). 
This provided a high degree of discrimination for identifying severe aortic stenosis 
(Figure 5.3).  The CT-AVC thresholds performed similarly well when 
echocardiographic disease severity was defined using MG and AVAi (c-statistic: 
0.93 women, 0.92 men; Table 5.5, (121) 
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Receiver operator curves for women (left) and men (right) assessing the accuracy of 
computed tomography aortic valve calcification (CT-AVC) scoring against echocardiography 
in patients with concordant echocardiographic measures (n=708).  The dashed lines 
represent 95% sensitivity (horizontal) and 95% specificity (vertical). 
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Table 5.4. Computed tomography aortic valve calcium scoring thresholds for severe 
aortic stenosis in patients with concordant echocardiographic measures.  
The peak velocity and aortic valve area were used to adjudicate stenosis severity. 
 
  THRESHOLD SENSITIVITY (%) SPECIFICITY (%) 
AORTIC VALVE CALCIUM (AU) 
WOMEN     
AUC=0.92 Clavel et al  1274 88 81 
 Optimum  1377 87 84 
 Most Specific 2646 51 96 
 Most Sensitive 774 95 62 
     
MEN     
AUC=0.88 Clavel et al  2065 80 82 
 Optimum  2062 80 85 
 Most Specific 3905 36 95 
 Most Sensitive 1196 95 58 
     
AORTIC VALVE CALCIUM INDEX (AU/m2) 
 
WOMEN     
AUC=0.92 Clavel et al 637 92 77 
 Optimum  784 88 83 
 Most Specific 1512 49 95 
 Most Sensitive 500 95 68 
     
MEN     
AUC =0.90 Clavel et al 1067 81 85 
 Optimum  1058 82 85 
 Most Specific 1814 45 95 
 Most Sensitive 659 95 69 
AORTIC VALVE CALCIUM DENSITY (AU/cm2) 
WOMEN     
AUC =0.93 Clavel et al 292 96 75 
 Optimum  420 88 88 
 Most Specific 706 61 96 
 Most Sensitive 307 95 77 
     
MEN     
AUC =0.91 Clavel et al 476 88 81 
 Optimum  527 83 84 
 Most Specific 909 52 95 
 Most Sensitive 376 95 73 
Abbreviations: AUC, area under curve. 
 
 
Clavel et al refers to thresholds proposed in reference (121) 
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Table 5.5. Computed tomography aortic valve calcium scoring (CT-AVC) thresholds 
for severe aortic stenosis in patients with concordant echocardiographic measures.  
 




  THRESHOLD SENSITIVITY (%) SPECIFICITY (%) 
AORTIC VALVE CALCIUM (AU) 
WOMEN     
AUC=0.92 Clavel et al 1274 89 81 
 Optimum  1377 86 83 
     
MEN     
AUC=0.88 Clavel et al 2065 81 87 
 Optimum  2062 81 87 
     
AORTIC VALVE CALCIUM INDEX (AU/m2) 
 
WOMEN     
AUC=0.92 Clavel et al 637 93 76 
 Optimum  784 89 80 
     
MEN     
AUC =0.90 Clavel et al 1067 82 88 
 Optimum  1058 83 88 
AORTIC VALVE CALCIUM DENSITY (AU/cm2) 
WOMEN     
AUC 
=0.93 
Clavel et al 292 96 77 
 Optimum  420 90 88 
     
MEN     
AUC 
=0.91 
Clavel et al 476 90 88 
 Optimum  527 85 89 






Clavel et al refers to thresholds proposed in reference (121) 
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Figure 5.3  Computed tomography aortic valve calcium (CT-AVC) scores in patients 
































In order to stratify for sex, CT-AVC scores were divided by the respective sex-specific 
thresholds for severe aortic stenosis (1277 AU in women and 2062 AU in men) to generate 
AVC ratios. A score above the dotted line represents CT-AVC above the sex-specific 
threshold and therefore severe aortic valve calcification. A CT-AVC score below the dotted 
line represents CT-AVC below the sex-specific threshold and non-severe calcification. 
Patients with concordant-severe aortic stenosis, as defined by echocardiography, had CT-
AVC ratios that were more than double those with concordant non-severe disease. Box and 
Whiskers plot, error bars are from the 10th to 90th centile and the horizontal line represents 
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5.4.2 Disagreement between CT calcium scoring and echocardiography 
Patients with concordant-severe disease (n=436) had CT-AVC scores that were more 
than double patients with concordant non-severe disease (n=272) (p<0.0001, Figure 
5.3).  However, overlap between these two groups was observed. Indeed, of the 436 
patients with concordant-severe disease on echocardiography, 69 (16%) had a 
calcium score consistent with non-severe disease on CT. Although a borderline score 
(defined as AVC ratio ≥0.80) was found in 29, 40 patients had clear disagreement 
between the echocardiographic and CT assessments. These patients appeared to be 
more likely to have a history of concomitant coronary artery disease, diabetes 
mellitus and hypertension (Table 5.6).  Similarly amongst the patients with 
concordant non-severe disease on echocardiography (n=272), 47 had severe 
calcification on CT, 11 of whom had borderline scores  (defined as a ratio <1.2). 
Clear disagreement therefore persisted in 36 of these subjects who had a similar 
demographic profile to the cohort as a whole. 
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Table 5.6 Patient characteristics of outliers 
 
  All Patients 
Severe 
AVC Ratio <0.8 
Non-Severe 
AVC Ratio≥1.2 
CLINICAL  918 40 36 
     
Age years ± SD 77±10 78±8 75±9 
Males % 60 65 73 
Height cm ± SD 165±12.0 161±8 171±9 
Weight cm ± SD 78±17 72±15 89±21 
Body Surface Area m2 ± SD 1.88±0.25 1.78±0.21 2.03±0.29 
Body Mass Index kg/m2± SD 28±6 28±6 30±6 
Systolic Blood Pressure mmHg ± SD 136±20 135±20 136±14 
Diastolic Blood Pressure mmHg ± SD 72±12 69±14 78±10 
Heart Rate bpm ± SD 69±13 71±12 66±10 
     
Possible Symptoms % 70 88 42 
Hypertension % 77 73 78 
Coronary Artery Disease % 45 68 36 
Ever smoked % 32 18 53 
Diabetes % 28 43 19 
Hyperlipidaemia % 65 70 53 
     









     
Peak aortic jet velocity mmHg ± SD 3.88±0.9 4.41±0.48 3.46±0.32 
Percentage ≥4m/s % 51 100 0 
Mean Gradient m/s ± SD 38±19 48±11 28±7 
Percentage ≥40 % 48 83 3 
Aortic Valve Area cm2 ± SD 0.90±0.35 0.71±0.15 1.23±.18 
Percentage ≤ 1.0 % 67 100 0 
Aortic Valve Area Index cm2/m2 ± SD 0.48±0.18 0.40±0.15 0.60±.10 
Percentage ≤ 0.6 % 77 100 0 
Bicuspid % 7 8 11 
     
COMPUTED TOMOGRAPHY 
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5.4.3 Prediction of Adverse Outcomes 
Clinical outcome data were available in 237 (26%) patients after a median of 1029 
[100-2,251] days. In total 100 patients were adjudicated to have reached the primary 
clinical end-point: with 73 having undergone AVR and 27 patients having died. On 
univariate analysis when examined as a continuous variable, the CT-AVC 
measurements (AU) predicted adverse events (HR per square root increase, 1.02 
[95% confidence intervals, 1.01-1.04]; p<0.001). Moreover CT-AVC remained the 
only significant independent predictor of clinical events after adjustment for age, sex, 
Vmax and AVA (HR per square root increase, 1.03 [95% confidence intervals, 1.00-
1.04]; p=0.004). 
 
Similar results were obtained when the sex-specific thresholds were applied and  CT-
AVC was considered as a categorical variable (severe versus non-severe). On 
univariate analysis, severe CT-AVC was associated with a 3-fold increase in the 
likelihood of AVR and death (hazards ratio, 2.73 [95% confidence intervals, 1.79– 
4.16]; p<0.001). In addition, severe CT-AVC was the only independent predictor of 
AVR and death on multivariable analysis after adjustment for age, sex, Vmax ≥4 m/s 
and AVA <1 cm2 (hazards ratio, 3.02 [95% confidence intervals, 1.83–4.99]; 
p<0.001; Figure 5.4).  
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Kaplan-Meier Curves demonstrating event free survival using the sex-specific thresholds for 
severe CT-AVC. Severe calcification was associated with an adverse prognosis (log-rank 




















Forrest plot for multivariate analysis. Sex-specific CT-AVC thresholds emerged as the only 
independent predictor of aortic valve replacement (AVR) and death.  Patients with a severe 
CT-AVC had a more than 3-fold increase in these events.  
 
 
Abbreviations: Severe CT-AVC, computed tomography aortic valve calcium score equal to or 
above the threshold for severe; AVA, aortic valve area; Vmax, peak aortic jet velocity; HR, 
hazard ratio; CI, confidence intervals; Sig, significance. 
  
HR 95% CI Sig 
   3.02 1.83 – 4.99 <0.001 
0.95 0.55 – 1.64 0.843 
0.87 0.47 – 1.60 0.653 
0.98 0.95 – 1.00 0.065 
0.89 0.58 – 1.38 0.61 
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5.5. Patients with Discordant Echocardiography 
A total of 210 (23%) patients in this study had discordant echocardiographic 
assessments of disease severity: 79 with low-flow and 131 with normal-flow. 
Considerable heterogeneity in CT-AVC scores was observed in these patients with 
103 (49%) having severe calcification and 107 (51%) having non-severe 
calcification. This heterogeneity persisted to differing extents in each of the 
subgroups examined (Figure 5.5). Within the low-flow category, 4 patients did not 
have an ejection fraction available. Severe calcification was present in 36 patients 
(52%) with paradoxical low-flow and 5 (71%) with classical low-flow aortic 
stenosis. Amongst discordant normal-flow patients, severe calcification was 
observed in 26 (74%) subjects with a high Vmax >4.0 m/s (AVA >1.0 cm2) and 33 
(34%) patients with a low Vmax <4.0 m/s (AVA <1.0 cm2).  
 
Within the discordant subgroup, outcomes were available in 44 patients in whom 21 
patients were adjudicated to have reached the primary endpoint. On univariate 
analysis, severe CT-AVC was again associated with a 3-fold increase in the 
likelihood of AVR and death (hazards ratio, 3.12 [95% confidence intervals, 1.31–
7.42]; p<0.010). On multivariate analysis, severe CT-AVC was once more an 
independent predictor of adverse outcomes (hazards ratio, 2.96 [95% confidence 
intervals, 1.12–7.80]; p=0.028) as a continuous variable after adjustment for age, sex, 
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In order to stratify for sex, CT-AVC scores were divided by the respective sex-specific 
thresholds for severe aortic stenosis (1277 AU in women and 2062 AU in men). A score 
above the dotted line represents CT-AVC above the sex-specific threshold and therefore 
severe aortic valve calcification. A CT-AVC score below the dotted line represents CT-AVC 
below the sex-specific threshold and non-severe calcification. Considerable heterogeneity in 
disease severity as assessed by CT-AVC was observed in all 4 sub-groups of patients with 
discordant echocardiographic findings. Box and Whiskers plot, error bars are from the 10th to 
90th centile and the horizontal line represents the median value.   
    
 
Abbreviations. EF, ejection fraction; Vmax, peak aortic jet velocity; AVA, aortic valve area. 
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5.6 Performance of Previously Published CT-AVC thresholds 
We repeated our analyses using the previously published CT-AVC thresholds, 
(women, 1274 AU and men, 2065 AU) which were nearly identical to the present 
thresholds (121). In women, the threshold of 1274 AU had a sensitivity of 88% and 
specificity 81%. Similarly, in men the threshold of 2065 AU had a sensitivity of 80% 
and a specificity of 82% (Table 5.4).  
 
These thresholds conferred very similar risk-prediction. On univariate analysis, 
severe calcification predicted AVR and death (hazards ratio, 2.69 [95% confidence 
intervals, 1.77– 4.11]; p<0.001) and was the only independent predictor of AVR and 
death on multivariable analysis after adjustment for age, sex, peak velocity ≥4 m/s 
and AVA <1 cm2 (hazards ratio, 2.97 [95% confidence intervals, 1.80–4.90]; 
p<0.001). 
 
When applied to the discordant population, the published thresholds reclassified 4 
patients so that numbers with severe calcification within each subgroup were as 
follows; 37 patients (54%) with paradoxical low-flow; 5 (71%) with classical low-
flow aortic stenosis; 27 (77%)  with a high Vmax >4.0 m/s (AVA >1.0 cm2) and 35 
(36%) patients with a low Vmax <4.0 m/s (AVA <1.0 cm2). For those with available 
clinical outcomes, severe calcification was again associated with a 2-3-fold increase 
in the likelihood of AVR and death on univariate analysis (hazards ratio, 2.90 [95% 
confidence intervals, 1.21–6.91]; p=0.016) and multivariate analysis (hazards ratio, 
2.70 [95% confidence intervals, 1.02-7.16]; p=0.046) after adjustment for Vmax ≥4 
m/s, age and sex.   
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5.7 DISCUSSION 
In a multicenter international registry, we present the largest study to date, 
simultaneously investigating both CT-AVC and echocardiography in patients with 
aortic stenosis. We have demonstrated that sex-specific thresholds for CT-AVC are 
highly reproducible across different patient populations and demonstrate excellent 
discrimination for detecting severe aortic stenosis. Moreover we have reaffirmed that 
CT-AVC thresholds are a powerful predictor of adverse clinical events independent 
of standard echocardiographic indices. On this basis, we believe that CT-AVC 
should be used as a complementary imaging test alongside echocardiography, 
particularly in the high proportion of aortic stenosis patients with discordant 
echocardiographic measurements and uncertain disease severity.  
 
The identification of severe aortic stenosis is essential, because in those patients with 
symptoms, this diagnosis often triggers major cardiac surgery and aortic valve 
replacement. CT-AVC holds promise as an alternative assessment of disease severity 
to complement echocardiography with the advantage that it is independent of loading 
conditions and hemodynamic influences.  CT-AVC thresholds for severe aortic 
stenosis have recently been proposed from a derivation cohort comprising 451 
patients (3), demonstrating good agreement with echocardiography and the 
prediction of clinical events in the same population (168, 181). However these 
thresholds had not previously been validated in an independent multicentre cohort 
and it was unclear if they were reproducible or generalizable in different patient 
populations or influenced by variations in imaging technology and analysis software. 
The primary objective of this study was to validate CT-AVC in aortic stenosis in an 
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independent international multi-center cohort and to investigate its widespread 
clinical applicability. We included patients from a variety of clinical settings, across 
five countries, imaged on an array of different scanners and analysed locally using a 
spectrum of different analysis software.  Moreover we tested CT-AVC against all 
four of the recommended echocardiographic measurements of disease severity in 
widespread clinical practice.  
 
Despite the heterogeneity present in our patient population, our thresholds (women 
1377 men 2062 AU) for severe disease were nearly identical to those originally 
proposed (women 1274 AU and men 2065 AU) and performed similarly well. Our 
data therefore confirm both the reproducibility of these CT-AVC thresholds for 
severe disease and their clinical utility as an alternative assessment of disease 
severity.  Whilst sex-specific thresholds for AVCi and AVCd also performed well 
compared to echocardiography, they appeared to offer little additional benefit 
especially given the added complexity of their derivation. 
 
Of primary importance is the ability of CT-AVC to predict clinical outcomes. Indeed 
assessing how quickly patients with aortic stenosis are likely to proceed to AVR and 
whether they are at risk of death are two major objectives in clinical practice. 
Echocardiographic estimation of valvular calcification has been overlooked as a 
measure of disease severity, despite conferring more powerful risk-prediction than 
all other variables currently in routine use (15). CT-AVC facilitates accurate, 
reproducible calcium quantification (116) and in a large subgroup of our population 
in whom prospective outcome data were available, we have confirmed the powerful 
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prognostic information that CT-AVC provides independent of standard 
echocardiographic and clinical variables. Indeed CT-AVC was associated with a 
three-fold increase in AVR or death, and emerged as the sole predictor of these 
events on multivariable analysis. This is despite the fact that decisions to refer for 
AVR would have been based largely on echocardiographic assessments not CT-AVC 
scores, the results of which were unavailable to clinicians.  
 
How then might CT-AVC be used in clinical practice? Consistent with previous 
studies, almost a quarter of our patients (n=210, 23%) had discordant 
echocardiographic measurements. In these patients, the severity of stenosis remained 
in question and we explored whether CT-AVC might act as an arbitrator or umpire 
test. Our results suggest that there is substantial heterogeneity in disease severity in 
these discordant patients that persisted within each of the different sub-groups 
examined. Given the lack of a gold-standard assessment of disease severity in 
discordant patients, it is important to note that CT-AVC provided similarly powerful 
prognostic information in these subjects as it did across the wider aortic stenosis 
population (hazard ratio of ~3 for AVR or death). CT AVC would therefore appear 
to hold particular value as both an arbitrator of disease severity and as a prognostic 
marker in this challenging and common cohort of patients. We believe that where 
diagnostic and prognostic uncertainty exists, CT-AVC appears to be a much more 
robust and powerful guide to patient management than the currently proposed arbiter 
of dobutamine stress echocardiography (15). The simplicity, generalizability and 
reproducibility of CT-AVC also lends itself to rapid application in the clinic and is 
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not reliant on advanced echocardiographic techniques that are more dependent on 
operator technique and expertise. 
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Patients with aortic stenosis (AS) should initially be assessed with echocardiography. In a 
quarter of patients there is discordance in echocardiographic assessments of disease 
severity, causing diagnostic uncertainty. CT-AVC provides an alternative and 
complementary assessment of disease severity.  Sex-specific thresholds (men 2062 AU, 
women 1377 AU) are highly reproducible across different patient populations and provide 
excellent discrimination for severe AS versus echocardiography (c-statistic: women 0.92, 
men 0.88). CT-AVC also provides powerful prognostic information and risk stratification. 
Patients with severe calcification have a 3-fold increase in AVR and death compared to 
those with non-severe calcification (hazards ratio, 3.02 [95% confidence intervals, 1.83–
4.99]; p<0.001 after adjustment for age, sex, peak aortic-jet velocity and aortic valve area). 
CT AVC Thresholds 
Men 2062 AU 
Women 1377 AU 
Computed Tomography   
  Aortic Valve Calcium  
             Scoring  
            (CT AVC)  
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Figure. Receiver operator curves for women (left) and men (right).  These identify aortic valve calcium score thresholds 
for severe aortic stenosis in those  patients (n=708) with concordant echocardiographic measures.  The dashed lines 
represent 95% sensitivity (horizontal) and 95% specificity (vertical).
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5.7.1 Limitations of CT-AVC scoring in aortic stenosis 
In patients with concordant measures, echocardiography is the gold-standard 
technique for defining disease severity.  We therefore first examined the diagnostic 
accuracy of the AVC thresholds in those patients with concordant measures only.  
The thresholds mostly agreed with echocardiography, however in approximately 
10% of cases there was clear disagreement. These apparent mismatches could be 
accounted for by a number of factors relating to both the disease process and the 
scanning techniques.  
 
Individual variations in pathobiology may affect the relationship between calcium 
burden and echocardiographic measurements (Figure 5.6). For example it is 
becoming increasingly appreciated that the contribution of valvular fibrosis to 
haemodynamic obstruction may have been underestimated, particularly in women 
and younger patients. Fibrosis is thought to be visible as non-calcific thickening on 
contrast CT angiography and efforts are currently underway to obtain volumetric 
measurements of this to determine whether a composite ‘fibro-calcific’ score 
improves the correlation with echocardiographic findings. Disparate findings may 
equally by explained by the pattern of calcium distribution. It is conceivable that, for 
the same volume of calcium, a diffuse pattern of calcification would restrict the 
motion of all three leaflets and have a greater impact upon the effective orifice area 
than would a focal pattern. Again, this can be visualised using CT angiography 
which, for patients undergoing work up for TAVI, is already within the imaging 
protocol.  
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Figure 5.6. Comparison of Echocardiographic and Computed Tomography Findings in 
Patients with Aortic Stenosis.  
 
In ~90% of patients echocardiography assessments of disease severity agreed with CT 
AVC. A. 71 year old male in whom both the Vmax and AVA suggested non-severe aortic 
stenosis by echocardiography. The CT AVC of 550 AU (non-severe) also indicated non-
severe disease, with no evidence of non-calcific valve thickening on CT angiography. B. 71 
year old male in whom the Vmax and AVA both indicated severe haemodynamic aortic 
stenosis. CT AVC confirmed severe calcification affecting all three cusps. 
In ~10% there was clear disagreement between the CT AVC and echocardiographic 
assessments of disease severity. C. A 72-year-old man where the Vmax and AVA confirmed 
severe aortic stenosis. However CT AVC was in the non-severe range. Contrast CT 
demonstrated non-calcific valve thickening, contributing to valve stiffening alongside the 
calcification and potentially explaining this discrepancy.  D. A 78 year old female where the 
Vmax and AVA both indicated non-severe aortic stenosis, yet the CT AVC suggested severe 
calcification. CT angiography demonstrated that this calcification was not evenly distributed 
but instead concentrated in the non-coronary cusp.  
 
Abbreviations: Vmax, peak aortic jet velocity, AVA aortic valve area; CTAVC, computed 
tomography aortic valve calcium score. 
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5.7.2 Inter-centre Variability 
In chapter 4, CT aortic valve calcium scoring was validated against 
echocardiography in a single-centre study which employed identical acquisition, 
reconstruction and analysis protocols for all the non-contrast CT scans. In addition, a 
single echocardiographer performed all of the echocardiograms. By contrast, within 
this multi-centre study, multiple different scanners and protocols were employed 
which would have inevitably introduced interscan variability. Before considering 
how this may have impacted the observed relationship between the CT calcium 
scores and echocardiographic measurements, it is important to note that the density 
factor applied in the Agatston method is arbitrary and was not validated 
histologically at the time of conception. Additionally the technique was developed 
utilising electron-beam CT, 3 mm slice thickness and increments, with a filtered back 
projection (FBR) reconstruction algorithm (182). In the intervening years, scanner 
models, acquisition methodology and imaging post-processing have advanced 
considerably.  
 
It is well recognised that image quality is inversely correlated with heart rate (183). 
Whilst CT imaging of the coronary arteries routinely utilises administration of beta-
blockers, there appears to be a perceived risk associated with their administration in 
aortic stenosis patients (with only 2 centres routinely administering beta-blockade in 
this study). Yet our experience (Chapter 4) has been that motion artefacts can have 
large effects on image quality and the final CT-AVC score. (184). Interestingly, 
variability in Agatston scores is also influenced by reconstruction intervals with 
larger scores observed at the 60% and 65% intervals (184) and optimal interscan 
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variability at the 70% interval (185). The choice of slice thickness and increment is 
also important as thinner slices are better able to detect smaller calcifications. Indeed 
almost half of small calcifications detectable on 1.5 mm scans are missed on 3.0 mm 
scans (186, 187). Lower slice thickness also minimises the effects of partial 
voluming by reducing voxel size (188, 189). The non linear weighting factor of the 
Agatston scoring means that even small artefacts can produce relatively large 
changes in the final score. 
 
Agatston scores also vary according to the scanner type (e.g. electron beam versus 
multi-detector CT) and vendor (190, 191).  This may be partly related to the  
algorithms utilised to transform the X-ray data into digital images. Whilst CT-
calcium scoring images at the University of Edinburgh utilised filtered back 
projection,  many vendors have moved to iterative reconstruction. This is thought to 
reduce noise and radiation dose without compromising image quality and has been 
associated with a trend for lower Agatston scores (190).  
 
Finally, this study has been designed on the basis that echocardiography is the gold-
standard imaging technique. It is well acknowledged however that it is subject to 
patient and operator dependent factors. Misalignment of the Doppler signal with 
aortic blood flow can result in underestimation of the peak velocity and therefore 
disease severity. Considered together, the cumulative impact of each of these 
variables may affect the observed relationship between measured CT aortic valve 
calcium scores and echocardiographic measurements (which was weaker than that 
observed in Chapter 4) and thereby explain some of the outliers. Reassuringly, 
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despite all of these difficulties, the  optimal sex-specific CT-AVC thresholds were 
still nearly identical to those previously published. However, if CT calcium scoring 
thresholds are indeed considered for incorporation into international guidelines, they 
may need to be accompanied by guidance on an optimal and unified approach to 
acquisition and reconstruction. 
 
5.8 CONCLUSIONS 
In this large multi-centre international registry of nearly a thousand patients with 
aortic stenosis, we have established the excellent accuracy of the sex-specific AVC 
thresholds for severe aortic stenosis and confirmed their independent prognostic 
capability. On this basis, we believe that CT-AVC is now ready for widespread 
clinical use as a complementary imaging test alongside echocardiography in patients 
with aortic stenosis.  
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Objectives 
To discern the utility of CT calcium scoring and the clinical accuracy of the 
continuity-derived estimations of the aortic valve area (AVACE) in patients with 
bicuspid aortic valves. 
 
Methods and Results 
This was an international, multicenter, multimodality observational imaging study. 
The study population consisted of 3 cohorts. In cohort 1, different measures of aortic 
stenosis severity were compared between bicuspid and tri-leaflet valves in patients 
who had undergone echocardiography and CT aortic valve calcium scoring (CT-
AVC). In cohort 2, the relationship between different measures of valve stenosis 
severity and the magnitude of left ventricular hypertrophy and myocardial fibrosis 
using cardiac magnetic resonance imaging (CMR) was examined. Finally the ability 
of continuity derived estimates of aortic valve area measurements to predict the 
primary endpoint of aortic valve replacement (AVR)/death was examined in those 
patients from cohorts 1 and 2 for whom outcomes were available (cohort 3). 
 
A total of 1099 patients (76±10 years, 59% male) were studied, of whom 125 had a 
bicuspid valve. Within cohort 1 (n=933), higher continuity derived estimates of 
aortic valve area (AVACE) were observed in those with bicuspid valves (n=68, 
1.07±0.35 cm) compared to those with tri-leaflet valves (0.89±0.36 cm p<0.001,). 
This was despite no differences in peak velocity (Vmax) measurements (p=0.152), or 
CT-AVC scores (p=0.313). Amongst the bicuspid population, weak correlations 
were observed between the CT-AVC scores and the AVACE r=-0.28, p<0.022 when 
compared to the Vmax, r =0.50, p<0.001. CT-AVC thresholds (women 1377, men 
2062 AU) provided excellent discrimination for severe stenosis in this population. 
 
Within cohort 2 (n=166), AVACE measurements in bicuspid valves (n=57) failed to 
correlate with either the MRI mass index (r = -0.14, p=0.310) or fibrosis volume (r= 
-0.12, p=0.376). This was not improved by substituting MRI planimetered AVA 
measurements. By contrast, in these patients, the Vmax correlated with both 
measurements: mass index, r=0.49, p=<0.001 and fibrosis volume, r=0.41, p=0.002. 
Finally within cohort 3 (n=365), AVACE measurements from patients with bicuspid 
valves (n=58) failed to independently predict AVR/death after adjustment for Vmax 
≥4 m/s, age and gender. By contrast in patients with tri-leaflet valves, an AVACE <1 
cm2 emerged as an independent predictor of AVR/death after adjustment for the 
same variables (hazard ratio =1.68, 95% confidence intervals 1.07 to 2.66, p=0.025). 
 
Conclusions 
In patients with bicuspid aortic valves, estimations of aortic valve area are larger and 
fail to correlate with objective markers of disease severity or predict clinical 
outcomes. AVA measurements in this population should therefore be interpreted 
with caution, and in low-flow states, CT-AVC thresholds could be used to arbitrate 
disease severity. 
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6.1 INTRODUCTION 
The bicuspid aortic valve was first described by Leonardo Da Vinci over 500 years 
ago (192) It is the commonest congenital heart defect and with a male 
preponderance, it is estimated to affect 0.9-1.3% of live births (84-87). Bicuspid 
valves are associated with different haemodynamic profiles to tri-leaflet valves and 
increased mechanical stresses (98, 99). This, in combination with increased genetic 
susceptibility, (93, 94) is thought to account for accelerated valvular degeneration. 
As a consequence, aortic stenosis is the commonest associated complication, 
occurring on average 5-10 years earlier than in patients with tri-leaflet valves (85). 
The predilection for aortic stenosis amongst bicuspid valves is further highlighted by 
their relatively high representation (30-50 %) amongst those undergoing surgical 
aortic valve replacement (85).  
 
Current guidelines recommend assessing bicuspid valves stenosis using 
echocardiography in the same way as for tri-leaflet valves with standard thresholds in 
the mean gradient, peak velocity and aortic valve area (175), From the previous 
chapter, it was noted that patients with bicuspid valves comprised 23% of those in 
whom the peak velocity was within the severe range (≥4 m/s), but the aortic valve 
area measurements were non-severe (≥1 cm2, Table 5.2). We hypothesized that 
differences may exist in how the different echocardiographic parameters of stenosis 
severity perform in bicuspid valves given their altered haemodynamics and opening 
profiles (127, 193, 194).  Our aim was to investigate this hypothesis in an 
international, multicenter, multi-modality imaging registry incorporating detailed 
                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
 161 
echocardiographic, magnetic resonance and computed tomography (CT) assessments 
as well as clinical outcomes.   
6.2 METHODS 
6.2.1 Study Populations 
The study involved three separate cohorts of patients with at least mild aortic 
stenosis (peak aortic jet velocity >2.5 m/s or mean gradient >10 mmHg, Figure 6.1). 
Cohort 1 compared the different measures of aortic stenosis severity on 
echocardiography and CT aortic valve calcium (AVC) scoring in bicuspid and tri-
leaflet valves within a large international aortic stenosis registry (as described in 
chapter 5). Cohort 2 examined the relationship between the different 
echocardiographic assessments of bicuspid valve stenosis and the magnitude of left 
ventricular hypertrophy and myocardial fibrosis on magnetic resonance. These 
patients had been recruited to a prospective cohort study conducted by Dr Calvin 
Chin at the Edinburgh Heart Centre, investigating the Role of Myocardial Fibrosis in 
Aortic Stenosis (NCT01755936, (195). Cohort 3 examined the relationship between 
echocardiographic measures of bicuspid aortic stenosis severity and clinical 
outcomes. It comprised patients from cohorts 1 and 2, in whom prospective outcome 
data were available. The presence or absence of a bicuspid valve was determined in 
each patient on the basis of all the available imaging data. 
6.2.3 Echocardiography 
Echocardiography was performed in all study patients according to the European 
Society of Echocardiography guidelines and used to classify patients into those with 
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bicuspid or tri-leaflet aortic valves. Measurements of aortic valve disease severity 
were performed as outlined in Chapter 2.  
6.2.4 CT Calcium Scoring 
Patients in cohort 1 were recruited as part of a large multicenter registry of patients 
with aortic stenosis. All these patients underwent CT-AVC scoring alongside 
echocardiography as an alternative assessment of aortic stenosis severity as 
previously described in Chapter 2.  
6.2.5 Cardiac Magnetic Resonance  
Patients in Cohort 2 were recruited from the Edinburgh Heart Centre as previously 
described (195). CMR was performed alongside echocardiography using a 3-T 
scanner (MAGNETOM Verio, Siemens AG, Erlangen, Germany). Aortic valve area 
was planimetered in systole on short-axis cine images of the aortic valve acquired at 
the tips of the leaflets (AVAplanim) by an observer who was blinded to 
echocardiographic measurements (Dr Russell Everett). Short-axis cine images were 
acquired and used to calculate ventricular volumes, mass, and function. Myocardial 
fibrosis was assessed in all patients using late gadolinium enhancement (LGE) and 
the T1 mapping-derived indexed extracellular volume (iECV) as a marker of the 
diffuse myocardial fibrosis volume (ECV multiplied by LV end-diastolic myocardial 
volume  (195). 
6.2.6 Outcomes 
Patients in cohorts 1 and 2 in whom prospective clinical outcome data were available 
formed cohort 3. In these patients the ability of the different echocardiographic 
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measures of severity to predict the time to the first event in the primary composite 
endpoint of aortic valve replacement (AVR) or death were examined.  
6.2.7 Statistical Analysis  
This was performed as described in Chapter 2. 






ALL PATIENTS  




Non-contrast Computed Tomography 




Cardiac Magnetic Resonance Imaging 
COHORT 3  
Clinical Outcomes Available  
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6.3 RESULTS   
In total, we examined data from 1099 patients (mean age 76±10 years, 59% male, 
with aortic stenosis, 125 of whom had a bicuspid aortic valve. CT-AVC was 
available in 933 patients in Cohort 1 (Table 6.1). Cohort 2 comprised of 166 patients 
who underwent CMR alongside echocardiography (Table 2). Prospective clinical 
outcome data were available from 365 patients who comprised Cohort 3.   
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Table 6.1. Patient characteristics COHORT 1 
 
  TRI-LEAFLET BICUSPID P value 
CLINICAL 
 
 865 68  
     
Age years ± SD 78±9 64±14 <0.001 
** 
Males %  59 72 0.039 * 
Height cm ± SD 165±11 169±8 0.009 * 
Weight cm ± SD 77±17 81±19 0.167 
Body Surface Area m2 ± SD 1.87±0.24 1.94±0.20 0.016* 
Body Mass Index kg/m2± SD 28±6 28±6.5 0.978 
Systolic Blood 
Pressure 
mmHg ± SD 137±20 131±17 0.05 * 
Diastolic Blood 
Pressure 
mmHg ± SD 72±13 75±9 0.0251* 
     
Possible Symptoms % 70 44 <0.001 
** 
Hypertension % 78 62 0.004 * 
Coronary Artery 
Disease 
% 46 27 0.001 * 
Ever smoked % 31 38 0.223 
Diabetes % 28 16 0.034 * 
Hyperlipidaemia % 67 43 <0.001 
** 




     
Peak aortic jet 
velocity 
mmHg ± SD 3.88±0.88 3.72±0.95 0.152 
Percentage ≥4m/s % 51 44  
Mean Gradient m/s ± SD 39±19 36±19 0.191 
Percentage ≥40 % 48 43  
Aortic Valve Area cm2 ± SD 0.89±0.36 1.07±0.35 <0.001*
* 
Percentage ≤ 1.0 % 68 43  
Aortic Valve Area 
Index 
cm2/m2 ± SD 0.48±0.17 0.55±0.18 0.001* 
Percentage ≤ 0.6 % 77 60  
     
LVOT Diameter cm ± SD 2.12±0.21 2.29±0.94 <0.001 
** 
Valsalva Diameter cm ± SD 3.29±0.44 3.64±0.65 <0.001*
* 
Tubular Diameter cm ± SD 2.92±0.71 3.48±0.94 <0.001 
** 
Ejection Fraction % ± SD 59±12 60±15 0.634 
     
 
COMPUTED TOMOGRAPHY 
Aortic Valve Calcium 
Score 





Abbreviations; LVOT, left ventricular outflow tract 
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6.4 COHORT 1 
6.4.1 Assessment of valve stenosis and calcification 
 
In Cohort 1, 865 patients had a tri-leaflet valve and 68 had a bicuspid valve. The 
latter were younger and had fewer co-morbidities. The severity of aortic stenosis was 
similar in the patients with bicuspid versus tri-leaflet valves according to the peak 
velocity, mean gradient, peak gradient and the CT calcium score. The only 
echocardiographic parameter that differed between the groups was the AVACE, 
which was higher in patients with bicuspid versus tri-leaflet valves (Table 6.1). This 
difference in AVA persisted after indexing for body surface area.  
 
Similar findings were observed when analysis was restricted to those patients with 
severe aortic stenosis (peak velocity of ≥4 m/s). Once again those with bicuspid 
aortic valves had values for AVACE that were more than 20% higher than patients 
with tri-leaflet valves (0.84 cm2 versus 0.69 cm2 respectively <0.001) despite having 
similar peak aortic jet velocities (p=0.994), mean gradients (p=0.821) and aortic 





















6.4.2 Computed Tomographic Calcium Scores. 
In bicuspid valves, whilst the correlations between CT-AVC and both Vmax and 
mean gradient were good, the association with AVACE was extremely weak (r2=0.08, 
p=0.022). By contrast, in tri-leaflet valves CT-AVC correlated well with all 
echocardiographic measurements of severity (Table 6.2, Figures 6.2 and 6.3). The 
observed association between CT-AVC and Vmax was stronger in younger patients 
(age ≤60 years; n= 22, r=0.67, p=0.001).  
 
To discern the ability of CT-AVC to act as an arbitrator of disease severity amongst 
patients with bicuspid valves and concordant echocardiographic measurements, an 
umpire test was performed using the validated sex-specific CT-AVC thresholds 
(1377 in women and 2062 in men). There was excellent agreement between the CT-
AVC scores and echocardiographic measurements. Patients with concordant severe 
disease had CT-AVC scores over double those with concordant-non severe disease 
(median CT-AVC of 3359 versus 1180 AU respectively, p<0.001, Figure 6.4). 
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Table 6.2. Correlation between computed tomography aortic valve calcium scores 
(CT-AVC) and echocardiography. 
 








BICUSPID CT-AVC     
Correlation 0.50 0.46 -0.28 -0.38 
95% CI 0.26  to 0.70 0.22  to  0.66 -0.48 to -0.08 -0.58 to - 0.17 
Sig. p<0.001 p=0.001 p=0.022 P=0.002 
N 68 68 68 68 
TRI-LEAFLET CT-AVC    	
Correlation 0.67 0.62 -0.50 -0.49	
95% CI 0.64  to 0.70 0.62 to 0.69 -0.54 to -0.45 -0.58  to -0.50 
Sig. p<0.001 p<0.001 p<0.001 p<0.001	
N 865 865 865 861	
Abbreviations; Vmax, peak aortic jet velocity; AVACE, continuity equation-derived aortic 
valve area; AVAi, indexed aortic valve area; CI, confidence intervals, CT-AVC; computed 
tomography aortic valve calcium scores. 
 
 
Correlations are shown between individual echocardiographic measures of severity (Vmax, 
mean gradient, aortic valve area and indexed aortic valve area) and the computed 




Figure 6.2 Peak velocity versus computed tomography aortic valve calcium (CT-AVC)  
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Figure 6.3. Linear regression curve for the computed tomographic aortic valve 






























Associations between the (CT-AVC) scores and the aortic valve area for bicuspid valves 
(blue) compared to tri-leaflet valves (black). The dotted grey lines indicate the 95% 
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Figure 6.4  Computed tomography aortic valve calcium (CT-AVC) scores in patients 



































Box and Whiskers plot. A score above the dotted line represents CT-AVC above the sex-
specific threshold and therefore severe aortic valve calcification. A CT-AVC score below the 
dotted line represents CT-AVC below the sex-specific threshold and non-severe calcification. 
Patients with concordant-severe aortic stenosis, as defined by echocardiography, had CT-
AVC ratios that were more than double those with concordant non-severe disease. Error 
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6.5 COHORT 2 
6.5.1  Assessments of left ventricular remodelling 
In Cohort 2, 109 patients had a tri-leaflet and 57 a bicuspid valve. In all patients, 
planimetered measurements from the MR were available for comparison with AVA 
measurements derived using the continuity equation. A strong correlation was 
observed between values for AVAplanim and the echocardiographic AVACE (r=0.75 
p<0.001). However measurements for AVAplanim were 50% higher than AVACE 
regardless of valvular morphology (mean AVA value 1.53 ± 0.55 cm2 versus 0.95 ± 
0.028 cm2 respectively,  p<0.001, average bias=0.49 ± 0.40 cm2, 95% limits of 
agreement = -0.29 to 1.28 cm2). When patients with a peak velocity of ≥4 m/s were 
selected, there appeared to be a trend for lower mean values for AVAplanim in 
bicuspid valves compared to tri-leaflet valves although this fell just short of 
statistical significance (mean AVAplanim value 1.20 ± 0.35 cm2 versus 1.36 ± 0.32 
cm2 respectively, p=0.053). A stronger correlation was seen between the peak 
velocity and the AVACE compared to the AVAplanim (-0.667 95% CI [-0.64 to -0.80] 
and r=-0.551 95% CI [-0.19 to -0.68], respectively, both p<0.001). CMR 
measurements again confirmed that the bicuspid patients had larger LVOT 
diameters.  
 
Data on the hypertrophic response and myocardial fibrosis were available in all the 
patients with a bicuspid aortic valve (Tables 6.3 and 6.4). Moderate but significant 
correlations were observed between these two markers of left ventricular remodelling 
and both the peak velocity and the mean gradient. By contrast the AVA whether 
assessed using planimetry or the continuity equation did not demonstrate any 
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association with either the LV mass index nor the fibrosis volume (Table 6.4).  
Amongst patients with tri-leaflet valves a significant correlation was observed 
between the AVACE and the LV mass index but not the fibrosis volume.  
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Table 6.3 Patient characteristics COHORT 2 
 
  
TRI-LEAFLET BICUSPID P value 
CLINICAL 
 
 109 57  
     
Age years ± SD 73±7 59±12 <0.001 ** 
Males %  59 72 0.054 
Height cm ± SD 165±8 170±7 <0.001 ** 
Weight cm ± SD 79±15 82±14 0.222 
Body Surface Area m2 ± SD 1.85±0.18 1.93±0.18 0.015* 
Body Mass Index kg/m2± SD 29±5 28±4 0.291 
     
Systolic Blood Pressure mmHg ± SD 154±20 144±21 0.003 * 
Diastolic Blood Pressure mmHg ± SD 83±11 86±12 0.107 
     





     
Peak aortic jet velocity mmHg ± SD 3.73±0.77 4.02±1.09 0.048* 
Percentage ≥4m/s % 40 53  
Mean Gradient m/s ± SD 32±14 40±25 0.009* 
Percentage ≥40 % 27 46  
Aortic Valve Area cm2 ± SD 0.95±0.35 0.94±0.36 0.751 
Percentage ≤ 1.0 % 65 65  
Aortic Valve Area Index cm2/m2 ± SD 0.51±0.18 0.49±0.19 0.441 
Percentage ≤ 0.6 % 74 82  
     
LVOT Diameter cm ± SD 2.17±0.19 2.054±0.23 <0.001** 
Valsalva Diameter cm ± SD 3.33±0.63 3.76±0.85 <0.001 ** 
Tubular Diameter cm ± SD 2.97±0.71 3.01±0.94 <0.001 ** 
Ejection Fraction % ± SD 59±12 60±15 0.634 
     
CARDIAC MRI 
CARDIAC MRI  
 
     
Planimetered AVA cm2 ± SD 1.60±0.50 1.39±0.62 0.018 
Mass Index mL/m2 87±19 92±25 0.129 
Fibrosis Volume mL/m2 23±8 24±9 0.438 
LVOT diameter cm ± SD 1.94±0.7 2.36±0.4 <0.001 ** 
Valsalva Diameter cm ± SD 2.59±1.2 3.14±0.9 0.002* 
Tubular Diameter cm ± SD 3.15±0.92 3.72±0.68 <0.001 ** 
Abbreviations; LVOT, left ventricular outflow tract 
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Table 6.4 Correlations between cardiac magnetic resonance (CMR) and 
echocardiography.  
 
 MASS INDEX FIBROSIS VOLUME 
BICUSPID    
AVACE  (cm2) 
Correlation -0.14 -0.12 
Significance p=0.310 p=0.376 
Number 56 56 
VMAX (m/s)   
Correlation 0.49 0.41 
Significance p<0.001 p-0.002 
Number 57 57 
MEAN GRADIENT (mmHg) 
Correlation 0.50 0.40 
Significance p<0.001 p<0.001 
Number 57 57 
TRI-LEAFLET   
AVACE  (cm2)   
Correlation -0.21 -0.10 
Significance p=0.028 p=0.286 
Number 108 108 
VMAX (m/s)   
Correlation 0.46 0.29 
Significance p<0.001 p=0.003 
Number 109 109 
MEAN GRADIENT (mmHg) 
Correlation -0.44 0.25 
Significance p<0.001  p=0.008 
Number  109 109 
PLANIMETERED AVA (cm2)  
BICUSPID VALVE   
Correlation -0.02 -0.06 
Significance p=0.873 P=0.695 
Number 56 56 
TRI-LEAFLET 
VALVE   
Correlation -0.07 -0.04 
Significance p=0.477 P=0.658 
Number 165 165 
Abbreviations; AVA, aortic valve area, AVACE; continuity equation 
derived aortic valve area; Vmax, peak aortic jet velocity;  
Correlations are shown between cardiac magnetic resonance imaging measurements of 
mass index and fibrosis volume with echocardiographic measurements of severity; aortic 
valve area; peak aortic jet velocity; mean aortic gradient and CMR planimetered aortic valve 
measurements.  
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6.6 COHORT 3. 
6.6.1 Outcomes 
Clinical outcomes of AVR and death were available for 58 of the patients with 
bicuspid aortic valves. Of these 29 reached the primary endpoint of AVR/death (28 
AVR, 1 died). On multivariate cox regression analysis, AVA did not emerge as an 
independent predictor of AVR or death after adjustment for age, gender and peak 
velocity >4 m/s, By contrast, both the peak velocity and mean gradient were 
independent predictor of these events after similar adjustment (hazard ratio 4.93 for 
Vmax ≥4 m/s, 95% confidence intervals 1.86 to 13.09, p=0.001; hazard ratio 4.32 for  
mean gradient ≥ 40mmHg, 95% confidence intervals 2.09 to 8.97, p<0.001). In 
patients with tri-leaflet aortic valves, outcomes were available for 307 patients of 
whom 40 reached the primary endpoint (28 AVR, 12 deaths). In this cohort, AVA 
provided powerful prognostic information. Indeed, an AVA <1 cm2 emerged as the 
sole independent predictor of AVR/death on multivariate analysis (hazard ratio 1.68, 
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Figure 6.5 Prediction of adverse clinical events.  
  
Multivariate cox regression analysis for prediction of the primary composite endpoint of aortic 
valve replacement or death. Hazard ratios are plotted with 95% confidence intervals for 
patients with bicuspid (white diamond) and tri-leaflet (black diamond) valves. Within the 
bicuspid population an AVA < 1cm2 fails to independently predict clinical events once 
entered into the multivariate model. 
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6.7 DISCUSSION 
The results of this large multimodality imaging study demonstrate that AVA 
measurements do not provide an accurate assessment of aortic stenosis severity in 
patients with a bicuspid valve. Specifically, in bicuspid valves, AVACE 
measurements tend to underestimate the severity of stenosis, demonstrate poor 
correlation with other markers of valve stenosis severity and markers of left 
ventricular remodeling, and do not predict the development of future clinical events. 
By contrast, and in line with clinical guidelines, AVACE measurements demonstrated 
good association with each of these parameters in patients with tri-leaflet valves.  
 
Our data suggest that in the bicuspid population continuity equation derived 
estimates of the AVA are higher than expected and therefore tend to underestimate 
aortic stenosis severity. This could either by explained by differences in valve 
geometry and flow-dynamics that exist between bicuspid and tri-leaflet valves or 
measurement errors in the continuity equation (possibly related to larger LVOT 
diameters) when applied to these patients. Further work is required to better 
understand this important issue, however it appears that irrespective of the method of 
calculation, AVA values underestimate stenosis severity in bicuspid valves.  
 
Having proposed a clinical role for computed tomography calcium scoring of the 
aortic valve in the previous 2 chapters, we next examined whether this technique 
could be applied to those with bicuspid aortic valves. There were no overall 
differences in CT-AVC scores between the bicuspid and tri-leaflet populations in our 
cohort and in contrast to the findings of a previous study (127),  we observed higher 
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correlations between CT-AVC scores and peak velocity measurements in the 
younger bicuspid patients. The extremely weak association between the AVACE and 
CT-AVC in the bicuspid population is likely to again reflect inaccuracies in 
continuity equation derived AVA estimates when applied to this population rather 
than problems with CT-AVC. Indeed, amongst those with bicuspid valves and 
concordant echocardiography, the new sex-specific CT-AVC thresholds provided 
excellent discrimination for severe stenosis supporting its utility as an umpire test in 
all discordant patients irrespective of whether the valve is bicuspid or trileaflet.  
 
AVACE measurements in patients with bicuspid valve disease also failed to correlate 
with alternative markers of stenosis severity as assessed using both echocardiography 
and CT calcium scoring. This was despite these markers correlating closely with 
each other. Moreover, AVA measurments failed to correlate with markers of LV 
remodeling including the magnitude of the hypertrophic response and the degree of 
myocardial fibrosis (as a maker of LV decompensation). These processes develop in 
response to the increased afterload associated with progressive valvular stenosis. The 
lack of association therefore adds to concerns regarding the ability of AVACE to 
assess bicuspid valve stenosis.  
 
Finally we assessed whether AVACE measurements might predict clinical events in 
patients with bicuspid valves. Once again whilst the Vmax and mean gradient both 
provided independent prediction of adverse clinical events AVACE failed to do so. 
Such events are closely related to the severity of valve narrowing providing a final 
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line of evidence that AVACE does not provide a clinically useful assessment of this 
parameter.  
 
Are the problems with AVA generic or simply confined to patients with bicuspid 
aortic valve disease? We were able to answer this question by investigating AVA in 
over 900 patients with tri-leaflet aortic valves. In these patients AVA performed well 
providing agreement with the other markers of aortic stenosis severity, assessments 
of LV remodeling and providing independent prediction of clinical events. Our data 
would therefore support continuing use of this parameter in the majority of patients 
with aortic stenosis whilst urging considerable caution in use of AVA in patients 
with bicuspid valves.  
6.7.1 Limitations 
As advanced imaging was not performed in all patients, the true incidence of 
bicuspid valves in patients undergoing echocardiographic assessment alone is likely 
to be underestimated. However any underestimation would dilute any differences 
between the two groups and reduce the likelihood of significant differences. 
6.8 CONCLUSION 
In summary, in patients with a bicuspid valve, the continuity equation estimates of 
the aortic valve area are larger and exhibit weaker associations with upstream and 
downstream markers of disease severity and clinical outcome. Considerable caution 
should be taken in interpreting AVA measurements in patients with bicuspid valves.  
This is of particular relevance in patients with discordant measurements in whom an 
AVACE value outwith the severe range could create false reassurance or clinical 
uncertainty thereby delaying referrals for aortic valve implantation. We would 
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therefore advocate that in patients with bicuspid aortic valves and normal flow, the 
values for peak aortic jet velocity should supercede all others. In those with low-flow 
states, the sex-specific CT-AVC could provide an alternative technique for 
identifying those with severe stenosis. 
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Conclusions and Future Directions 
8.1 18-F-FLUORIDE POSITRON EMISSION TOMOGRAPHY 
18F-Fluoride PET-CT detects and quantifies novel microcalcification beyond the 
resolution of CT, making this the earliest biological process in aortic stenosis which 
we are currently able to image. On this basis, it is anticipated that detectable changes 
in the PET signal will long precede those identified using CT calcium scoring or 
echocardiography. Additionally, 18F-fluoride PET activity correlates with aortic 
stenosis disease severity, predicts disease progression and adverse clinical events 
(104, 147, 196). On the basis of these findings, it is hoped that 18F-fluoride may be 
able to predict the natural history of patients with aortic stenosis. Additionally these 
properties inform its future promise as surrogate clinical endpoint in aortic stenosis 
clinical trials testing the efficacy of novel therapeutic agents. If this potential is 
realised, this would transform the design of these trials by obviating the requirement 
for very large sample sizes and protracted follow up. 
8.1.1  Optimised 18F-Fluoride Reproducibility. 
The revised methodology of right atrial blood pool sampling and calculation of the 
mean standard uptake value for the most diseased segment of the valve has improved 
scan-rescan reproducibility to an error of only 10%. Given that a novel agent with a 
clinically relevant impact is likely to have an efficacy exceeding this (~>20%), 
meaningful drug effects should be detectable.  However enhanced reproducibility 
does not necessarily translate to enhanced accuracy, and the sensitivity of 18F-
fluoride PET to the effects of disease modifying therapies is yet to be established. 
Furthermore, it is not yet known whether this technique is able to track disease 
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progression in aortic stenosis, nor whether it truly offers incremental information 
over and above the far simpler technique of CT calcium scoring. In order to truly 
discern and validate the application of 18F-fluoride in this context, these outstanding 
issues are currently being addressed in the Saltire 2 randomised controlled trial in 
which 18F-fluoride PET uptake of the valve at 12 months is an exploratory 
secondary endpoint. 
8.1.2 Optimised Methods for Spatial Localisation of Radiotracer Uptake 
Previous work has suggested that the baseline valvular 18F-fluoride PET predicts the 
subsequent spatial distribution of macrocalcification on CT (Figure 1.4, (147). 
Modified techniques have sufficiently improved image quality so that calcification 
activity can be now localized more accurately. Therefore this key hypothesis, which 
is central to the utility of 18F-fluoride PET as a calcification biomarker, can also 
now be verified prospectively. Further work first needs to be done to achieve a more 
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8.2 COMPUTED TOMOGRAPHY AORTIC VALVE CALCIUM SCORING 
 
Computed tomography calcium scoring (CT-AVC) is cheap, widely accessible, has 
an acquisition time of seconds, requires no contrast and is associated with low 
radiation doses. Additionally, the process of assigning a calcium score using 
commercially available software is relatively quick and straightforward. On this 
basis, the technique holds appeal for patients and practitioners alike. In a series of 
studies, we sought to determine how this tool may be harnessed to improve clinical 
care for patients with aortic stenosis. 
8.2.3   Reproducibility of Aortic Valve Computed Tomography Calcium Scoring  
Within the context of a single-centre study we established that the reproducibility of 
CT calcium scoring is within acceptable limits for clinical application. Inter and intra 
observer reproducibility were excellent and scan-rescan reproducibility was 
associated with an error of approximately 14%. The two challenges with the greatest 
impact on reproducibility were motion artefact and confluent calcium, both of which 
produce falsely elevated calcium scores. The presence and degree of motion artefact 
can be minimised by judicious use of rate-limiting medication. A subjective 
judgement on the scan quality then needs to be made before analysis. Deciding how 
to exclude calcium extending into extra-valvular structures is a commonly 
encountered challenge and can only be overcome by operator experience and 
consistent methodology. This may explain some of the proportional bias seen with 
the technique whereby higher scores were associated with worse reproducibility. 
Reassuringly the impact of this is minimal beyond a certain threshold. Indeed the 
clinical application of CT-AVC is expected to involve the categorical classification 
of patients using sex-specific thresholds for severe calcification. On this basis, the 
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absolute score is less significant and the aforementioned limitations are only likely to 
influence patients with borderline scores. Indeed when scan-rescan agreement for CT 
calcium scoring as a categorical variable was tested in the substudy, agreement was 
100%. 
8.2.4 Aortic Valve Calcium and Disease Severity 
In the Ring of Fire study (Chapter 4), strong linear correlations were observed 
between the CT calcium scores and the echocardiographic measurements. This was 
in contrast to the more moderate relationship observed in the multicenter study 
(Chapter 5). Some of this discrepancy will relate to the different sample populations. 
Whilst a full spectrum of disease (from controls to very severe) were examined in the 
Ring of Fire study, the multicentre study consisted mainly of a cluster of patients 
with moderate or severe aortic stenosis. Other factors likely to have influenced the 
observed correlation between these two variables within the multicentre study were 
explored in detail in chapter 5. These included scanner type, scanner vendor, 
acquisition protocols, reconstruction algorithms and observer expertise. The 
correlation coefficients derived from the research cohorts were generally higher than 
those observed in clinical cohorts. This is perhaps unsurprising and to ensure a more 
seamless transition into the clinical arena, guidelines describing the clinical 
application of CT calcium scoring in aortic stenosis should be accompanied by 
guidance on image acquisition, reconstruction and analysis to ensure a unified 
approach. 
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8.2.5 Sex Differences in Aortic Valve Calcification 
CT calcium scoring needs to be interpreted in light of patient demographics. A 
consistent finding in this thesis and in previous studies was that women need less 
calcium than men to achieve the same degree of obstruction, even after correction for 
smaller body size (121). Whilst generally accepted, this observation remains 
unexplained. The current working hypothesis is that it relates to a greater degree of 
valvular fibrosis in women. This has not yet been conclusively substantiated 
although it is supported by anecdotal evidence (Figure 7.1). Similarly, whilst 
biological differences are likely to be explained by androgen-receptor pathways, this 
is not confirmed and available data examining the effect of sex hormones on 
inflammation, fibrosis and calcification is conflicting (197, 198). Volumetric analysis 
of non-calcific thickening using contrast CT scans is currently being performed in 
the Saltire 2 cohort to discern whether its inclusion improves the correlation between 
echocardiography and CT-AVC scores. Ultimately the development of a composite 
fibro-calcific score which may better reflect the disease process and facilitate tailored 
treatment plans is envisaged. It is conceivable that a predominantly fibrotic disease 
process may follow a more indolent course and respond better to antifibrotic 
therapies, such as Angiotensin Converting Enzyme inhibitors. Regardless of the 
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A 58-year-old woman with aortic stenosis investigated by echocardiography and CT. (A) 
Doppler echocardiography demonstrating a peak aortic valve (AV) velocity of 3.6 m/s, a 
mean gradient of 27 mm Hg and an aortic valve area (AVA) of 0.8 cm2 based upon the 
continuity equation. (B) Non-contrast calcium scoring CT in the axial plane showing minimal 
aortic valve calcification (AV calcium score 37 AU). (C) Images from contrast-enhanced CT 
in the en face plane and (D) coronal plane revealing marked leaflet thickening with low 
attenuation signal suggestive of valve fibrosis. AO, aorta; AV, aortic valve; AVA, aortic valve 
areas; PG, pressure gradient; VTI, velocity time integral. 
 
  
Timothy R G Cartlidge et al. Heart 2017;103:8-9 
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8.2.7 Sex-specific CT-AVC thresholds 
On the basis of observed gender differences, sex-specific CT thresholds (women 
1274 AU and men 2065 AU) have previously been proposed from a derivation 
cohort comprising 451 patients (121, 168). This cohort only consisted of patients 
recruited into prospective clinical studies being conducted in expert centres (121). To 
determine how these thresholds performed in a ‘real-world’ scenario, we determined 
our own thresholds for severe calcification in an international, multicenter, 
multivendor registry. Despite the intentional heterogeneity present in our patient 
population, our thresholds (women 1377 men 2062 AU) for severe disease were 
nearly identical to those originally proposed and demonstrated excellent 
discrimination for detecting severe aortic stenosis. Indeed CT calcium scoring agreed 
with echocardiography in approximately 90% of cases and patients with concordant-
severe disease had AVC scores that were more than double those in patients with 
concordant non-severe disease. 
8.2.7 Bicuspid aortic valves 
When applied to the bicuspid population, these sex-specific CT thresholds again 
provided excellent discrimination for identifying those with severe aortic stenosis. 
This is of particular importance in these patients as we also identified that both 
continuity-derived and MRI planimetered assessments of aortic valve area were 
inaccurate. Indeed the peak velocity measurements provided the best assessment of 
disease severity when compared to downstream markers of disease severity and 
clinical outcomes. Sex-specific CT-AVC thresholds could provide a complementary 
technique for the assessment of disease severity, particularly in patients with 
suspected low-flow states or poor echocardiographic windows. 
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Previously published data has advised caution when applying CT-AVC scoring in 
younger patients with bicuspid aortic valves (127). These authors observed weaker 
correlations between CT calcification and echocardiographic measurements in this 
subgroup and speculated whether this could be explained by valvular fibrosis. By 
contrast, within our cohort, the highest correlations between peak velocity and CT 
calcification were actually observed in the youngest bicuspid valve patients. The 
reasons for this discrepency are unclear although our sample size was considerably 
larger and where possible, a multimodality approach to the identification of bicuspid 
valves was adopted. Nonetheless to examine this further, volumetric analysis of non-
calcific thickening is being performed within bicuspid subgroups in an attempt to 
determine the fibrotic burden in these patients.  
 
8.2.8  CT Aortic Valve Calcium and Clinical Course. 
In comparison to echocardiography, the baseline calcium score appeared to offer the 
best prediction of disease progression whether this was measured using annualised 
changes in calcium score or peak velocity. In addition, annualised changes were 
more easily detectable using CT calcium scoring than echocardiography. Of primary 
importance, CT aortic valve calcium scoring was the most powerful predictor of the 
primary composite endpoint of death and aortic valve replacement. Furthermore sex-
specific CT thresholds predicted aortic valve replacement and death independently of 
all the variables used to guide clinical decision-making (age, peak velocity and aortic 
valve area). This was despite clinicians being blinded to the calcium scores.  
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Vascular calcification is a recognised marker of adverse cardiovascular prognosis. 
Aortic arch calcification, abdominal aortic calcification and aortic sclerosis have all 
been shown to provide powerful risk prediction of coronary heart disease (199-201) 
and as previously discussed, even a crude, subjective echocardiographic assessment 
of valvular calcium burden provides more powerful risk prediction than all other 
echocardiographic variables (15). Vascular calcification is likely to be a marker of 
endothelial dysfunction, inflammation, altered calcium metabolism, lipid 
accumulations and genetic polymorphisms, all processes which contribute to adverse 
cardiovascular events (26). On this basis it was reassuring that the adverse events 
observed in this thesis were primarily driven by aortic valve replacements. This 
indicates that the thresholds predict clinical decompensation in patients who are 
candidates for invasive treatments as opposed to simply those who are at high risk of 
cardiovascular mortality. 
8.2.9 Clinical Application of sex-specific CT-AVC thresholds 
On the basis of the above findings, we believe that sex-specific CT-AVC thresholds 
should enter routine clinical practice to arbitrate disease severity in patients for 
whom clinical decision making is being hampered by inconclusive 
echocardiographic findings. The current ESC guideines recommend dobutamine 
stress echo as the first line investigation for patients with suspected low-flow, low 
gradient aortic stenosis (152). CT-AVC scoring is advised as a last resort only, 
however it is a far simpler technique and would be of particular value in those 
patients suboptimal echocardiographic windows or in centres where there is 
insufficient technical expertise.  
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It is important to note however that there was clear disagreement between CT and 
echocardiography in approximately 10% of patients with concordant 
echocardiography. This raises an interesting conundrum. Given that the calcium 
score is the more powerful predictor of adverse events, which is of more clinical 
significance for the patient; an echocardiographic diagnosis of severe aortic stenosis 
or a CT diagnosis? Current data suggest the latter, in which case should all patients 
with symptoms and a calcium score above the threshold be referred for surgery. To 
take this a step further should asymptomatic patients with severe CT calcification 
also be referred for surgery? These questions can only be definitively addressed in 
prospective studies. Although it is first important to note that, to date, CT-AVC 
thresholds have been derived from patients recruited from Europe and North 
America. The Multi-Ethnic study of atherosclerosis has demonstrated that coronary 
artery calcium scores need to be interpreted in light of age, gender and ethnicity 
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8.3 CLINICAL PERSPECTIVE 
Aortic stenosis is a significant and growing public health burden. Whilst the 
prevalence is undoubtedly higher in older patients, there is considerable 
heterogeneity within this population with respect to age, co-morbidity, clinical 
course and pathophysiology. Despite this, there is a failure to individualise strategies 
for defining disease severity, surveillance and intervention. Echocardiography is the 
gold-standard investigation for guiding clinical decision however the emergence and 
refinement of complementary calcification imaging techniques in tandem with 
advancements in deciphering the pathophysiology will facilitate a clinical approach 
tailored to individual patients.  This could avoid protracted and potentially 
unnecessary follow-up for the large proportion of patients in whom aortic stenosis 
never progresses beyond the mild stage whilst appropriately diverting resources to 
those who are at risk of adverse clinical events. This will translate to improved care 
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8.4 FUTURE PERSPECTIVES 
This thesis has examined at length how the measurement of valvular calcification can 
be applied to improve patient care. However it remains to be established whether 
calcium metabolism can also be targeted by drug therapies. A medical treatment 
capable of modifying the clinical course of aortic stenosis is highly desirable yet 
remains elusive and as the complexity of aortic stenosis pathophysiology is being 
gradually unmasked, so too are attractive novel therapeutic targets. This is likely to 
form the cornerstone of future research in aortic stenosis. 
8.4.1 Medical Treatment of Aortic Stenosis 
Saltire 2 is a proof of concept clinical trial exploring whether currently available 
osteoporosis medications can be repurposed to modify disease progression in aortic 
stenosis (Appendix 1). Patients have been randomised to alendronic acid (n=50), 
denosumab (n=50) or their respective matched placebos (n=50). The  primary 
endpoint is the aortic valve calcium score at 2 years. 18F-Fluoride PET uptake at 1 
year is a major exploratory secondary endpoint. Other secondary endpoints include 
the change in thoracic aortic and coronary 18F-fluoride uptake at 1 year and the CT 
calcium score at 2 years. In an attempt to futher understand the calcification paradox, 
nested mechanistic studies will explore associations between serum and imaging 
biomarkers and relate these to histological findings when possible. The study design 
also provides a unique platform upon which to further optimise and validate the 
current calcification and fibrosis imaging techniques within the context of a 
longitudunal study. If a positive outcome was subsequently confirmed in a larger 
phase 3 trial powered for clinical endpoints, this would represent a major clinical 
breakthrough. 
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Even if these therapies prove ineffective, it is likely that that future treatments should 
still be directed at breaking the self-perpetuating cycle of valvular injury, osteogenic 
differentiation and calcium deposition. A rapidly expanding list of signaling 
pathways and molecular processes governing the pathogenesis of aortic stenosis have 
been elucidated uncovering many additional targets at different phases of the disease. 
Ultimately many of the pro-calcific pathways in the valve appear to converge on the 
up regulation of osteogenic differentiation factors (e.g. BMP-2, Wnt-catenin) that 
establish osteoblast-like function within the valve. These factors therefore provide an 
attractive therapeutic strategy although given the overlap in factors governing 
calcification in the bone and the valve, the major challenge will be to slow aortic 
stenosis progression without compromising bone health.  One potential approach 
would be to target the upstream cytokines that activate BMP such as using inhibitors 
of IL-6 or TNF-α (as already used in rheumatoid arthritis). However, once again it 
remains unclear whether targeting inflammation will be effective in the propagation 
phase once the pro-calcific processes have become established. Targeting 
ectonucleotidases may be more effective given their apparently central role in 
establishing the positive feedback loop by which calcium begets calcium.  Indeed 
ectonucleotidase inhibitors have already been tested in the warfarin rat model and 
have been shown to prevent the development of calcific aortic valve disease (203), 
whilst interest also surrounds P2Y2 receptor antagonists as a means of reducing VIC 
apoptosis and the calcification that this induces. Therapeutic administration of 
Fetuin-A, or a mimetic of MGP could simultaneously target multiple pathways 
thought to drive valvular calcification. In addition further investigation is warranted 
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to assess whether potentially pro-calcific drugs, including calcium supplements and 
coumarins, should be avoided in patients with aortic stenosis. 
 
Therapies targeting non-calcific pathways may also be of importance. The ability of 
Lipoprotein (a) lowering therapies to modify aortic stenosis disease progression, is 
likely to form the basis of a future clinical trial.  Given the failure of the statin trials, 
it will be of great interest to determine whether a more targeted lipid intervention 
will have greater success in reducing disease progression in the propagation phase 
(204).  
 
Based on the apparent contribution of the renin-angiotensin system (RAS) to the 
initiation of aortic stenosis, it is also not unreasonable to consider the therapeutic 
potential of angiotensin-converting enzyme inhibitors, selective angiotensin 1 
receptor antagonists or novel renin inhibitors as treatments particular in patients 
assumed to have a higher susceptibility to valvular fibrosis (205). Indeed, these 
agents are also likely to have a beneficial effect with respect to hypertension and left 
ventricular remodelling in aortic stenosis, given the role that the RAS system also 
plays in driving myocardial hypertrophy, fibrosis and the transition to heart failure. If 
CT angiography is confirmed as being capable of quantifying non-calcific valvular 
thickening and fibrosis, this could be employed in combination with calcification 
imaging techniques to better direct therapeutic strategies, although it is likely that 
most patients will require simultaneous targeting of calcification and fibrosis 
pathways. 
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8.4.2 Early surgical intervention 
There has been much debate on the role of  early surgical intervention in patients 
with asymptomatic severe aortic stensosis. The landmark paper by Ross and 
Braunwald which continues to guide current clinical practice, (14) was published in 
1968, long before the advent of advanced cardiac imaging. Whilst many patients 
with truly asymptomatic severe stenosis do enjoy a good prognosis, it is not 
unreasonable to question whether those with high risk features should undergo aortic 
valve replacement prior to clinical decompensation. Indeed this forms the basis of 
the early surgical intervention trial EVOLVED-AS (NCT03094143) in which 
patients with asymptomatic, severe aortic stenosis and myocardial fibrosis are being 
randomised to either continued watchful waiting or early surgery. This important 
question is therefore being addressed. However, given the overwhelmingly powerful 
risk prediction afforded by CT calcium scoring, another potentially exciting 
approach would be to investigate whether severe calcification on CT should be a 
criterion for aortic valve replacement in the context of a similar prospective 
randomised controlled trial.  
8.4.3 Conclusion 
To conclude, in recent years there has been a paradigm shift with respect to the 
perceived role of calcification in aortic stenosis. Formerly considered a passive 
process, it is now appreciated to be complex, potentially modifiable and the principle 
factor dictating both disease progression and clinical outcomes. Calcification should 
therefore take centre stage with respect to the development of complementary 
imaging modalities and future therapies. 
 



































































































































































































































































































































































































































































































































































































































































































































































Bisphosphonates	 and	 RANKL	 Inhibition	 in	 Aortic	 Stenosis.		
Study	Protocol	for	Randomized	controlled	trial	
 
                                        IMAGING CALCIFICATION IN AORTIC STENOSIS 
 213 
1.0 STUDY DESIGN 
Saltire 2 (NCT02132026) will be a prospective, randomized-controlled, double-
blinded clinical trial.  We have obtained the relevant approvals from the South East 
Scotland Ethics Committee and the Medicines and Health Regulatory Authority. 
This trial is being funded by the British Heart Foundation.  150 patients who fulfil 
the inclusion and exclusion criteria will be recruited from cardiology clinics at the 
Royal Infirmary of Edinburgh. Recruitment is anticipated to take one year with 
follow up lasting two years.   
1.1 OBJECTIVES 
The primary objective of this study is to determine whether denosumab or alendronic 
acid are able to slow or halt disease progression in aortic stenosis as measured by the 
computed tomography (CT) calcium score of the valve.  Additional major objectives 
are to measure the impact of these drugs on active calcification in the valve and 
aortic valve jet velocity as measured by 18F-Fluoride PET and echocardiography 
respectively.  Non-contrast CT  will also be used to determine their effects on bone 
mineral density, aortic and coronary calcification.  Finally we will measure 
parameters such as quality of life and 6 minute walk times. 
1.2 ENDPOINTS 
The primary endpoint of this study will be the aortic valve calcium score at 2 years.  
Secondary endpoints will include i) change in aortic valve 18F-NaF uptake at 6 
months determined by positron emission tomography, ii) change in aortic-jet velocity 
at two years determined by Doppler echocardiography, iii) change in thoracic aortic 
and coronary artery calcium score at two years determined by computed tomography, 
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iv) change in thoracic aorta and coronary 18F-Fluoride uptake at 6 months 
determined by positron emission tomography, v) change in thoracic spine bone 
mineral density at two years determined by quantitative computed tomography, vi) 
change in quality of life determined by SF-EQ 36.   
1.3 PATIENT POPULATION 
Participants attending cardiology clinics at the Royal Infirmary of Edinburgh who 
meet the inclusion and exclusion criteria will be invited to participate in the study 
and provided with an information sheet.  We anticipate recruiting predominantly 
patients with mild and moderate aortic stenosis to minimize the number of patients 
referred for surgery during the course of the study Those who express an interest will 
then be invited to attend a screening visit where eligibility will be confirmed and 
written consent will be obtained. 
Inclusion criteria 
• age >50 years 
• peak aortic jet velocity of >2.5 m/s on Doppler echocardiography  
• grade 2-4 calcification of the aortic valve on echocardiography 
Exclusion Criteria 
• Anticipated or planned aortic valve surgery in the next 6 months,  
• Life expectancy less than 2 years,  
• Treatment for osteoporosis with bisphosphonates or denosumab. 
• Known allergy or intolerance to alendronate or denosumab, or any of their 
excipients 
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• Abnormalities of the oesophagus or conditions, which delay 
oesophageal/gastric emptying. 
• Inability to sit or stand for at least 30 minutes. 
• Hypocalcaemia 
• Regular calcium supplementation  
• Dental extraction within 6 months 
• Long-term corticosteroid use. 
• History of osteonecrosis of the jaw 
• Poor dental hygiene 
• Major or untreated cancers  
• Women of child-bearing potential who have experienced menarche, are pre-
menopausal, have not been sterilized or who are currently pregnant. 
• Women who are breastfeeding  
• Renal failure (estimated glomerular filtration rate of <30 mL/min)  
• Inability to undergo scanning  
• Allergy or contraindication to iodinated contrast 
• Inability or unwilling to give informed consent 
• Likelihood of non-compliance to treatment allocation or study protocol. 
 
1.4 RANDOMISATION  
All recruited patients will first undergo baseline clinical assessment before 
randomisation.  These include routine haematological and biochemical profiling, 12-
lead electrocardiography, echocardiography, computed tomography aortic valve 
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calcium scoring and 18F-NaF positron emission tomography scanning. They will 
subsequently be randomised using a web-based computer-generated randomisation 
process with minimisation techniques employed to ensure balancing of key variables 
age (<73 and ≥73 years), sex, presence or absence of a bicuspid valve and baseline 
aortic valve calcium scores (‘≤1607, >1607 Agatston Units).   
 
Seventy-five patients will be randomised (2:1) to either subcutaneous denosumab 60 
mg (n=50) or matched placebo (n=25) every 6 months; and a further 75 will be 
randomised (2:1) to oral alendronate 70 mg (n=50) or matched placebo (n=25) once 
weekly (Figure 1.1). The active alendronate will be overencapsulated with lactose 
monohydrate in order to appear identical to the matched alendronate placebo which 
will consist of hard gelatin capsules containing lactose monohydrate.  Denosumab is 
manufactured as a prefilled syringe therefore denosumab placebo will consist a 1mL 
subcutaneous injection of 0.9% saline solution.  Both syringes will be covered in foil 
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Figure 1.1 Randomisation of study drugs 
 
 
1.5 FOLLOW UP 
Patients will then undergo 6 monthly assessments for 2 years.   
1.5.1 Clinical Assessment: At 6, 12, 18 and 24 months, participants will undergo 
repeat clinical assessment which includes a clinical examination and assessment of 
their symptoms.  Blood sampling and 12-lead electrocardiogram will also be 
performed. For those randomized to the tablet arm,  compliance will be recorded by 
patient history and tablet count. At baseline and 24 months, patients will also be 
asked to complete a 6 minute walk test and a SF-36 Questionnaire. 
1.5.2 Echocardiography: Aortic stenosis severity will be assessed at baseline and 
every 6 months by a single, dedicated research ultrasonographer to assess aortic 
stenosis severity using the peak aortic valve velocity, the mean gradient, aortic valve 
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ACID TABLETS 
 (N=25)  
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TABLETS 
 (N=50)  
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1.5.3 Computed Tomography Calcium Scoring: Non-contrast CT calcium scoring 
of the aortic valve will be assessed at baseline, 12 months and 2 years.  It will be 
performed using the same protocol and scanner (Biograph 128, Siemens) at each 
time point. 
1.5.4 18F-Fluoride  PET CT Imaging: Study scans will be performed at baseline 
and at 12 months.  
 
1.5.5 Blood samples: These will be collected at baseline and 6, 12, 18 and 24 
months. Blood samples will be used for routine clinical biochemistry and 
haematology.  Blood will also be used for cardiac and bone biomarker measurements 
including troponin, galectin, brain natriuretic and C-Telopeptide.  A single blood 
sample will also be taken for genotyping studies.  
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Table 1.1 Study Follow up 
 
 










Examination ✔  ✔ ✔ ✔ ✔ 
18F-Fluoride 
PET-CT ✔   ✔   
CT-AVC ✔  ✔   ✔ 
Echo ✔  ✔ ✔ ✔ ✔ 
12 lead ECG ✔  ✔ ✔ ✔ ✔ 








✔      
SF-36 
Questionnaire ✔     ✔ 
6 minute 




✔ ✔ ✔ ✔  
Alendronate 
Dispensed  ✔ ✔ ✔ ✔  
Abbreviations: PET-CT, positron emission tomography- computed tomography; CT-AVC, 
computed tomography aortic valve calcium scoring; Echo, echocardiography; ECG, 
electrocardiography; SF, short form. 
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1.6 POWER CALCULATIONS 
In the absence of pilot data, we powered the study based on what we considered to 
be a clinically relevant treatment effect of 40%.  Using baseline and 2-year aortic 
valve calcium scores from patients with aortic stenosis from our previous studies.  
The change in aortic valve calcium score was skewed [median (interquartile range) 
565 (190.5, 910.0)] so a log-transformation was applied to the data resulting in a 
mean (standard deviation) of 6.103 (0.867).  To detect a difference of 40% in the 
back transformed mean aortic valve calcium score (i.e. 447.2 to 268.3) would need a 
sample size of 47 participants per group assuming a two-sided, two-sample test with 
5% level of significance and 80% power.  This calculation assumes that it is 
appropriate to combine both of the placebo arms to compare against denosumab and 
also alendronate.  It also does not take into account multiple comparisons and to 
account for potential drop-outs we have increased the total sample size to 150. 
1.7 DISCUSSION 
Severe Aortic Stenosis is a major cause of morbidity and mortality. (9) Identification 
of an efficacious medical therapy for aortic stenosis would therefore potentially solve 
a global health issue and spare patients from the risks associated with aortic valve 
replacement or implantation. Even in the event of a negative result, an important 
outstanding question will have been addressed.  Furthermore refinement and 
validation of 18F-Fluoride PET CT as an imaging modality capable of generating 
real time readouts of calcification activity could facilitate its application in future 
clinical studies on aortic stenosis which have previously relied on echocardiographic 
parameters. 
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THE PRESENT AND FUTURE
STATE-OF-THE-ART REVIEW
Calcification in Aortic Stenosis
The Skeleton Key
Tania A. Pawade, MD,*y David E. Newby, MD, PHD,*y Marc R. Dweck, MD, PHD*yz
ABSTRACT
Aortic stenosis is a common, potentially fatal condition that is set to become an increasing public health burden. Once
symptoms develop, there is an inexorable deterioration with a poor prognosis. Despite this, there are no medical ther-
apies capable of modifying disease progression, and the only available treatment is aortic valve replacement, to which
not all patients are suited. Conventional teaching suggests that aortic stenosis is a degenerative condition whereby “wear
and tear” leads to calcium deposition within the valve. Although mechanical stress and injury are important factors, it
is becoming increasingly appreciated that aortic stenosis is instead governed by a highly complex, regulated pathological
process with similarities to skeletal bone formation. This review discusses the pathophysiology of aortic stenosis with an
emphasis on the emerging importance of calcification, how this can be visualized and monitored using noninvasive
imaging, and how our improved knowledge may ultimately translate into novel disease-modifying treatments.
(J Am Coll Cardiol 2015;66:561–77) © 2015 by the American College of Cardiology Foundation.
A ortic stenosis is the most common form ofvalve disease in the Western world and isset to become an ever-increasing public
health burden (1,2). Despite this, there are no medical
therapies to halt or delay disease progression, and the
only available treatment is aortic valve replacement
or implantation, to which not all patients are suited.
There is, therefore, a major unmet clinical need to
identify pharmacological treatments capable of modi-
fying this disease process.
Aortic stenosis was long considered to be a
degenerative condition whereby “wear and tear”
resulted in progressive calcium formation within the
valve. Although mechanical stress and injury remain
central to its pathophysiology, emerging evidence has
indicated that aortic stenosis develops as part of a
highly complex and tightly regulated series of pro-
cesses, each of which may be amenable to medical
intervention (3). In particular, aortic stenosis can be
divided into 2 distinct phases: an early initiation
phase dominated by valvular lipid deposition, injury,
and inflammation, with many similarities to athero-
sclerosis, and a later propagation phase where pro-
calcific and pro-osteogenic factors take over and
ultimately drive disease progression (Figure 1) (4).
This review discusses the pathophysiology of aortic
stenosis, with an emphasis on the emerging impor-
tance of calcification, how this can be imaged
with modern noninvasive techniques, and how our
improved knowledge might ultimately lead to the
development of novel therapies.
PATHOLOGY OF AORTIC STENOSIS
INFLAMMATION, LIPIDS, AND THE INITIATION
PHASE OF AORTIC STENOSIS. Under normal cir-
cumstances, the aortic valve is composed of 3 leaflets,
each of which is a thin (<1 mm), smooth, flexible, and
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mobile structure (3). In aortic stenosis, these
leaflets become thickened, fibrosed, and
calcified, resulting in reduced leaflet mobility
and progressive valvular obstruction.
The early stages of aortic stenosis are in
many ways similar to atherosclerosis.
Indeed, the 2 conditions share many common
risk factors, with large longitudinal studies
consistently demonstrating that the incidence
of aortic stenosis is linked to factors such as
smoking, age, and hypertension (5–7). As in
atherosclerosis, endothelial damage due to
increased mechanical stress and reduced
shear stress is believed to be the initiating
injury, perhaps best illustrated by bicuspid
valve disease. The characteristic 2-leaflet
structure of these valves results in less effi-
cient dissipation of mechanical stress and
accelerated endothelial damage, so that patients
almost universally develop aortic stenosis and
display more rapid disease progression (8).
Following endothelial damage, the same lipids
implicated in atherosclerosis infiltrate the valve, in
particular, lipoprotein(a) and oxidized low-density
lipoprotein (LDL) cholesterol. Consequently, obser-
vational studies have identified cholesterol and its
related lipoproteins as independent risk factors for
the development of aortic stenosis (5–7,9). Indeed, a
strong genome-wide association was recently estab-
lished between a single-nucleotide polymorphism in
the locus of lipoprotein(a) and the incidence of aortic
valve calcification (10). Progressive endothelial injury
and lipid oxidization then establishes an inflamma-
tory response within the valve that is characterized
predominantly by infiltration of macrophages, but
also involves T lymphocytes and mast cells (11).
At this early stage, regions of stippled micro-
calcification that colocalize with sites of lipid depo-
sition are observed (11). The formation of these
microcalcifications may be mediated by cell death
and the release of apoptotic bodies in these areas.
Such apoptotic bodies are similar to the matrix vesi-
cles found in bone, which contain the prerequisite
components for calcium crystal deposition (including
calcium and inorganic phosphate ions) and facilitate
the formation of needle-like crystals of hydroxyapa-
tite (4,12). In bone, as these hydroxyapatite crystals
expand, they pierce the outer membrane of the
vesicle and become exposed to the extracellular
environment, thereby forming nucleation sites for
further calcium deposition. It is probable that similar
processes also occur within the valve (13). Further-
more, hydroxyapatite deposition evokes further pro-
inflammatory responses from macrophages, creating
a positive feedback loop of calcification and inflam-
mation in the early stages of disease (14). It seems
likely that these mechanisms underlie early calcium
formation in aortic stenosis and its association with
lipid and inflammation.
The apparent link between lipid, inflammation,
and calcification in these early stages and the patho-
logical similarities with atherosclerosis led to the
hypothesis that statins might be beneficial in patients
with aortic stenosis. This was supported by encour-
aging nonrandomized human data (15) and studies in
hypercholesterolemic animal models demonstrating
that lipid deposition and oxidative stress precede the
conversion of valvular interstitial cells to those with
an osteoblastic phenotype, and that this process is
inhibited by atorvastatin (16,17). However, when
statins were formally tested in 3 independent ran-
domized controlled trials of patients with aortic ste-
nosis, each demonstrated a failure of this therapy to
halt or retard aortic stenosis progression, despite
reducing the serum LDL cholesterol concentrations
by more than one-half (18–20). This has led in-
vestigators to re-examine the pathophysiology un-
derlying aortic stenosis and to the realization that
although inflammation and lipid deposition may be
important in establishing the disease (the initiation
phase), the later stages are instead characterized by
an apparently self-perpetuating cycle of calcium for-
mation and valvular injury (the propagation phase)
(4). Indeed, once this propagation phase has become
established, disease progression is dictated neither by
inflammation nor by lipid deposition, but rather by
the relentless accumulation of calcium in the valve
leaflets. This may explain the failure of statins to
modify disease progression in aortic stenosis, which
commonly presents beyond the initiation phase.
Moreover, there is some data that statins may even be
procalcific in the vasculature (21,22).
CALCIFICATION AND THE PROPAGATION PHASE. Ske-
letal bone formation is characterized by the initial
deposition of collagen matrix, which provides a
scaffold upon which progressive calcification can
develop. With time, this calcium acquires a more or-
dered crystalline structure until the characteristic
features of lamellar bone are finally observed. Similar
structural processes are believed to occur in the aortic
valve, with many of the same cell mediators and
proteins implicated (23). Indeed, in aortic stenosis,
collagen is deposited in anticipation of the procalcific
processes that subsequently dominate. This fibrotic
process within the valve may be mediated, in part,
by reduced nitric oxide expression following endo-
thelial injury (24); however, the renin-angiotensin
system (RAS) is also believed to play a central
ABBR EV I A T I ON S
AND ACRONYMS
BMP = bone morphogenetic
protein
CT = computed tomography
FDG = fluorodeoxyglucose
LDL = low-density lipoprotein
OPG = osteoprotegerin
PET = positron emission
tomography
RANK = receptor activator of
nuclear factor kappa B
RANKL = receptor activator of
nuclear kappa B ligand
TGF = transforming growth
factor
VIC = valvular interstitial cell
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role. Angiotensin-converting enzyme (ACE) is up-
regulated in calcific aortic valve disease and is likely
to be delivered to the valve by LDL, its natural vehicle
(25). Here it facilitates the conversion of angiotensin
I to II, which mediates profibrotic effects via the
angiotensin II type 1 (AT1) receptor. Although angio-
tensin II is also able to mediate antifibrotic and anti-
inflammatory effects via angiotensin II type 2 (AT2)
receptors, differential expression of these re-
ceptors in favor of AT1 has been demonstrated in
calcified aortic valves, so that a profibrotic
profile dominates. Likewise, although angiotensin-
converting enzyme type 2 (ACE-2) exerts antifibrotic
and anti-inflammatory influences via the Ang1-7/Mas
pathway, this pathway is down-regulated in calcified
aortic stenosis, with reduced expression of both
ACE-2 and Mas receptors in calcified valves compared
with control subjects (26). Increased RAS expression
is, therefore, implicated in the development of
fibrosis within the valve. On a systemic level, RAS
is implicated in the development of hyperten-
sion, which often accompanies aortic stenosis and












































INITIATION PHASE PROPAGATION PHASE
Initiation phase: endothelial injury (1) facilitates the infiltration of oxidized lipids and inflammatory cells (2) into the valve and the release of proinflammatory medi-
ators (3). These trigger the very early stages of valve calcification. The propagation phase: these proinflammatory processes subsequently induce VICs to undergo
osteogenic differentiation (5) via several different mechanisms, including the binding of RANKL to RANK (4). Differentiated cells within the aortic valve first lay down a
collagen matrix and other bone-related proteins causing valvular thickening and stiffening before producing calcium (6). Additionally, apoptotic remnants of some VICs
and inflammatory cells (7) create a nidus for apoptosis-mediated calcification (8). Calcification of the valve (9) induces compliance mismatch, resulting in increased
mechanical stress and injury (10). This results in further calcification via osteogenic differentiation and apoptosis (11). Hence, a self-perpetuating cycle of calcification,
valve injury, apoptosis, and osteogenic activation is established that drives the propagation phase of the disease. BMP ¼ bone morphogenetic protein; ENPP1 ¼
ectonucleotide pyrophosphate 1; LDL ¼ low-density lipoprotein; RANK ¼ receptor activator of nuclear kappa B; RANKL ¼ receptor activator of nuclear kappa B ligand;
RAS ¼ renin-angiotensin system; VIC ¼ valvular interstitial cell.
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may accelerate its progression given the increased
mechanical stress it imposes upon the valve (27).
Beyond this initial fibrosis, valvular calcification in
aortic stenosis ultimately dominates and appears
dependent upon the presence of osteoblast-like cells
that develop an osteogenic phenotype. In support of
this hypothesis, gene-profiling studies have demon-
strated increased valvular expression of several
osteoblast-specific proteins, including the Cbfa1/
Runx2 transcription factor, essential for osteoblastic
differentiation and regulation of osteoblast function
(28,29). A number of other extracellular matrix pro-
teins closely associated with osteoblast function and
more commonly associated with skeletal bone for-
mation are also up-regulated in calcific aortic valves.
These include osteopontin and bone sialoprotein,
which are facilitators of the attachment of osteoblasts
to the bone matrix, and demonstrate up to a 7-fold
elevation in gene expression at sites of developing
calcification (30,31). Importantly, valvular ossification
also appears to be dependent upon angiogenesis,
supporting the hypothesis that this is an active,
highly regulated, pathological process (23).
The source of osteoblast-like cells within the
aortic valve remains controversial. In vitro, multiple
cell types present in the vasculature are capable of
undergoing differentiation into those with an
osteoblast-like phenotype. The most likely candi-
date appears to be the myofibroblast, a highly
plastic cell that is also commonly referred to as the
valve interstitial cell (VIC) (32). The differentiation
of this cell into an osteoblast phenotype is not fully
characterized, but appears to be a central step in the
development of aortic stenosis and is regulated by a
rapidly growing list of molecules and complex
pathways. In vivo molecular imaging has demon-
strated that in the early stages of aortic stenosis,
this differentiation appears coordinated by macro-
phages (33,34) via the action of proinflammatory
cytokines (interleukin [IL]-1b, IL-6, IL-8, tumor ne-
crosis factor [TNF]-a, insulin-like growth factor-1,
and transforming growth factor [TGF]-b) (4,35,36).
However, in the later stages, this differentia-
tion again appears to be dominated by calcific
pathways, including the Notch, Wnt/b-catenin, and
receptor activator of nuclear factor kappa B (RANK)/
receptor activator of nuclear factor kappa B ligand
(RANKL)/osteoprotegerin (OPG) pathways, which we
discuss here.
Notch belongs to a family of cell surface receptors
(Notch 1 to 4) that are highly expressed in the aortic
valve, playing an important role in its morphological
development (37). Individuals with loss-of-function
mutations in Notch-1 have higher rates of
cardiovascular calcification and aortic stenosis. In 2
unrelated families with a high incidence of con-
genital aortic valve disease, genome-wide linkage
analysis identified loss-of-function Notch-1 muta-
tions as the cause (37). In particular, Notch-1 ap-
pears to be important in establishing osteogenic
cells in the valve via the action of bone morphoge-
netic protein (BMP)-2 (38). BMP-2 is a potent oste-
ogenic differentiation factor and part of a family of
multifunctional cytokines belonging to the TGF-b
superfamily. Expression of BMP-2 is increased in
calcified atherosclerotic lesions and aortic valves
(29,39), and it appears to have a central role in the
differentiation of plastic cell populations toward an
osteogenic phenotype. Indeed, exposure of normal
human VICs to BMP-2 induces osteoblastic features
in these cells (40,41). In addition, binding of Wnt to
LDL receptor-related protein 5 receptors may acti-
vate the canonical Wnt/b-catenin pathway that is
also implicated in osteogenic cell differentiation
(42). Similarly, TGF-b1 is able to induce nuclear
translocation of b-catenin and increased Wnt
signaling, stimulating the osteogenic differentiation
of mesenchymal progenitor cells (43). The latter
process can increase in response to mechanical stress
and may therefore explain, in part, the self-
perpetuating and exponential increase in calcifica-
tion activity observed once osteogenic differentiation
has occurred and the propagation phase is estab-
lished (Figure 1) (43,44).
Systemic regulators that govern calcification
activity, both in the bone and in the vasculature,
tightly control calcium homeostasis; consequently,
there is an inverse correlation between bone mineral
density and vascular calcification. Osteoporosis
is associated with age-independent increases in
vascular calcification and even cardiovascular mor-
tality (45). A prospective study of 25,639 men and
women demonstrated an inverse correlation between
bone mineral density and incident aortic stenosis
in older women (46). Moreover, other disorders of
bone turnover, including chronic kidney disease
and Paget’s disease, also manifest changes in the
vasculature (47–50). This dichotomy has been termed
the “calcification paradox” and is likely to be
explained by common pathological pathways having
reciprocal effects on the bone and vasculature
simultaneously.
A potential mechanism for this association lies in
the activity of the RANK/RANKL/OPG pathway
(Figure 2A). In bone, RANKL (a member of the TNF
cytokine family) binds to RANK (a transmembrane
protein expressed on marrow stromal cells and pre-
osteoclasts), acting as a potent inducer of osteoclast
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differentiation and activity. This drives demineral-
ization of bone, but is policed by osteoprotegerin
(OPG), a soluble decoy receptor, which binds RANKL
and prevents it from activating RANK (Figure 2). In
contrast, RANKL appears to have the opposite effect
on cells in the vasculature, inducing an osteoblastic
phenotype in human VIC cells that results in
increased matrix calcification, the formation of
calcific nodules, and increased expression of alkaline
phosphatase and osteocalcin (Figure 2A) (51). RANKL
also promotes the osteogenic properties of vascular
smooth muscle cells, once again via the up-regulation
of BMP-2. As a consequence, whilst OPG-deficient
mice develop osteoporosis, they simultaneously
accelerate vascular calcification in association with
increased expression of RANKL in both regions (52).
A potential explanation for the differential effects of
RANK/RANKL/OPG in these 2 tissues is that in bone
there is an abundance of pre-osteoclasts that favors
the pro-osteoclastic properties of RANKL (36). In
contrast, this pool is absent in the vasculature so that
RANKL’s pro-osteoblastic effects on myofibroblast
and smooth muscle cells predominate.
Imbalances in RANKL/OPG signaling have been
demonstrated in calcific aortic valves. In human
valve tissue taken from patients with aortic stenosis,
immunochemistry revealed less OPG-positive cells in
areas of focal calcification, whereas western blotting
demonstrated that OPG was not expressed at rele-
vant levels in aortic stenosis, but was detectable in
control subjects. The converse is true of RANKL,
with increased levels observed in stenotic aortic
valves (51). In combination, these data support the
hypothesis that the RANK/RANKL/OPG axis is
implicated in the development of aortic valve calci-
fication and provide 1 explanation for the link be-
tween aortic valve calcification and bone mineral
density. Other investigators have suggested that the
differential effects of oxidized LDL might also be of
importance, with this molecule appearing to pro-
mote calcification and the osteoblastic differentia-
tion of vascular cells in vitro, whilst inhibiting these
processes in a bone-derived pre-osteoblast cell line
(4,53,54).
Fetuin-A is a circulating protein that can
exist in isolation or as a complex with matrix
g-carboxyglutamic acid protein (MGP). Both are
powerful guardians against ectopic calcification and
simultaneously inhibit many of the procalcific pro-
cesses discussed earlier (55). MGP needs to be both
carboxylated and phosphorylated to be activated, a
process dependent on vitamin K. There is speculation
that use of the vitamin K antagonists, such as couma-
rins, may be associated with increased vascular
calcification (56). The actions of fetuin-A and MGP
include inhibition of BMP2 and TGF-b, reduction of
apoptosis-mediated calcification, and direct preven-
tion of calcification by binding to calcium crystals.
Reduced circulating levels of Fetuin-A and MGP are
thought to explain the vascular calcification seen with
end-stage renal failure. Moreover, plasma fetuin-A
concentrations are decreased in aortic stenosis
and inversely associated with the rate of disease pro-
gression (57,58). Interestingly, this association was
seen only in older patients (>70 years of age) (59).
Conversely, increased plasma dephosphorylated
(inactive) MGP was a strong independent predictor of
faster stenosis progression, but only in younger pa-
tients (#57 years of age) (60).
WHY DOES CALCIUM BEGET CALCIUM? Once calci-
fication is established in the valve, it would appear
to initiate further calcium formation. This self-
perpetuating cycle of calcification and valve injury
appears to be the central driver of disease progres-
sion and the propagation phase of aortic stenosis
(Figure 1).
The mechanism for this may, in part, relate to the
compliance mismatch caused by calcific deposits in
the leaflets that results in increased mechanical
stress, injury-induced activation of the Wnt/b-catenin
pathway, and further osteoblast differentiation.
However, it may also be explained by the actions of
membrane-bound ectonucleotidases. These are pro-
duced by VICs and regulate the extracellular pro-
duction of inorganic phosphate (a promoter of
calcification) and inorganic pyrophosphate, an in-
hibitor of pyrophosphate. Ectonucleotide pyrophos-
phatase 1 (ENPP1) is highly up-regulated in calcific
aortic valve disease, with a polymorphism associated
with increased transcripts of ENPP1 identified in ste-
notic valves (61). Hydrolysis of extracellular adeno-
sine triphosphate (ATP) by ENPP1 produces a net
increase in inorganic phosphate, thus favoring calci-
fication and promoting the production of further
ENPP1 in a positive feedback loop (61). Moreover,
because ATP acts as a cell survival signal for VICs via
the P2Y2 receptor, its depletion also triggers apoptosis
of these cells, providing a further key stimulus to
calcification (61). Finally, loss of P2Y2 signaling
increases the secretion of IL-6, a cytokine that pro-
motes further osteogenic differentiation of VICs via
the actions of BMP (62). Thus, via these multiple
mechanisms, the ectonucleotidase pathway appears
to have a central role in amplifying procalcific pro-
cesses within the valve during the propagation phase
of aortic stenosis.
Given that the pathophysiology and the progres-
sion of aortic stenosis are dominated by calcification,
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FIGURE 2 Mechanisms Underlying the Relationship Between Bone Mineral Density and Valvular Calcification and Potential Mechanisms
of Action for Denosumab and Bisphosphonates
RANKL
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we will next discuss how this process can be imaged
to better understand the pathophysiology of aortic
stenosis, to predict disease progression and clinical
outcomes, and to help develop novel treatments




The burden and activity of aortic valve calcification
can be measured using noninvasive imaging. In
particular, echocardiography, computed tomography
(CT), and positron emission tomography (PET) can all
be used to provide progressively more detailed as-
sessments of the calcific processes occurring within
the valve (Figure 3). These techniques have not only
informed our understanding as to the importance of
calcification in aortic stenosis, but have also aided our
ability to assess disease severity and to predict pro-
gression and adverse cardiovascular outcomes. The
latter is of particular importance. Aortic stenosis
progression frequently does not occur in a linear or
predictable manner, making estimation as to when
valve replacement will be required challenging.
Annual or biannual clinical review is generally
required, with serial echocardiography performed to
track progressive valve narrowing. The development
of a noninvasive method capable of predicting the
future natural history of aortic stenosis and the likely
timing of valve surgery would represent a major
advance and help streamline patient care. Given
FIGURE 2 Continued

































(A) Schematic representation of the differential effects of the RANK/RANKL/OPG axis upon skeletal bone and the calcifying aortic valve. Aortic
valve: binding of RANKL to RANK on valvular interstitial cells induces osteogenic differentiation and calcium deposition. Bone: binding of
RANKL to RANK on osteoclast precursors induces osteoclastic maturation and differentiation, resulting in bone resorption and increased
availability of calcium and phosphate. Osteoprotegerin binds to RANKL, preventing it from binding to RANK, thus reducing both bone
resorption and calcium deposition within the valve. (B) Proposed mechanism of action of bisphosphonates in the treatment of aortic stenosis.
Bisphosphonates reduce the production of inflammatory cytokines, thereby reducing osteogenic differentiation of VICs. They also inhibit the
production of matrix metalloproteinases and regulate extracellular mineralization within the vasculature. Simultaneously, the prevention
of bone resorption by bisphosphonates also reduces the availability of procalcific substances. In combination, this is likely to result in reduced
calcium deposition in the valve, along with reduced bone resorption. (C) Proposed mechanism of action of denosumab in the treatment of aortic
stenosis. Binding of denosumab to RANKL prevents its binding to RANK, which inhibits the osteogenic differentiation of valvular interstitial
cells. It simultaneously prevents osteoclast differentiation in the bone, and inhibits bone resorption and availability of procalcific substances.
In combination, this is likely to result in reduced calcium deposition in the valve and reduced bone resorption. OPG ¼ osteoprotegerin; other
abbreviations as in Figure 1.
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the central role that mineralization plays in disease
progression, it is, perhaps, not surprising that as-
sessments of aortic valve calcification have, to date,
provided the best prediction.
ECHOCARDIOGRAPHY
Echocardiography is a cheap, safe, and widely used
method of assessing aortic stenosis severity in the
clinical setting. International guidelines recommend
grading aortic stenosis severity using the following
hemodynamic echocardiographic assessments: the
peak velocity, the mean gradient, and the aortic valve
area (63). However, echocardiography can also be used
to categorize valves according to their degree of
valvular calcification into those with no, mild, mod-
erate, and severe calcification. Indeed, in a series of 128
patients with severe, asymptomatic aortic stenosis,
this semiquantitative assessment provided powerful
prognostic information, acting as a strong indepen-
dent predictor of death or aortic valve replacement
that outperformed the more conventional hemody-
namic measures (64). Although this observation has
been confirmed in another study of 141 asymptomatic
patients (65), the clinical utility of this approach has
been limited by disappointing interobserver agree-
ment in grading the calcification (66,67).
CT CALCIUM SCORING
CT provides a much more detailed, reproducible,
and accurate assessment of the calcific burden in the
aortic valve than echocardiography (66). Using the
same protocols used for coronary calcium scoring,
electrocardiography-gated noncontrast CT can pro-
vide information with respect to the density, vol-
ume, and mass of macroscopic calcium deposits
within the valve (66). However, as in the coronary
arteries, the aortic valve calcium burden is generally
described using Agatston units (AU), which take both
the radiodensity and volume of calcium into ac-
count. In a series of explanted aortic valves, scores
of 500, 1,100, and 2,000 AU approximated to 300,
1,100, and 1,200 mg of aortic valve calcium, respec-
tively (66).
Early studies demonstrated that CT calcium
scoring of the aortic valve could be used as an alter-
native marker of stenosis severity, demonstrating a
good relationship with hemodynamic echocardio-
graphic assessments (66,68,69). However, until
recently, we lacked appropriate thresholds that might
differentiate patients with and without severe aortic
stenosis, thereby limiting its utility (Table 1) (70).
These thresholds are now available as a consequence
of a landmark series of papers published by Clavel
et al. (71–73). Across 3 sites in Europe and North
America, they performed both echocardiography and
CT calcium scoring in 646 patients with moderate or
severe aortic stenosis and good left ventricular func-
tion. In those subjects whose severity of stenosis was
not in doubt on echocardiography (n ¼ 460), the au-
thors examined the optimal CT calcium score for
differentiating moderate from severe aortic stenosis.
Interestingly, female subjects required less calcium to
develop severe hemodynamic stenosis than male
subjects (even after correcting for body surface area
and the left ventricular outflow tract area calculated
by echocardiography), so that the optimal thresholds
were found to be 1,275 AU in women and 2,065 AU in
men. These thresholds then appeared to be of use in
adjudicating the severity of the stenosis when echo-
cardiographic markers were discordant. More impor-
tantly, the authors went on to demonstrate that, in a
population of 794 patients, these thresholds pre-
dicted all-cause mortality independent of all other
markers of an adverse prognosis (73). Standard he-
modynamic parameters on echocardiography were
included in this analysis, suggesting that CT can
provide additional, complementary information to
FIGURE 3 Different Methods for Imaging Calcification in a Single Subject
With Aortic Stenosis
(A) 2-dimensional echocardiography. (B) CT calcium scoring. (C) CT angiography.
(D) 18F-fluoride PET-CT. CT ¼ computed tomography; PET ¼ positron emission
tomography.
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that obtained during routine clinical care, as had
previously been hinted at by earlier studies (Table 2)
(66,73–75).
An expanding body of published data has also
demonstrated the ability of CT calcium scoring to
predict disease progression in aortic stenosis. Initial
studies indicated that the aortic valve CT calcium
score progresses fastest in patients with the highest
baseline calcium burden (76). We have recently
confirmed this predictive ability in a large prospective
study of patients with the full range of calcific aortic
valve disease. The fastest rates of progression were
again observed in subjects with the most advanced
disease. Indeed, a good correlation was observed
between the baseline calcium score and disease pro-
gression at 1 year (r ¼ 0.58; 95% confidence interval
[CI]: 0.15 to 0.82; p ¼ 0.01) (77), which strengthened
further after 2 years of follow-up (r ¼ 0.90; 95% CI:
0.84 to 0.93; p < 0.001) (67). Moderate associations
between the baseline CT calcium score and echocar-
diographic measures of disease progression were also
observed (e.g., change in mean gradient; r ¼ 0.40;
95% CI: 0.21 to 0.56; p < 0.001) (67), and very similar
observations were recently reported in a different
patient population (Figure 4) (78).
In summary, CT calcium would, therefore, appear
to be a useful alternative method for grading
disease severity in aortic stenosis, offering powerful
TABLE 2 Studies Using Aortic Valve Computed Tomography Calcium Scoring to Predict Outcomes
First Author (Ref. #) Year n
Duration of
Follow-Up Outcomes Key Findings
Messika-Zeitoun et al. (66) 2004 100 2.0 " 2.3 yrs Event-free survival
Survival without dyspnea,
angina, syncope, heart failure,
or need for surgery
AVC independently predicted event-free survival, with
an adjusted relative risk of 1.06 (95% CI: 1.02–1.10)
per 100-AU increment (p < 0.001). 5-year event free
survival rate was 90 " 4% for those with AVC <500 AU
vs. 29 " 14% for those with AVC $500 AU (p < 0.0001).
Feuchtner et al. (73) 2006 34 18–24 months Major adverse clinical event
Symptoms due to hemodynamic
progression
Cardiac death
AVC strongest predictor of a major adverse clinical event
(p < 0.001) among all parameters assessed (1,928 " 789 AU
vs. 5,111 " 2,409 AU).
Utsunomiya et al. (109) 2013 64 29 months Cardiac events
Cardiac death, AVR, nonfatal MI,
and heart failure requiring
urgent hospitalization
AVC predictor of cardiac events (HR: 1.09; 95% CI: 1.04–1.15)
per 100-AU increment
AVCS $723 (the median value) had significantly worse
outcomes than those with AVCS <723 (p < 0.0001)
Clavel et al. (75) 2014 794 3.1 " 2.6 yrs Mortality Severe AVC (defined as $1,274 AU in women and $2,065 AU
in men) was an independent predictor of overall mortality
(HR: 1.71; 95% CI: 1.12 to 2.62; p ¼ 0.01)
AU ¼ Agatston units; AVC ¼ aortic valve calcium; AVCS ¼ aortic valve calcium score; AVR ¼ aortic valve replacement; CI ¼ confidence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction.
TABLE 1 Studies Attempting to Define Computed Tomography Calcium Scoring Thresholds for the Diagnosis of Aortic Stenosis
First Author
(Ref. #) Year n
Method and Criteria for Defining
Severe Aortic Stenosis
Calcium Score





Cowell et al. (107) 2003 157 Echocardiography
aortic valve velocity >4 m/s
>3,700 100 50 39 100
Messika-Zeitoun et al. (66) 2004 100 Echocardiography
aortic valve area <1 cm2
>500 100 69 57 100
Koos et al. (74) 2004 72 Cardiac catheter
aortic valve area <1 cm2
>563 85 92 95 77
Clavel et al. (72) 2013 460 Echocardiography
aortic valve area index
#0.6 cm2/m2, mean











Cueff et al. (108) 2011 179 Echocardiography
aortic valve area <1 cm2
>1,651 82 80 70 88
Cueff et al. (108) 2011 20 Echocardiography
low flow/low gradient severe AS
Aortic valve area <1 cm
and ejection fraction #40%
and mean pressure gradient
#40 mm Hg2
>1,651 95 89 97 80
Values are % unless otherwise indicated.
AS ¼ aortic stenosis; AU ¼ Agatston units.
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prediction of both disease progression and adverse
clinical events. It is potentially complementary to
standard echocardiographic assessments and may
have some advantages, most notably that it is not
dependent on cardiac loading conditions, geometric
assumptions, or on the presence of other cardiovas-
cular conditions, such as mitral regurgitation and
hypertension. Further work is now required to vali-
date the proposed thresholds in other patient pop-
ulations and to explain the observed sex differences.
POSITRON EMISSION TOMOGRAPHY
PET is a noninvasive imaging technique that allows
the activity of specific biological processes to be
measured in vivo within specific structures, including
the aortic valve. In principle, any disease process can
be evaluated dependent on the availability of a suit-
able tracer. To date, studies in aortic stenosis have
largely investigated tracers targeted to inflammation
(18F-fluorodeoxyglucose [FDG]) and calcification
(18F-fluoride), aiming to establish the relative contri-
butions of these processes to disease development
and progression (79–81).
INFLAMMATION. The PET radiotracer 18F- FDG is a
glucose analog taken up by metabolically active cells.
Because it is unable to proceed through the glycolytic
pathway, it accumulates within these cells without
further metabolism. Because vascular macrophages
have higher metabolic requirements than the sur-
rounding tissue, 18F-FDG has emerged as a useful
tool for the identification of vascular inflammation.
Uptake in regions of carotid atheroma correlates well
with macrophage density (mean percent staining of
CD68-positive cells, r ¼ 0.85; p < 0.0001) (82,83) and
is modifiable with statin therapy (84).
To determine the contribution of inflammation to
the pathogenesis of calcific aortic stenosis, we per-
formed PET imaging of the aortic valve using 18F-
FDG in a prospective cohort of 121 patients with the
full spectrum of calcific aortic valve disease
(including 20 patients with aortic sclerosis and 20
control subjects) (79). 18F-FDG activity was increased
in patients with aortic stenosis compared with con-
trol subjects (1.58 " 0.21 vs. 1.30 " 0.13; p < 0.001),
and this correlated with disease severity (79). How-
ever, unlike previous work on carotid atheroma, the
18F-FDG signal did not correlate with macrophage
(CD68) staining, raising the possibility that 18F-FDG
may not be acting as a marker of inflammation in the
calcifying aortic valve, but instead might reflect
glucose utilization by other metabolically-active
cells, such as myofibroblasts or differentiated oste-
ogenic cells (77).




















































(A) Studies using PET have demonstrated that calcification activity in the valve (as measured using 18F-fluoride) steadily increases with disease severity. As a conse-
quence, activity is highest in those with the most advanced disease, and a good correlation exists between 18F-fluoride activity and the baseline CT calcium score (79).
(B) Subsequently, this increased calcification activity appears to translate to more rapid disease progression (as measured by both echocardiography and CT calcium
scoring) in patients with the most advanced forms of aortic stenosis (78). Reproduced with permission from Nguyen V, et al. (78). AS ¼ aortic stenosis; AU ¼ Agatston
units; CT ¼ computed tomography.
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CALCIFICATION. 18F-fluoride has been used safely as
a bone tracer for more than 40 years, exchanging
with hydroxyl groups in hydroxyapatite to form flu-
oroapatite. Similar hydroxyl bonds are also present in
the different forms of calcium in the vasculature
(including hydroxyapatite and amorphous calcium)
so that 18F-fluoride binding acts as a marker of
vascular calcification. In particular, the binding of
18F-fluoride to calcium appears to be critically
dependent upon the surface area of calcium ortho-
phosphate available for incorporation. 18F-fluoride,
therefore, preferentially binds regions of newly
developing microcalcification (beyond the resolution
of CT), which have a nanocrystalline structure and
very high surface area, rather than to large, estab-
lished, macroscopic deposits, where much of the
calcium is internalized and, therefore, not available
for binding (85). On this basis, increased 18F-fluoride
uptake is observed in regions of actively developing
calcification, demonstrating a close association with
alkaline phosphatase staining (r ¼ 0.65; p ¼ 0.04) on
excised aortic valve tissue removed at the time of
surgery (77).
When the same cohort of 121 patients was imaged
with 18F-fluoride, the observed PET signal in the
aortic valve was stronger and more clearly demar-
cated than was seen with 18F-FDG (Figure 3). More-
over, the spatial distribution of the 18F-fluoride signal
was often discrete from the macroscopic calcium de-
posits identified by CT, indicating that 18F-fluoride
uptake provides distinct, but complementary infor-
mation to CT alone. Uptake was increased in patients
with aortic stenosis compared with healthy control
subjects (2.87 " 0.82 vs. 1.55 " 0.17; p < 0.001) and
correlated with disease severity (r ¼ 0.73; p < 0.001)
(79). Indeed, the highest calcification activity, as
measured using this tracer, was observed in patients
with the most advanced disease (Figure 4A). Again,
this supports the hypothesis that calcification begets
calcification activity in aortic stenosis and would
explain the rapid rates of disease progression in those
at the severe end of the spectrum.
When patients were recalled for repeat CT calcium
scoring of the valve at 1 and 2 years, new calcium
could be observed in the areas of increased 18F-
fluoride activity seen on the baseline scan (Figure 5).
As a consequence, a close correlation was observed
between the baseline valvular 18F-fluoride uptake and
the progression of the aortic valve CT calcium score
(r ¼ 0.80; 95% CI: 0.69 to 0.87; p < 0.001), with PET
appearing to offer some additional predictive infor-
mation over and above the baseline calcium score.
Moreover, this translated into an ability to predict
valve hemodynamic progression, with moderate
correlations also observed between 18F-fluoride ac-
tivity and the mean (r ¼ 0.32; 95% CI: 0.13 to 0.50;
p ¼ 0.001) and peak (r ¼ 0.32; 95% CI: 0.12 to 0.49;
p ¼ 0.002) aortic valve gradients (67). Finally, after a
median of 1,526 days of follow-up, 18F-fluoride
emerged as a prognostic marker serving as an inde-
pendent predictor of the combined endpoint of aortic
valve replacement and cardiovascular mortality
(hazard ratio: 1.55; 95% CI: 1.33 to 1.81, after adjusting
for age and sex; p < 0.001).
In summary, these data highlight the potential
application of 18F-fluoride as an immediate, nonin-
vasive measure of disease activity in aortic stenosis
with the ability to predict its natural history. The
instantaneous readout of disease activity holds
particular promise in assessing the early efficacy of
novel therapeutic agents, in which treatment effects
are likely to be discernible over a much shorter time
period than could be resolved using clinical end-
points, echocardiography, or CT.
Should 18F-fluoride PET be used as a clinical tool?
Although PET performed well in predicting the nat-
ural history of aortic stenosis, the far simpler tech-
nique of CT calcium scoring appeared to provide
almost equivalent prediction of disease progression.
Moreover, in agreement with the work by Clavel et al.
(72,73), CT again provided incremental prediction of
clinical outcomes to even echocardiographic assess-
ments of hemodynamic severity. Whilst supporting a
greater role for CT, this would argue against the use of
PET in the routine clinical arena. It also raises the
question as to why an anatomic measure of calcium
burden can provide such effective prediction of
future disease progression? We believe that this
reflects the close association between calcification
activity in the valve (as assessed by 18F-fluoride) and
the baseline calcium score (r ¼ 0.80; p < 0.001), and
provides further evidence for the model of calcium
begetting further calcium formation in the propaga-
tion phase of the disease (Figure 1). Regardless of the
mechanism, the close link between calcium burden
and calcification activity in the valve ensures that
even the simplest methods of aortic valve calcium
burden provide a surrogate of disease activity and
effective prediction of disease progression.
The imaging techniques described previously allow
us to image calcification in the valve in progressive
detail. They have helped to confirm the important
role that calcification plays in driving aortic stenosis
and have allowed us to both characterize the severity
of disease and to better predict disease progression.
We anticipate that CT calcium scoring will assume a
greater clinical role, whereas PET will prove a
powerful research tool, in particular as an endpoint
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in clinical trials assessing the efficacy of novel,
potentially disease-modifying therapies. Indeed,
18F-fluoride PET has the potential to provide both
mechanistic insights and a far more rapid readout of




As our understanding of the pathophysiology of aortic
stenosis has improved, the key role that calcification
plays in driving disease progression has led us away
from targeting inflammation and lipid deposition and
toward therapies capable of directly halting valve
calcification (86). How might this be achieved? The
close association between disorders of skeletal bone
metabolism and increased calcification in the vascu-
lature offers a potential starting point. A growing
body of pre-clinical and clinical data indicates that
treatments for osteoporosis, such as bisphosphonates
and denosumab, can reduce vascular calcification and
that these agents hold considerable promise as novel
therapies for aortic stenosis (87).
BISPHOSPHONATES. Bisphosphonates are inhibitors
of osteoclast-mediated bone resorption, are well
tolerated in elderly patients, and have been widely
used for the treatment of osteoporosis (88). Inter-
estingly, bisphosphonates also have important car-
diovascular effects, demonstrating a consistent
reduction in calcification of the vasculature and the
aortic valve (87,89,90). This, in part, appears to be a
consequence of their inhibition of bone resorption,
which results in reduced release of calcium and
phosphate into the circulation and, therefore, in the
reduced systemic availability of these procalcific
substances (Figure 2B) (87). However, bisphospho-
nates also appear to exert direct anticalcific effects on
the aortic valve tissue itself. They reduce the pro-
duction of IL-1b, IL-6, and TNF-a (key inflammatory
cytokines implicated in the early stages of aortic
stenosis [91]) and inhibit the secretion of matrix
FIGURE 5 Change in Aortic Valve CT Calcium Score and 18F-Sodium Fluoride PET Activity After 1 Year
Baseline CT calcium scores (left) for patients 1 and 2 (top and bottom). Fused coaxial 18F-fluoride PET-CT scans (middle) show fluoride uptake in red and yellow.
The 1-year follow-up (right) suggests that the baseline PET signal predicts the spatial distribution of subsequent macrocalcification (77). Abbreviations as in Figure 3.
Pawade et al. J A C C V O L . 6 6 , N O . 5 , 2 0 1 5
Calcification in Aortic Stenosis A U G U S T 4 , 2 0 1 5 : 5 6 1 – 7 7
572
Downloaded From: http://content.onlinejacc.org/ by Tania Pawade on 07/28/2015
metalloproteinases 2 and 9, which remodel the valve
as aortic stenosis progresses (Figure 1) (92,93). More-
over, nitrogen-containing bisphosphonates act as
inorganic pyrophosphate analogs (48), which, as dis-
cussed, have powerful anticalcific properties in the
vasculature. Finally, bisphosphonates attenuate the
differentiation of aortic valve myofibroblasts into
cells with an osteogenic phenotype (94), the key step
in triggering the propagation phase of aortic stenosis
(86). In combination, these data offer support for
bisphosphonates as a treatment strategy for aortic
stenosis that is increasingly being supported by
observational clinical data. A recent analysis of 3,710
women in the MESA (Multi-Ethnic Study of Athero-
sclerosis) indicated that bisphosphonate use was
associated with less valvular and vascular calcifica-
tion in older women (users vs. nonusers: aortic valve
ring calcium 38% vs. 59%; p < 0.0001) (95). Other
studies appear to support these findings with a direct
beneficial effect of these drugs on echocardiographic
measures of aortic stenosis progression (96–98), as
well as reducing valvular calcification in patients with
renal failure and amongst those with bioprosthetic
valves (87,99). Although encouraging, such retro-
spective, observational studies are prone to bias,
cannot assess cause-and-effect, have provided con-
flicting results (100), and are confounded by the un-
derlying effects of the osteoporosis for which these
agents were prescribed. Indeed, the true effect of
bisphosphonates in aortic stenosis will only become
clear within the context of a randomized controlled
trial (101).
DENOSUMAB. As discussed, the OPG/RANK/RANKL
axis appears to play a pivotal role in aortic valve
calcification and may provide an explanation for the
link between osteoporosis and increased vascular
calcification. It, therefore, represents an attractive
therapeutic target for reducing vascular calcification
(Figure 2C). Denosumab is a human monoclonal anti-
body to RANKL that prevents its binding to RANK,
thereby recapitulating the actions of OPG. In a trial of
7,868 post-menopausal women with osteoporosis,
denosumab increased bone mineral density and
reduced vertebral fracture rates by 68% over a 3-year
period (102). Importantly, denosumab was extremely
well tolerated, with very few adverse side effects and
no major excess of adverse events. Given the central
regulatory role of the OPG/RANK/RANKL system in
vascular and aortic valve calcification, denosumab
also holds considerable promise as a novel treatment
for aortic stenosis. Again, this is supported by pre-
clinical data, with denosumab halving the aortic
calcification observed in a murine model of osteopo-
rosis (103). Interestingly, in the same study, this
reduction was closely associated with inhibited
bone resorption from the skeleton, indicating
that the cardiovascular effects of denosumab are,
like bisphosphonates, in part related to reduced
calcium and phosphate release from bone into the
circulation.
FUTURE PERSPECTIVES
Bisphosphonates and denosumab hold promise as
novel treatments for aortic stenosis and are currently
being investigated as part of an ongoing randomized
control trial (NCT02132026) (104). However, even if
these prove ineffective, we believe that future treat-
ments should still be directed at the propagation
phase and at breaking the self-perpetuating cycle of
valvular injury, osteogenic differentiation, and cal-
cium deposition. As discussed, a rapidly expanding
list of signaling pathways and molecular processes
governing the pathogenesis of aortic stenosis have
been elucidated, uncovering many additional targets
at different phases of the disease; these are discussed
in the following paragraphs. In addition, further
investigation is warranted to assess whether poten-
tially pro-calcific drugs, including calcium supple-
ments and coumarins, should be avoided in patients
with aortic stenosis.
Ultimately, many of the procalcific pathways in
the valve appear to converge on the up-regulation
of osteogenic differentiation factors (e.g., BMP-2,
Wnt-b-catenin) that establish osteoblast-like func-
tion within the valve. These factors therefore pro-
vide an attractive therapeutic strategy, although,
given the overlap in factors governing calcification
in the bone and the valve, the major challenge will
be to slow aortic stenosis progression without
compromising bone health. One potential approach
would be to target the upstream cytokines that
activate BMP, such as using inhibitors of IL-6 or
TNF-a (as already used in rheumatoid arthritis).
However, once again, it remains unclear whether
targeting inflammation will be effective in the
propagation phase once the procalcific processes
have become established. Targeting ectonucleoti-
dases may be more effective, given their apparently
central role in establishing the positive feedback
loop by which calcium begets calcium. Ectonucleo-
tidase inhibitors have already been tested in the
warfarin rat model and have been shown to prevent
the development of calcific aortic valve disease
(105). Interest also surrounds P2Y2 receptor antago-
nists as a means of reducing VIC apoptosis and the
calcification that this induces. Therapeutic admin-
istration of fetuin-A, or a mimetic of MGP, could
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simultaneously target multiple pathways thought to
drive valvular calcification.
The ability of lipoprotein(a)-lowering therapies to
modify aortic stenosis disease progression is likely to
form the basis of a future clinical trial. Given the
failure of the statin trials, it will be of great interest to
determine whether a more targeted lipid intervention
will have greater success in reducing disease
progression in the propagation phase (106). On the
basis of the apparent contribution of the RAS to the
initiation of aortic stenosis, it is also not unreasonable
to consider ACE inhibitors, or even selective AT1 re-
ceptor antagonists or novel renin inhibitors, as novel
treatments. Indeed, these agents are also likely to
have a beneficial effect with respect to hypertension
and left ventricular remodeling in aortic stenosis,
CENTRAL ILLUSTRATION The Pathogenesis of Aortic Stenosis in 2 Stages
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Initiation phase: similar to the early stages of atherosclerosis, endothelial injury facilitates the infiltration of oxidized lipids and inflammatory cells into the
valve and the release of proinflammatory mediators. These trigger the very early stages of valve calcification so that the incidence of aortic stenosis closely
relates to traditional cardiovascular risk factors for atherosclerosis. Propagation phase: these proinflammatory processes subsequently induce VICs to
undergo osteogenic differentiation. The VICs first lay down a collagen matrix and other bone-related proteins before producing calcium (7,8). Calcification
of the valve induces compliance mismatch, resulting in increased mechanical stress, injury, and apoptosis (9), which triggers further calcification (10).
Hence, a self-perpetuating cycle of calcification, valve injury, and osteogenic activation is established that drives the propagation phase of the disease. As a
consequence, disease progression in aortic stenosis more closely relates to procalcific factors, rather than lipid infiltration or inflammation. The different
stages of calcification in the valve can be imaged using 18F-Fluoride PET (newly developing microcalcification) and CT calcium scoring (macroscopic calcific
deposits). Given the central role of calcification in the propagation phase of aortic stenosis, it is perhaps unsurprising that these imaging techniques provide
important information with respect to prognosis and disease progression. Moreover, calcification represents an important potential therapeutic target, with
the use of drugs, such as denosumab and bisphosphonates, to interrupt the vicious cycle of calcification that drives progressive narrowing of the valve.
ACE ¼ angiotensin-converting enzyme; CT ¼ computed tomography; FDG ¼ fluorodeoxyglucose; PET ¼ positron emission tomography; VIC ¼ valvular
interstitial cell.
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given the role that the RAS system also plays in
driving myocardial hypertrophy, fibrosis, and the
transition to heart failure.
CONCLUSIONS
Aortic stenosis is a common condition that is set to
become an increasing health care burden. We lack
effective medical therapies capable of slowing its
relentless progression toward major surgery or
adverse events. Recent insights into the pathophysi-
ology of aortic stenosis have indicated that although
lipid and inflammation may be important in estab-
lishing the disease (initiation phase), it is the
self-perpetuating processes of calcification that are
predominantly responsible for driving disease
progression (propagation phase) (Central Illustration).
On this basis, imaging modalities capable of quanti-
fying aortic valve calcification will be best placed to
predict its natural history, whereas novel anticalcific
therapies hold major promise as methods of treat-
ment. Randomized controlled trials of such agents,
perhaps using imaging endpoints such as CT calcium
scoring and 18F-fluoride PET activity, are now
required to establish their early efficacy.
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Aortic stenosis is the most common form of valve disease in the Western world and a major healthcare burden that 
is set to treble by 2050. However, we currently lack any dis-
ease-modifying therapies. Calcification seems to be the pre-
dominant pathological process driving disease progression, 
leading to major interest in novel treatment strategies aimed at 
reducing calcification activity in the valve.1 However, assess-
ing the efficacy of new therapies requires large trials with 
prolonged follow-up to demonstrate an impact on disease 
progression and clinical end points.2 A noninvasive imaging 
technique capable of measuring calcification activity in the 
valve would be highly desirable to assess treatment efficacy 
in phase 2 clinical trials.
See Editorial by Chang and Chareonthaitawee
See Clinical Perspective
18F-Fluoride is a positron-emitting radiotracer that binds 
to regions of newly developing microcalcification beyond the 
Background—18F-Fluoride positron emission tomography (PET) and computed tomography (CT) can measure disease 
activity and progression in aortic stenosis. Our objectives were to optimize the methodology, analysis, and scan–rescan 
reproducibility of aortic valve 18F-fluoride PET-CT imaging.
Methods and Results—Fifteen patients with aortic stenosis underwent repeated 18F-fluoride PET-CT. We compared 
nongated PET and noncontrast CT, with a modified approach that incorporated contrast CT and ECG-gated PET. We 
explored a range of image analysis techniques, including estimation of blood-pool activity at differing vascular sites and 
a most diseased segment approach. Contrast-enhanced ECG-gated PET-CT permitted localization of 18F-fluoride uptake 
to individual valve leaflets. Uptake was most commonly observed at sites of maximal mechanical stress: the leaflet tips 
and the commissures. Scan–rescan reproducibility was markedly improved using enhanced analysis techniques leading 
to a reduction in percentage error from ±63% to ±10% (tissue to background ratio MDS mean of 1.55, bias −0.05, limits 
of agreement −0·20 to +0·11).
Conclusions—Optimized 18F-fluoride PET-CT allows reproducible localization of calcification activity to different regions 
of the aortic valve leaflet and commonly to areas of increased mechanical stress. This technique holds major promise in 
improving our understanding of the pathophysiology of aortic stenosis and as a biomarker end point in clinical trials of 
novel therapies.
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resolution of computed tomography.3 It is readily taken up by 
the valves of patients with aortic stenosis, and, on histology, 
correlates with markers of calcification activity.4 Importantly, 
this technique predicts disease progression both with respect 
to echocardiography and computed tomography (CT) calcium 
scoring and with respect to adverse cardiovascular events.5–7 
18F-Fluoride positron emission tomography (PET) imaging 
therefore holds major promise as a marker of calcification 
activity in aortic stenosis and is an exploratory secondary end 
point in the ongoing SALTIRE2 clinical trial (NCT02132026). 
Briefly, this is a randomized controlled trial investigating the 
ability of therapies targeting calcium metabolism (denosumab 
and alendronic acid) to modify disease progression in aortic 
stenosis.
Here, we sought to optimize 18F-fluoride PET scanning 
of the aortic valve, reduce the effects of cardiac motion, and 
assess the scan–rescan reproducibility of this technique to 
inform its future application as a novel biomarker of calcifica-
tion activity in clinical trials.
Methods
Study Population
Patients aged >50 years with mild, moderate, and severe calcific 
aortic stenosis were recruited prospectively from outpatient clinics 
at the Edinburgh Heart Center. Aortic stenosis severity was deter-
mined by clinical echocardiograms and graded according to accord-
ing to American Heart Association/American College of Cardiology 
guidelines. This is a substudy of the ongoing SALTIRE2 clinical trial 
(NCT02132026), and consequently patients had to meet the same 
exclusion criteria as those entering the main trial. These included re-
nal failure and women of childbearing potential (full list in Table I 
in the Data Supplement). The study was approved by the Scottish 
Research Ethics Committee and has a Clinical Trial Authorization 
from the Medicines and Healthcare products Regulatory Authority 
of the United Kingdom. It was performed in accordance with the 
Declaration of Helsinki. All patients gave written informed consent.
Initial Image Acquisition and Analysis
Each patient underwent 18F-fluoride PET and CT scanning on 2 oc-
casions. Patients were given 25 mg of oral metoprolol if their resting 
heart rate was >65 beats/min before being administered 125 MBq 
of 18F-fluoride IV. After 60 minutes, patients were imaged with a 
hybrid PET and CT scanner (Biograph mCT; Siemens). Attenuation-
correction CT scans were performed before acquisition of PET data 
in list mode using a single 30-minute bed position centered on the 
valve in 3-dimensional mode. Finally, ECG-gated aortic valve CT 
calcium scoring and contrast-enhanced CT angiography were per-
formed in diastole and in held expiration.
CT calcium scoring was performed by an experienced operator 
using dedicated software (Vitrea Advanced; Toshiba Systems) on 
axial views, with care taken to exclude calcium originating from the 
ascending aorta, left ventricular outflow tract, and coronary arteries. 
The calcium score was recorded in Agatston units.
Analysis was performed using an OsiriX workstation (OsiriX ver-
sion 3.5.1 64-bit; OsiriX Imaging Software, Geneva, Switzerland). 
As previously reported, regions of interest were drawn around the 
perimeter of the valve on the fused nongated PET and noncontrast 
CT images.6 These generated mean and maximum standard uptake 
values (SUV) for each slice. Averaging these values across the entire 
valve produced whole valve SUVmean and SUVmax values, respective-
ly. These SUV values were then corrected for blood-pool activity to 
generate tissue to background ratio (TBR): whole valve TBRmean and 
TBRmax. The blood-pool uptake was determined using SUVmean val-
ues averaged from across regions of interest drawn on 5 contiguous 
slices in the brachiocephalic vein. For consistency, the most caudal 
region of interest was positioned at the point where the innominate 
vein joined the brachiocephalic vein.6
To optimize the spatial localization and scan–rescan reproduc-
ibility of 18F-fluoride PET-CT imaging, we assessed different ap-
proaches to both image acquisition and image analysis.
Optimization of PET Image Acquisition
Contrast CT of Aortic Valve
Our original technique required the reorientation and coregistration 
of noncontrast CT images of the aortic valve. This technique posed 
several challenges, particularly with respect to aligning with the true 
plane of the valve and accurately defining its perimeter. Moreover, 
the structure of individual leaflets was not visible on these scans pre-
cluding more detailed localization of 18F-fluoride uptake. Contrast 
CT offered potential solutions to these challenges given its superior 
anatomic detail and the well-established methodology for finding the 
true plane of the valve8 (Figure 1).
ECG-Gated PET Data
PET is susceptible to motion, limiting accurate coregistration and the 
spatial assessment of PET activity within the valve. As a solution, we 
used ECG gating of list-mode PET data. These data were reconstructed 
into 4 gates at 25% intervals of the cardiac cycle. Only data acquired 
between 50% and 75% of the RR interval were assessed because this 
period corresponds with diastole when cardiac motion is at a minimum. 
Given that 3 quarters of the PET data are therefore discarded, the bed-
time was increased to 30 minutes to preserve signal to noise ratio.
Optimization of PET Image Analysis
Measurement of Blood-Pool Activity
The stability of blood-pool measurements in the SVC for 18F-fluoride–
based tracers has recently been questioned,9 and we were concerned 
about variation in the measured blood-pool activity at different levels 
of the brachiocephalic vein. We reasoned that this may be explained 
by the relatively small diameter of this vein rendering it susceptible to 
partial volume effects, amplified by the low PET signal in surround-
ing lung tissue (especially in the cranial aspects of the brachocephalic 
vein). We hypothesized that sampling blood-pool activity from the 
center of the right atrium (a much larger structure) may improve the 
ease and accuracy with which these measurements could be made and 
the consequent scan–rescan reproducibility. Using the same coregis-
tered PET and CT images of the heart, reorientated to the plane of the 
valve, a 2-cm2 region of interest was drawn in the center of the right 
atrium at the level of the right coronary ostium and again in the same 
position one slice superiorly. Averaging the mean SUV for these 2 slic-
es gave an alternative measure of blood-pool activity, which was used 
to correct valvular uptake measurements using 2 different approaches. 
First, we used the conventional method of dividing aortic valve SUV 
measurements by the blood pool to generate TBR values. Second, we 
subtracted the blood-pool value from the valvular uptake, to generate 
the corrected aortic valve SUV as described recently.9
Most Diseased Segment and Whole Valve Approach
One of the biggest difficulties in quantifying uptake in the valve is 
defining its limits in the z-plane. To overcome this challenge, our 
original whole valve technique was compared with a most diseased 
segment (MDS) approach where the 2 contiguous slices with the 
highest SUV values (frequently in the center of the valve) were av-
eraged to generate SUVMDSmean, SUVMDSmax, and corresponding TBR 
values. This is similar to the approach previously used for quantify-
ing 18F-fluorodeoxyglucose uptake in carotid and aortic atheroma.10
Scan–Rescan Reproducibility
Scan–rescan repeatability and intra- and interobserver reproducibil-
ity of valvular 18F-fluoride PET quantification was assessed for each 
of the established and novel image analysis approaches described 
above. Two experienced operators (T.P. and T.C.) quantified uptake 
values on each of the scan pairs, on 2 occasions separated by ≥2-week 
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Figure 1. Creation of coregistered en face short-axis positron emission tomography (PET)/computed tomography (CT) images of the 
aortic valve. First, the CT angiogram is reorientated to get into the approximate plane of the aortic valve by lining up the axial cross hair 
(purple in this example) using the images in the coronal (A) and sagittal planes (C). This creates an approximate cross-sectional image of 
the aortic valve in the axial frame (B). Scrolling down in the axial frame, the center of the crosshairs is then placed over the exact point 
at which the right coronary cusp disappears, identifying the base of that leaflet (D). Similarly, the base of the noncoronary cusp is identi-
fied, and orthogonal planes adjusted so that the purple plane goes through the base of both these 2 cusps (D). Finally, the base of the 
left coronary cusp is found by rotation of the axial crosshairs so that first the cusp comes into view. The image is then slowly rotated in 
the opposite direction until the point where the leaflet first disappears (the base) is again found (F). This produces an en face image of the 
valve aligned with the base of all 3 leaflets (G). Adjacent 3-mm slices are then created in that plane and used for subsequent assessment. 
These slices are fused with the 18F-fluoride PET images (H) and careful coregistration performed in 3 dimensions to ensure accurate 
alignment between the PET and CT images (I).
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interval to avoid recall bias. Observers were blinded to both their own 
previous measurements and those of the other operator.
Spatial Resolution
The effect of our modifications on spatial resolution and scan–rescan 
reproducibility were then assessed in comparison with the original 
approach. First, we assessed the ability of the technique to localize 
increased 18F-fluoride activity to individual valve leaflets and their 
different regions. This was done visually using a standardized method 
for windowing the fused PET/CT images that incorporated the blood-
pool activity in right atrium as the minimum. Scan–rescan and ob-
server agreements were assessed.
Statistical Analysis
Continuous variables were expressed as mean±SD, and categori-
cal variables were expressed as total and percentage. Kappa sta-
tistics (with 95% confidence intervals) were used to measure the 
intraobserver and scan–rescan agreement in presence or absence of 
18F-fluoride uptake across coronary cusps. The κ values were inter-
preted as follows: poor <0.20, fair 0.21 to 0.4, moderate 0.41 to 0.60, 
good 0.61 to 0.80, and very good >0.81.
Intraobserver, interobserver, and scan–rescan reproducibility 
of several 18F-fluoride PET uptake approaches were analyzed and 
presented using Bland–Altman analysis and percentage error.11 
Variability in the different techniques was expressed using the width 
of the 95% limits of agreement from Bland–Altman analyses. For 
the final approach, we considered the scan–rescan reproducibility to 
be good and acceptable for use in our future trial if the width of the 
95% limits of agreement were within ±0.2 for the TBRMDSmean mea-
surements. Percentage errors for the mean bias were calculated using 
twice the SD of the difference divided by the overall mean measure-
ments. The intraclass correlation coefficient was used to examine the 
reliability for both intra and interobserver variability.
Statistical analysis was performed using SAS for Windows ver-
sion 9.4. Graphs were produced using PRISM version 6.0 for Mac.
Results
Patient Characteristics
Fifteen patients (73±7 years, 67% men) had 2 scans (Table 1), 
3.9±3.3 weeks apart between November 2014 and May 2015. 
Seven patients had mild aortic stenosis, 4 had moderate and 4 
had severe aortic stenosis. In 3 participants, the between-scan 
interval exceeded 4 weeks (5 weeks, 8 weeks, and 14 weeks). 
The dose of 18F-fluoride was similar on each visit (123±8 and 
125±4 MBq; P=0·49).
Altered PET Acquisition and Image Quality
Good image quality allowing complete image analysis was 
achieved on all 15 scan pairs. The prolonged bedtimes of 30 
minutes did not result in increased patient motion during the 
18F-fluoride PET scans. The impact of each stepwise change 
in the acquisition and analysis protocol on scan–rescan repro-
ducibility is summarized in Table 2.
On visual assessment, contrast CT imaging of the valve 
provided much clearer anatomic detail of the leaflets and valve 
structure compared with noncontrast CT (Figure 2). This made 
it technically easier to get into the true plane of the valve and 
allowed more accurate regions of interest to be drawn around 
its perimeter (Figures 1 and 2). Coregistration with ECG-gated 
PET data then allowed localization of 18F-fluoride uptake to 
individual leaflets and their different regions. This was pre-
viously impossible using noncontrast CT and nongated PET. 
Most commonly increased activity was observed across all 3 
coronary cusps (n=10), it involved 2 cusps in 4 patients and 
was isolated to 1 cusp in just 1 patient. The noncoronary cusp 
was involved in all patients apart from that latter case. Activity 
was most frequently observed at the valve commissures: the 
Table 1. Patient Characteristics
 n (%) Total=15
Demographics
  Age 73.3±7.4
  Male sex 10 (67)
Vital signs
  Body mass index, kg/m2 29.7±5.6
  Pulse, beats/min 67.7±15.5
  Body surface area, m2 1.9±0.2
  Mean arterial pressure, mm Hg 100.1±9.3
  Smoker status 
   Current 1 (7)
   Never 9 (60)
   Ex 5 (33)
Symptoms
  Chest pain 4 (27)
  Breathlessness 7 (47)
  Syncope 2 (13)
Duration between scans
  Weeks 3.9±3.3
Relevant medical history
  Hypertension 11 (73)
  CABG 2 (13)
  PCI 4 (27)
  Liver disease 1 (7)
  Rheumatic fever 0 (0)
  MI 3 (20)
  Hypercholesterolemia 10 (67)
  Diabetes mellitus 4 (27)
  Renal disease 0 (0)
  TIA/CVA 2 (13)
Laboratory results
  Serum creatinine, mg/dL 70.1±11.2
Normal eGFR 14 (93)
Concomitant medications
  ACE inhibitor 6 (40)
  AIIRB 3 (20)
  β-Blocker 7 (47)
  Statin 9 (60)
ACE indicates angiotensin converting enzyme; AIIRB, angiotensin II receptor 
blocker; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; 
eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCI, 
percutaneous coronary intervention; and TIA, transient ischemic attack.
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point where the valve cusps meet the aortic ring (n=10) and at 
the tips where the leaflets coapt during diastole (n=8; Figure 2).
When examining intraobserver reproducibility for 
detecting the presence or absence of 18F-fluoride uptake 
on individual valve leaflets, this was very good for the right 
coronary cusp (κ=1.00), good for the noncoronary cusp 
(κ=0.63), and moderate for the left (κ=0.58) coronary cusps. 
The scan–rescan agreement was good for the right coronary 
cusp (κ=0.76), good for the noncoronary cusp (κ=0.63), and 
very good for the left coronary cusp (κ=0.81) coronary cusps 
(Tables 3 and 4).
Effect of Altered Image Analysis on PET 
Reproducibility
Interobserver and intraobserver reproducibility was good 
using both the original and modified approaches as previously 
reported. Intraclass correlation coefficient values for intra- and 
interobserver reproducibility were 0.88 and 0.80, respectively 
(Table 5). However, the scan–rescan reproducibility of our orig-
inal approach produced percentage errors of ±26% and ±27% 
for the mean and maximum SUV measurements, respectively 
(Table 2). Scan–rescan reproducibility for TBR measurements 
were disappointing with percentage errors of ±63% and ±65%.
Blood-Pool Measurements
The percentage error of our original TBR values was dou-
ble that of the SUV values, suggesting a problem with our 
blood-pool measurements. Interestingly, a stepwise and non-
physiological reduction in our original brachiocephalic vein 
measurements was observed on moving cranially up the axial 
slices away from the heart and into the lung. On average, a 
20% difference in values was observed between the top and 
bottom slices, but this difference could be as high as 66%. 
By comparison, blood-pool sampling from the right atrium 
was easier to perform, allowed larger regions of interest to be 
drawn, and was consistent, demonstrating a <1% difference 
in measurements acquired on adjacent slices (Figure 3).
Sampling the blood pool in the right atrium led to a sub-
stantial improvement in the scan–rescan reproducibility of 
all our TBR measurements. Indeed, after implementing this 
approach, the reproducibility of our TBR values consistently 
outperformed those for SUV values with percentage errors 
of between ±12% and ±22% for mean and maximum val-
ues, respectively. In contrast, the approach of subtracting the 
blood-pool uptake from the tissue SUV to produce corrected 
aortic valve SUV measures did not greatly improve repro-
ducibility resulting in percentage errors of ±43% and ±39% 
for mean and maximum measurements, respectively, despite 
similar limits of agreement (Table 2).
Considerable variation was observed in 18F-fluoride 
blood-pool PET activity across our population (blood-pool 
SUV 1.10±0.35) and even between different scans on the 
same patients. This is likely related to physiological variation 
in the distribution of the tracer.
Table 2. Bland–Altman Values and Percentage Errors for Each Stepwise Change to the Image Acquisition and Analysis Technique
 
Mean Values Maximum Values
Overall 
Mean




Difference 95% Limits of 
Agreement
% 
ErrorMean SD Mean SD
Original approach
  Whole valve, ungated PET, 
noncontrast CT
          
   Original standard uptake value 1.523  0.008 0.194 −0.373 to 0.389 26 1.955 0.094 0.263 −0.421 to 0.608 27
   Original tissue to background 
ratio (using brachiocephalic)
1.439  0.047 0.451 −0.836 to 0.930 63 1.869 0.154 0.612 −1.045 to 1.354 65
  RA blood-pool correction           
   Corrected standard uptake 
value (subtracting RA)
0.425  0.008 0.091 −0.170 to 0.186 43 0.858 0.094 0.168 −0.236 to 0.423 39
   Tissue to background ratio 
(using RA)
1.418 −0.002 0.086 −0.171 to 0.167 12 1.842 0.064 0.200 −0.328 to 0.456 22
  Most diseased segment approach           
   Standard uptake value 1.652  0.007 0.207 −0.400 to 0.413 25 2.129 0.131 0.265 −0.389 to 0.651 25
   Tissue to background ratio 
(using RA)
1.547 −0.005 0.075 −0.151 to 0.142 10 2.012 0.107 0.145 −0.177 to 0.391 14
Final approach
  RA blood pool, most diseased 
segment, gated PET, contrast CT
          
   Final standard uptake value 1.662  0.044 0.291 −0.527 to 0.615 35 2.528 0.275 0.633 −0.966 to 1.515 50
   Final tissue to background 
ratio (using RA)
1.546 −0.046 0.078 −0.199 to 0.107 10 2.385 0.111 0.439 −0.750 to 0.971 37
CT indicates computed tomography; PET, positron emission tomography; and RA, right atrium.
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MDS Approach
The MDS technique improved the technical ease of image 
analysis, removing the difficulty in deciding on the upper and 
lower limits of the valve in the z-plane. This translated into 
further improvements in scan–rescan reproducibility for mean 
TBR values with the percentage error for TBRMDSmean mea-
surements reduced to ±10%. Similarly, maximum TBR values 
were optimized on addition of the MDS approach (percentage 
error TBRMDSmax ±14%) as were the SUV measurements (per-
centage errors: SUVMDSmean ±25%; SUVMDSmax ±25%; Table 2).
Final Approach: Addition of Contrast-CT and 
ECG-Gated PET
The addition of contrast CT and ECG-gated PET data, while 
markedly improving image quality as described above, did not 
have a major effect on scan–rescan reproducibility. Reproduc-
ibility of our final approach, however, remained good with 
a percentage error of ±10% for TBRMDSmean measurements 
(Figure 4). This, combined with its ability to localize PET 
uptake to individual leaflets, made the final approach our 
preferred strategy. TBRMDSmean values using the final approach 
did not show any proportional bias with disease severity (Fig-
ure I in the Data Supplement) and were again superior to the 
equivalent SUVMDSmean values (percentage error ±35%) and to 
measurements quantifying maximum valvular 18F-fluoride 
uptake, which were less reproducible after the addition of 
gated-PET and contrast-CT (percentage errors: SUVMDSmax 
±50% and TBRMDSmax ±37%, respectively; Table 2).
Discussion
In this study, we have systematically investigated the acqui-
sition and analysis of 18F-fluoride PET imaging of the aor-
tic valve. First, we have improved the spatial localization of 
tracer uptake using ECG-gated PET data and contrast CT 
imaging, so that activity can now be localized to individual 
leaflets and regions within those leaflets. This has demon-
strated that calcification activity is most commonly observed 
at sites of maximal mechanical stress: in particular, in regions 
of leaflet coaptation and at the commissures. Second, we have 
improved the scan–rescan reproducibility by using blood-pool 
sampling of right atrium and the MDS methodology and ulti-
mately demonstrated good agreement for repeat TBRMDSmean 
measurements in the valve (percentage error ±10%). This has 
important implications for application to future clinical trials, 
indicating that 18F-fluoride might provide a useful imaging 
end point of drug efficacy.
Figure 2. Improved localization of positron emission tomography (PET) signal within the aortic valve and its leaflets. Paired nongated, 
noncontrast PET/computed tomography (CT) scans (original approach A–C and G–I) and gated, contrast-enhanced PET/CT images (final 
approach D–E and J–L). Images demonstrate the typical distribution of the tracer uptake within the valve at sites of increased mechanical 
stress, that is, at the leaflet tips (left: A–F) and at the commissures (right: G–L).
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In this study, we have modified our previous image acqui-
sition protocol to include contrast-enhanced CT imaging of the 
aortic valve, thereby providing greater definition of the indi-
vidual valve leaflets and their components. Moreover, we have 
included ECG-gated PET data to reduce the effects of cardiac 
motion and more accurately localize the pattern of activity on 
to the valve. The combined effect of these changes has been 
to improve the spatial localization of PET activity within the 
valve, which after accurate 3D coregistration, is now possible 
within specific regions of individual leaflets. This has demon-
strated that 18F-fluoride activity predominantly localizes to 
sites of increased mechanical stress within the valve, support-
ing mechanical injury as a key driver to the disease process. 
For example, 18F-fluoride activity was observed at the edges 
of the valve leaflets exactly at the sites of leaflet impact during 
valve closure. Additionally, uptake was observed at the valve 
Table 3. Scan–Rescan and Intraobserver Reproducibility for Presence or Absence of 18F-Fluoride Uptake
Subject
Right Coronary Cusp Noncoronary Cusp Left Coronary Cusp
1a 1b 2 1a 1b 2 1a 1b 2
1 + + + + + + + + −
2 + + + + + + + + +
3 + + + − + + − + −
4 + + + + + + + + +
5 + + + + + + + + +
6 + + + − − − − − −
7 + + + + + + + + +
8 − − − + + + + + +
9 + + + + + + + + +
10 + + + + + + + + +
11 − − − + + + + + +
12 + + − + + + − − −
13 + + + + + + + + +
14 + + + + + + + − +
15 + + + + + + + + +
Presence or absence of 18F-fluoride PET signal is denoted (+ and −, respectively) for each individual valve leaflet. The distribution of 18-fluoride signal on scan 1 
images (1a) were reassessed (1b) to assess intraobserver reproducibility and compared with scan 2 (2) to determine scan–rescan reproducibility. PET indicates positron 
emission tomography.
Table 4. Kappa Statistics for Interobserver and Scan–Rescan Agreement for 18F-Fluoride PET Signal Distribution
 
Scan 1 (Reading 2)  
 
Scan 2
Absence Presence Absence Presence
Right coronary cusp
  Scan 1 
(first reading)
Absence 2 0 Scan 1 
(first reading)
Absence 2 0
Presence 0 13 Presence 1 12
  Intraobserver agreement 1.00, 95% CI (0.00–0.00 Scan/rescan agreement 0.76, 95% CI (0.32–1.00)
Noncoronary cusp
  Scan 1 
(first reading)
Absence 1 1 Scan 1 
(first reading)
Absence 1 1
Presence 0 13 Presence 0 13
  Intraobserver agreement 0.63, 95% CI (0.00–1.00) Scan/rescan agreement 0.63, 95% CI (0.00–1.00)
Left coronary cusp
  Scan 1 (first 
reading)
Absence 2 1 Scan 1 
(first reading)
Absence 3 0
Presence 1 11 Presence 1 11
  Intraobserver agreement 0.58, 95% CI (0.07–1.00) Scan/rescan agreement 0.81, 95% CI (0.47–1.00)
The numbers of presence or absence of 18F-fluoride for right coronary cusp, noncoronary cusp, and left coronary cusp are provided. κ Statistics and 95% CIs 
for intraobserver (ie, scan 1 [first reading] vs scan 1 [second reading]) and scan–rescan (ie, scan 1 [first reading] vs scan 2) agreement are also shown. CI indicates 
confidence interval; and PET, positron emission tomography.
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commissures where mechanical stress is concentrated before 
being transferred to the aortic wall.12,13 Although these find-
ings need to be confirmed in larger studies with further refine-
ment of thresholding techniques, they here provide key insight 
into the triggers to calcification activity in aortic stenosis and 
the importance of mechanical injury. Recent data have indi-
cated that the relationship between the valve calcium burden 
and hemodynamic obstruction is not perfect.14,15 The ability of 
PET to accurately localize calcification activity may be useful 
in trying to understand whether calcium formation at different 
sites of the valve has different hemodynamic impacts.
We have modified our image analysis protocol, optimiz-
ing the scan–rescan reproducibility of 18F-fluoride imaging 
in the aortic valve using several different approaches. To date, 
it has been standard practice for 18F-fluorodeoxyglucose PET 
to measure the blood-pool SUV in the brachiocephalic vein.16 
This has the benefit of avoiding contamination of myocar-
dial 18F-fluorodeoxyglucose uptake that would overestimate 
the blood-pool activity if measured in the heart. However, 
this benefit does not exist for 18F-fluoride, which has no 
background myocardial uptake. We, therefore, measured 
blood-pool activity in both the right atrium and the brachio-
cephalic vein. Measurements in the right atrium are easily 
performed on the en face (short-axis) images of the valve and 
resulted in much more consistent blood-pool measurements. 
Moreover, this approach led to a dramatic improvement in 
the scan–rescan reproducibility of our TBR measurements 
such that they then outperformed equivalent SUV measures. 
We think that sampling the blood-pool activity in the right 
atrium improved reproducibility because these measurements 
are less susceptible to the partial volume effects of adjacent 
lung tissue and because any minor inaccuracies in coreg-
istration with the PET signal will not have a great impact. 
Furthermore, it seems important to correct for variations in 
background blood-pool activity that can occur between scans 
perhaps because of minor changes in renal function, tracer 
dose, and pharmacokinetic distribution. Chen et al9 recently 
surmised that subtracting the blood pool from tissue SUV 
would improve accuracy. However, our study findings did 
not support this, and their approach produced lower TBR 
values, thereby increasing the percentage error of our repeat 
measurements.
Another major improvement in reproducibility was obtained 
using the MDS approach: measuring activity in the 2 hottest 
adjacent slices in the valve, rather than attempting to sample 
the entire valve. The major advantage of this technique is that 
it removes the considerable difficulty in deciding the limits and 
boundaries of the valve. Such uncertainty can lead to major dif-
ferences in valve measurements because uptake is much lower 
at the extremes of the valve where the volume of tissue is small 
and inclusion of extraneous tissue will dilute down mean values.
In this article, although our stepwise changes to the proto-
col generally improved the reproducibility of mean measures 
of PET uptake, the effects on maximum measures were more 
variable. This finding is somewhat at odds with experience 
in oncology where the maximum values are often preferred. 
This may reflect the use of contrast-enhanced CT (not used 
in cancer imaging), which allowed accurate and reproducible 
regions of interest to be drawn around the perimeter of the 
valve, facilitating reproducible measurement of mean PET 
uptake. In addition, it may reflect ECG gating of the PET data, 
which discards 75% of the counts, potentially having a greater 
detrimental impact on maximum values (which rely on counts 
from only a few pixels and are therefore particularly suscep-
tible to noise) than mean values. It is possible that advanced 
image analysis approaches that model and correct for cardiac 
motion without discarding any PET data will improve the 
reproducibility of TBRMDSmax measurements as has recently 
been described for coronary 18F-fluoride activity.17
This is the first study to assess scan–rescan reproducibil-
ity for 18F-fluoride uptake in the aortic valve. For a technique 
to be clinically applicable, clinicians and clinical researchers 
need the reassurance that a given methodology is robust and 
reproducible. We have demonstrated this here. However, we 
acknowledge that scan–rescan reproducibility does not nec-
essarily translate to accuracy and sensitivity. The value of 
18F-fluoride as an imaging marker of calcification activity 
will ultimately be determined by its ability to predict disease 
progression and to detect changes in calcification activity in 
response to novel therapies. These aspects are both currently 
being studied within the SALTIRE 2 clinical trial. We have 
already shown that the TBRMDSmean can predict disease progres-
sion and clinical events in patients with aortic stenosis.18 We 
can now report TBRMDSmean measurements, made using our opti-
mized image acquisition and analysis protocols, can quantify 
valvular 18F-fluoride activity with good reproducibility and a 
10% error. This translates directly into the requirement for low 
patient numbers for studies investigating the effects of interven-
tions on 18F-fluoride PET uptake (as a marker of calcification 
activity), because any true effect will not be swamped by noise 
within the measuring technique. Indeed, based on our repro-
ducibility data, we have provided estimates of the sample sizes 
required for different effect sizes (Figure 4). For example, 57 
patients would be required in each group to detect a 10% differ-
ence in mean 18F-fluoride activity based on 80% power and an 
α error probability of 0.05. However, although these estimates 
provide a framework for minimum sample sizes, they should 
be interpreted with a degree of caution, because they assume 
a perfect agreement between changes in the TBRMDSmean signal 
and underlying changes in valve calcification activity.
Limitations
We acknowledge the small sample size in this study; how-
ever, it is similar to that used in previous studies examining the 
Table 5. Intra-/Interobserver Variability of 18F-Fluoride PET 
Uptake (Expressed as a Continuous Variable)
 
Difference
95% Limits of Agreement ICCMean SD
Intraobserver* 0.053 0.124 −0.189 to 0.296 0.876
Intraobserver† 0.028 0.083 −0.134 to 0.190 0.979
Interobserver‡ −0.092 0.166 −0.418 to 0.234 0.796
ICC indicates intraclass correlation; and PET, positron emission tomography.
*Rater 1 scan 1 (first reading) vs rater 1 scan 1 (second reading).
†Rater 2 scan 1 (first reading) vs rater 2 scan 1 (second reading).
‡Rater 1 scan 1 (first reading) vs rater 2 scan 1 (first reading).
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reproducibility of vascular PET19and, in part, reflects attempts 
to minimize the radiation exposure associated with repeat 
PET/CT imaging. Moreover, although previous studies have 
indicated that 18F-fluoride uptake correlates with histologi-
cal markers of calcification activity and accurately predicts 
the progression in the CT calcium score, we currently lack 
data to show that 18F-fluoride is modifiable with drug therapy. 
Largely, this is because no drug has yet demonstrated an abil-
ity to reduce disease activity in aortic stenosis, and we lack 
reliable animal models of this condition.
In conclusion, we have optimized 18F-fluoride PET-CT 
imaging in the aortic valve. Excellent localization of the PET 
signal within the aortic valve is now possible, with uptake 
observed in regions of maximal mechanical stress. Moreover, 
quantification of valvular 18F-fluoride uptake is now possible 
with good scan–rescan reproducibility. 18F-Fluoride PET-CT 
holds major promise as a method to better understand calcifi-
cation activity in aortic stenosis and as a surrogate end point 
in clinical trials assessing the efficacy of potential therapeutic 
interventions.
Figure 3. Measuring blood-pool activity 
in the brachiocephalic vein and the right 
atrium. Regions of interest for measuring 
blood-pool activity in the brachiocephalic 
vein (top) and right atrium (bottom) are 
shown in the en face of the valve (left) and 
coronal (right) planes. Note that the right 
atrium is a much larger structure allow-
ing for larger regions of interest with less 
potential for partial volume artifact prob-
lems related to poor registration. Tukey 
plot demonstrates mean standard uptake 
values (SUV) for 5 contiguous slices from 
brachiocephalic (blue) and 2 from the right 
atrium (purple). Note the variation in bra-
chiocephalic vein measurements between 
those taken most caudally vs those taken 
most cranially.
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CLINICAL PERSPECTIVE
18F-Fluoride positron emission tomography (PET) is being increasingly used as a research tool to study calcification activity 
in the vasculature. It binds preferentially to regions of newly developing microcalcification beyond the resolution of com-
puted tomography (CT) and, in aortic stenosis, correlates closely with calcification activity on histology (alkaline phospha-
tase staining). Moreover, clinical 18F-fluoride PET-CT in aortic stenosis offers accurate prediction of disease progression 
and adverse cardiovascular events. 18F-Fluoride PET-CT, therefore, has major potential to improve our understanding of the 
role of calcification in aortic stenosis and also as a surrogate end point in studies of novel therapies for this condition. This 
article adds to current literature demonstrating that optimized 18F-fluoride PET-CT in aortic stenosis can localize calcifica-
tion activity to individual leaflets and regions of the valve associated with increased mechanical stress. Moreover, it shows 
that the scan–rescan reproducibility of aortic valve PET measurements is good, with a percentage error of ±10%. These data 
strongly support the use of 18F-fluoride PET-CT as a tool to study the mechanisms underlying aortic stenosis and also as an 
end point in novel therapies for this common condition.
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Table 1.  Full list of inclusion and exclusion criteria 
 
Inclusion Criteria Age >50 years 
Peak aortic jet velocity of >2.5 m/s on Doppler echocardiography  
Grade 2-4 calcification of the aortic valve on echocardiography 
Exclusion Criteria Women of childbearing potential who have experienced menarche, are premenopausal,  
Women who have not been sterilized or who are currently pregnant. 
Women who are breastfeeding  
Renal failure (estimated glomerular filtration rate of <30 mL/min)  
Inability to undergo scanning  
Allergy or contraindication to iodinated contrast 
Inability or unwilling to give informed consent 
Likelihood of non0compliance to treatment allocation or study protocol. 
Anticipated or planned aortic valve surgery in the next 6 months,  
Life expectancy less than 2 years,  
Treatment for osteoporosis with bisphosphonates or denosumab. 
Known allergy or intolerance to alendronate or denosumab, or any of their excipients 
Abnormalities of the oesophagus or conditions, which delay oesophageal/gastric emptying. 
Inability to sit or stand for at least 30 minutes. 
Hypocalcaemia 
Regular calcium supplementation  
Dental extraction within 6 months 
Long term corticosteroid use. 
History of osteonecrosis of the jaw 
Poor dental hygiene 
Major or untreated cancers 
 
  



































Deviation from zero p=0.42
Figure	1.	Linear regression analysis of scan-rescan reproducibility versus calcium burden.  The mean difference between 18F-Fluoride TBRMDSmean 
measures for the 15 scan pairs is plotted against the log-transformed Computed Tomography calcium score (log10 Agatston Units).  No proportional bias is 
observed. 
	
